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The default developmental choice for both female and male Murine Germ Cells 
(GCs) is to commit to oogenesis and begin meiosis, which occurs in vivo in the 
developing ovary, and in vitro, at E12.5-E13.5.  Prior to this commitment, female 
and male GCs are receptive to masculinising signals from the developing male 
gonad that induce GCs to commit to spermatogenesis at E11.5-E12.5, followed 
by temporary mitotic arrest.  A previous differential expression study identified 
2 candidate genes upregulated sex-specifically.  Inhibitor of DNA Binding 1 (Id1) 
mRNA was upregulated in female E13.5 GCs and has not been studied in relation 
to this developmental paradigm; while Lipocalin-Type Prostaglandin D2-Synthase 
(Ptgds) mRNA was upregulated in XY E13.5 GC preparations and precious 
studies show that its high expression by male supporting cells augments 
masculinisation of cells in the developing male gonad.  This thesis aims to firstly 
confirm sex-specific GC expression of these genes at E13.5, a stage when GCs 
have committed to spermatogenesis or oogenesis, and secondly, to use this sex-
specific expression to shed light upon the molecular events driving GC sexual 
commitment. 
Id1 belongs to the Basic Helix-loop-helix (bHLH) family of transcriptional 
effectors that operate as homo- or heterodimers.  Id1 suppresses cellular 
commitment and exit from the cell cycle partly by binding to and inhibiting the 
action of pro-differentiation bHLHs.  A 40-fold female-specific enrichment of Id1 
mRNA and protein in E13.5 XX GCs was confirmed by Quantitative Real-time 
PCR and by Quantitative Immunofluorescence, respectively.  Male GC nuclei had 
very low levels of Id1 immunofluorescence, whereas female GC nuclei had 
heterogeneous but significantly higher average Id1 immunofluorescence levels.  
GCs in both XX and XY E11.5 gonads had heterogeneous Id1 
immunofluorescence levels, similar to E13.5 female GCs, but no obvious sex-
specific difference was seen at E11.5.  However, in E12.5 gonads a sex-specific 
difference was seen, with XY GCs expressing very low Id1 levels.  It appears, 
therefore, that XY GCs’ Id1 protein expression drops sharply at E11.5-E12.5, 




mitotically.  Female GCs on the other hand continually express heterogeneous 
Id1 protein levels at E11.5-E13.5.   
In order to discover candidate Id1-interacting bHLHs in female E13.5 GCs, a 
Quantitative Real-time PCR expression screen was performed to identify bHLHs 
enriched sex-specifically in E13.5 GC cDNA.  5 bHLH genes were significantly 
enriched or detected only in male E13.5 GC cDNA and 16 bHLH genes (including 
Id2 and Id3, close family members to Id1) were significantly enriched or 
detected only in female E13.5 GC cDNA.  Mnt, a negative regulator of the 
oncogene Myc, was one of the male-enriched genes and male-specific 
enrichment of Mnt protein was confirmed by Quantitative Immunofluorescence 
on E13.5 gonad sections, and qualitatively by immunofluorescence on E12.5 
gonad sections.  Both female and male GCs expressed high Mnt protein levels at 
E11.5, so sex-specific Mnt protein expression probably first appears at E11.5-
E12.5 due to a downregulation by female GCs.  To conclude, 21 genes were 
enriched or expressed sex-specifically in E13.5 GC cDNA, 16 in female cDNA and 
are interesting candidates for Id1 interaction in female GCs during commitment 
to oogenesis and meiotic entry.  Mnt protein was enriched male-specifically in 
E12.5 and E13.5 GC nuclei, when female GCs appear to downregulate Mnt 
protein levels. 
Semi-quantitative PCR detected weak Ptgds in purified E13.5 male, but not 
female, GC cDNA.  Also, weak Ptgds immunofluorescence was seen in male, but 
not female, GC cytoplasm.  In conclusion, weak Ptgds mRNA and protein 
expression was detected sex-specifically in male GCs.  A study was then 
undertaken to test whether molecular signals that are known to affect Ptgds 
expression in other tissues were able to affect Ptgds expression in developing 
GCs.  E11.5 and E12.5 XX or XY genital ridges were cultured with the phorbol 
ester Phorbol 12-myristate 13-acetate, Ionomycin, Dexamethoasone or Thyroid 
Hormone for 3 days and Ptgds expression examined by whole mount in situ 
hybridisation. All 4 compounds failed to induce or suppress Ptgds expression 
levels detectably.  This suggests that Ptgds expression in GCs may be stimulated 
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AP:  Alkaline phosphatase 
Amh:   Anti-mullerian hormone 
bHLH:  Basic helix-loop-helix 
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CDKI:   Cyclin-dependent kinase inhibitor 
ESCs:   Embryonic stem cells 
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GC:   Germ cell 
GCNA:  Germ cell nuclear antigen 
GFP:   Green fluorescent protein 
GR:  Genital ridge 
Ig:  Immunoglobulin 
LIF:   Leukemia inhibitory factor 
Mvh:   Mouse vasa homologue 
NBT:  4-nitro blue tetrazolium chloride 
nt:   nucleotide(s) 
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PgD2:   Prostaglandin D2 
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RA:  Retinoic acid 
Rb:   Retinoblastoma protein 
RT:  Reverse transcription 
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TPA:   12-O-tetradecanoylphorbol-13-acetate 
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Unlike the somatic cells making up most mammalian tissues, germline cells 
undergo meiosis to form mature germ cells (GCs) that generate the zygote of the 
next generation.  Primordial GCs are the progenitors of the germline and 
differentiate sex-specifically during embryogenesis, after a period of non-sex-
specific development, to produce populations of self-renewing spermatogonial 
stem cells in the adult male testis or meiotically-arrested oocytes in the adult 
female ovary.  In the adult testes of normal XY males, the germline stem cells 
undergo repeated rounds of mitosis followed by meiosis to give rise to mature 
sperm.  In the adult ovary of normal XX females, meiotically-arrested oocytes 
reside in primordial follicles until estrous hormones direct their maturation into 
fertilisation-competent oocytes.   
 
1.1. Germ Cell (GC) Specification and Migration 
 
As with other organisms –flies, worms and chickens for example - mammalian 
GCs are specified and initially develop outside of the gonads then actively 
migrate to them once they are formed (McLaren, 2000).  Mammalian GC 
progenitors (primordial GCs) are specified after implantation from proximal 
epiblast cells that contribute to both germline and somatic cell lineages.  due to 
extracellular signals emanating from the extraembryonic ectoderm (Saitou et 
al., 2002).  Bmp4, Bmp2 , Bmp8b and Smad signaling are involved in GC 
specification (Saitou et al., 2002; Saitou et al., 2003).  Once specified, the founder 
GCs are distinguished from their non-germline neighbouring cells by the 
expression of several molecular markers, including Tissue non-specific alkaline 
phosphatase, Oct4, SSEA1, Stella, Blimp1 and Fragilis1 (McLaren, 1984; Ohinata 
et al., 2005; Saitou et al., 2002). 
Molyneaux and Wiley describe several stages of mouse GC migration from the 
proximal epiblast to the gonad (Molyneaux and Wylie, 2004; Molyneaux et al., 




E9.5-E10.5, GCs are seen exiting the hindgut and actively migrating towards the 
forming genital ridges.  Some ectopic GCs do not migrate to the genital ridges 
and find themselves in ectopic locations.  In wildtype embryos, these ectopic 
GCs fragment and apoptose (Stallock et al., 2003). 
On leaving the hindgut at E9.5, the migrating GCs begin to link up with each 
other via extended processes, and by E10.5 have formed interconnected 
networks that migrate together towards the genital ridges then form even 
tighter aggregates when in the genital ridges (Gomperts et al., 1994).  In vitro 
aggregates were seen to consist of non-sister as well as sister GCs, showing that 
this interconnectivity is an active, rather than passive, process.  This 
aggregation behaviour may be a mechanism to ensure proper germ cell 
organisation in the gonad, to aid in the colonisation/migration of GCs into the 
genital ridge, and/or to prevent ectopic GCs from migrating to inappropriate 
places with the possibility of forming tumorigenic cells. 
Various experiments have shown that Stl/c-kit and SDF1/CXCR4 signaling is 
involved in the survival and migration of migratory GCs and additionally show 
that Stl/c-kit may be involved in post-migratory GC survival and/or 
proliferation (McLaren, 2003; Molyneaux and Wylie, 2004).  Migratory GCs 
change their adhesive properties to extracellular matrix substrates found along 
their migration path during their embryonic development (Garcia-Castro et al., 
1997).  Further work has shown that GCs actively participate in their migration 
during migration and genital ridge colonisation (Donovan et al., 1986; Gomperts 
et al., 1994; Molyneaux et al., 2001), and this involves the action of several 
cellular adhesion/receptor proteins, including β1-integrins (Anderson et al., 
1999), E-cadherins (Okamura et al., 2003) and possibly c-kit (Molyneaux and 
Wylie, 2004). 
The initial founder population of 40 or so specified GCs expands via several 
rounds of mitosis during migration to a population of approximately 3000 cells 
on reaching the genital ridges by E11.5 (Lawson and Hage, 1994; Tam and 




factor (LIF) as having positive mitogenic effects on migratory and post-
migratory GCs in vitro (Matsui et al., 1991).  However, others (Takeuchi et al., 
2005) find that FGF2 affects motility, but not proliferation, of migratory GCs in 
cultured embryo slices.  This suggests that the mitogenic affects of FGF2 on 
migratory GCs in vitro (Matsui et al., 1991) might be an artificial phenomenon 
induced by culture conditions, or that the lack of mitogenic effect on FGF2 in 
embryo slices (Takeuchi et al., 2005) indicates the presence of compensatory 
factors provided in the embryo.  Another indication that FGF2 has a redundant 
role in vivo is that embryonic GC development proceeds normally in Fgf2 
knockout mice (Ortega et al., 1998).  Migratory GCs express multiple FGF 
receptors and signaling through them specifically controls either the motility or 
the number of migratory GCs (Takeuchi et al., 2005). 
The precise in vivo role of LIF is not completely clear at present, because 
embryonic GC development proceeds normally in LIF (Stewart et al., 1992) or 
LIF receptor (Ware et al., 1995) knockout mice.  The shared receptor Gp130 for 
the IL-6 family of cytokines (of which LIF belongs) is expressed by GCs at 
multiple stages during their embryonic development (Molyneaux et al., 2003) 
and treatment of post-migratory, and to a much lesser extent of migratory, GCs 
with antibodies against Gp130 blocks the mitogenic action of LIF in vitro 
(Koshimizu et al., 1996).  Knockout of Gp130 results in a sex-specific reduction 
in male GC numbers at E13.5, whereas embryonic female GC development is 
unaffected (Molyneaux et al., 2003).   This in vitro and in vivo data suggests that 








1.2. GC Markers Associated With Pluripotency 
 
GCs express several genes associated with pluripotency during their 
development – including Stella, Oct4, Nanog and Blimp1.  GC expression of these 
genes is dynamic and for some is sensitive to sex-specific developmental 
choices. 
Oct4 is a Pou-domain containing transcription factor and has a crucial role in 
maintenance of pluripotency in cells of the early embryo (Nichols et al., 1998; 
Niwa et al., 2000).  Embryonic stem cells (ESCs) in culture lose Oct4 expression 
when they differentiate, as do cells of the inner cell mass when overt 
differentiation and body patterning begins (Rosner et al., 1990).  The only cells 
to retain detectable expression after E8.5 are GCs.  Conditional knockout of Oct4 
in GCs resulted in loss of GCs due to apoptosis in late migration between the 
hindgut and the genital ridges (Kehler et al., 2004).  Oct4 protein is expressed 
highly by both male and female post-migratory GCs between E11.5 and E13.5, 
but at E14.5 female GCs transiently downregulate Oct4 protein levels as they 
proceed through the earliest stages of meiosis, while mitotically-arrested XY 
GCs retain Oct4 protein expression (Pesce et al., 1998).  Down-regulation of 
Oct4 protein by E14.5 female GCs is mirrored by downregulation of Oct4 mRNA 
at E13.5/E14.5 that occurs in an anterior-to-posterior wave (Menke et al., 
2003).  After birth, female GCs once again begin to express Oct4, and this 
expression becomes high in most, if not all, female GCs by 7 days post partum.  
In adult testes, the undifferentiated A-type spermatogonia are the highest 
expressing cell type.  B-type spermatogonia and more mature male GCs, on the 
other hand, do not express Oct4 protein (Pesce et al., 1998). 
The way in which Oct4 mediates pluripotency is complex, as both ectopic 
expression or reduction of expression of Oct4 cause cultured embryonic stem 
cells to differentiate (Niwa et al., 2000).  Nanog, together with Oct4 and other 
pluripotency-associated genes such as Sox2, regulates the pluripotency in the 




Nanog, Sox2 and Oct4, along with other ESC-expressed transcripts such as Esg1, 
are all expressed by post-migratory GCs before sex-specific differentiation 
(Western et al., 2005), indicating that these 3 pluripotency-associated 
transcription factors may regulate GC pluripotency.  GCs begin expressing 
Nanog when they enter the hindgut and retain expression while migrating.  Both 
male and female GCs downregulate Nanog expression after colonising the 
genital ridges but with a slight sex-specific difference in timing (Yamaguchi et 
al., 2005).  Female GCs downregulate Nanog concomitantly with meiotic entry at 
E13.5-E14.5, while male GCs retain expression until E14.5-E15.5.  Ectopic 
expression of Nanog in cultured ESCs relieves their dependence on LIF for 
maintenance of pluripotency and proliferative capacity (Chambers et al., 2003; 
Mitsui et al., 2003).  Nanog overexpression also reduces differentiation of ESCs 
in response to differentiation factors like retinoic acid (Chambers et al., 2003), 
while Nanog knockout embryos develop abnormally and die, with loss of 
pluripotent inner cell mass between E3.5 and E5.5 (Mitsui et al., 2003).  
Therefore, Nanog appears to be a potent pluripotency factor that is required to 
maintain inner cell mass cells in the pre-implantation embryo.  On the other 
hand, Nanog is not required for maintenance of ESC pluripotency because 
removal of Nanog does not prevent ESCs from contributing to all 3 germ layers 
in chimaeric mice (Chambers et al., 2007).  Removal of Nanog does, however, 
prevent post-migratory GC development beyond E11.5 (Chambers et al., 2007).  
Currently, the cause of loss of Nanog knockout GCs after E11.5 is not known, but 
this loss does coincide with epigenetic changes in GCs at this time (Allegrucci et 
al., 2005).  Therefore, Nanog may be required for these epigenetic changes to 
take place in post-migratory GCs.   
Blimp1 is a transcriptional repressor associated with the repression of somatic 
gene expression programs and is required for the earliest stages of GC 
development after primordial GC specification (Ohinata et al., 2005).  Blimp1 is 
expressed in the founder GC population in the proximal epiblast concomitantly 
with GC specification (Ohinata et al., 2005; Saitou et al., 2002), and is believed to 




transferases (Ancelin et al., 2006).  Blimp1 is reported to silence certain genomic 
loci, such as that containing  Dhx38, the mouse homologue of C. elegans Mog1, 
which is involved in the C. elegans spermatogenesis-oogenesis switch (Graham 
and Kimble, 1993), in migratory GCs, but not in post-migratory female and male 
E11.5 GCs (Ancelin et al., 2006). 
Stella is another gene whose expression begins in GCs around the time when 
they are specified (Saitou et al., 2002) and is downregulated with slightly 
different sex-specific timing in post-migratory GCs (Bowles et al., 2003).  
However, Stella appears not to have an in vivo role in GC development, instead 
being required during pre-implantation embryonic development in some mouse 




1.3. Mouse Gonad Development 
1.3.1. Non-Sex-Specific Gonad Development 
Development of the gonads begins as thickenings of the ventrolateral surfaces of 
the mesonephroi at each side of the intermediate mesoderm, and the gonads 
become visible by ~E10.0 (Swain and Lovell-Badge, 1999).  These earliest 
stages of gonad development are identical in XX (female) and XY (male) 
embryos, and the gonad is therefore described as indifferent, until obvious sex-
specific differences appear at ~E12.0.  Early development of the indifferent 
gonad depends upon the presence of, among other genes, SF-1, Lim1, Wt1 and 
Emx2, as homozygous knockout of these genes results in either a complete lack 
of gonads or severely underdeveloped gonads.   
 
1.3.2. Sex-Specific Gonad Development 
Between E10.5 and E12.5 sex-specific differentiation of the various gonadal cell 
populations begins, resulting in the development of ovaries in XX embryos or 
testes in XY embryos.  Release of sex hormones, such as testosterone and anti-
Mullerian hormone (Amh), by the testes results in masculinisation of the XY 
embryo (Parker et al., 1999).  In the absence of testes in the XX embryo, this 
masculinisation does not occur and the embryo develops female genitalia and 
secondary sexual characteristics.  
 
Morphological Characteristics of Sex-specific Gonad Development 
Sex-specific gonad development begins at ~E10.5 with the expression of Sry in 
the XY gonad, and this leads to the formation of testis cords and pronounced 
vasculature that clearly distinguishes the testes from the ovary by E12.0-E12.5 
(Parker et al., 1999).  The testis cords, themselves surrounded by muscle-like 
peritubular myoid cells, consist of Sertoli cells surrounding spermatogenic GCs 




are crucial to the formation of characteristic testes morphology and gene 
expression.  Firstly, proliferation of Sry-expressing pre-Sertoli cells between 
~E10.8-E11.2 is required for the differentiation of Sertoli cells, which is itself a 
requirement for testes formation (Schmahl and Capel, 2003; Schmahl et al., 
2000).  Secondly, endothelial and peritubular myoid cells migrate into the XY 
gonad from the mesonephros and contribute to the formation of testis cords and 
pronounced vasculature (Buehr et al., 1993; Martineau et al., 1997; Merchant-
Larios et al., 1993; Tilmann and Capel, 1999).  This migration is induced by the 
differentiating XY gonad (Merchant-Larios et al., 1993) and is critical for the 
formation of testis cords, because XY gonads cultured without a mesonephros, 
even though Sertoli cell differentiation still occurs, do not form testis cords 
(Tilmann and Capel, 1999).  Recent work shows that it is the migration of 
endothelial cells that is critical to the formation of basal lamina of the testis 
cords and cord formation (Combes et al., 2009), rather than peritubular myoid 
cells (Cool et al., 2008). 
The E12.0-E14.0 XX ovary is more unstructured and less well defined, with GCs 
spread homogeneously throughout the gonad and intermingled with somatic 
cells, some of which are differentiating into stromal cells (Swain and Lovell-
Badge, 1999).  There is some vasculature throughout the ovary, and this is 
irregular and indistinct rather than clearly pronounced as in age-matched 
testes. 
 
Sry and Sox9 Drive Sertoli Cell Differentiation and Maintenance 
Experiments by Palmer and Burgoyne (Palmer and Burgoyne, 1991) showed 
that in the embryonic testes of male chimaeras composed of XX and XY cells, 
Sertoli cells are the only major cell type in the testes that have a bias towards 
having an XY rather than an XX sex chromosome complement.  The other major 
gonadal cell populations – peritubular myoid cells, Leydig cells and germ cells – 
were equally comprised of XX and XY cells.  These experiments revealed 2 




are the only cell type to differentiate due to cell-autonomous expression of a 
testis-determining factor on the Y chromosome, and secondly that Sertoli cell 
differentiation then triggers the masculinisation of the other cell types in the 
gonad.  Therefore, Sertoli cell development is the defining event of testis 
development. 
A critical region of the Y chromosome, the Sxr region, is the minimum piece of 
DNA required to induce testis formation, because natural transposition of this 
Sxr region to the pseudoautosomal region on the X chromosome results in sex 
reversal of XXSxr mice (Roberts et al., 1988).  This region contains a number of 
genes that were suggested as testis-determining genes.  However, several lines 
of evidence show that Sry is the one gene contained in this region that is 
required for testis-determination.  Firstly, Sry is an active Sox family 
transcription factor (Polanco and Koopman, 2007).  Secondly, mutations in Sry, 
many of which occur in its HMG DNA-binding domain (Hawkins 1993) and 
impair DNA-binding (Polanco and Koopman, 2007), are commonly associated 
with XY sex reversal in mouse and humans (Gubbay et al., 1990; Hawkins, 
1993).  Thirdly, Sry expression begins just before the morphological events of 
early testis development (Bullejos and Koopman, 2001).  The most crucial piece 
of evidence is that a 14kb region of DNA containing Sry and its flanking 
regulatory sequences is sufficient to drive complete testis formation and 
masculinisation of XX embryos (Koopman et al., 1991). 
Sry mRNA expression in the XY gonad occurs in a dynamic and transient centre-
to-pole pattern, first appearing at the centre of the indifferent gonad at ~E10.5 
and receding at the poles by ~E12.5 (Bullejos and Koopman, 2001; Wilhelm et 
al., 2005), and is closely followed by Sry protein expression (Wilhelm et al., 
2005). This transient Sry expression results in cell-autonomous differentiation 
of the vast majority of Sertoli cells (Sekido et al., 2004; Wilhelm et al., 2005), 
from sexually bipotential supporting cells that become granulosa cells in the 
absence of Sry expression in an XX embryo (Albrecht and Eicher, 2001).  The 
centre-to-pole pattern of Sry expression means that testis formation is slightly 




the poles is probably what causes development of ovarian regions at the poles 
of partially sex-reversed testes, or ovotestes, in mice in which Sry expression is 
generally delayed such as in C57BL/6 mice (Wilhelm et al., 2009).  The further 
delay in Sry expression may allow the ovarian program to suppress testis 
development at the poles.  
The transient expression pattern of Sry mRNA and protein suggests that Sry acts 
as a trigger, rather than a mechanism for maintaining, Sertoli cell differentiation 
and testis formation.  There is now evidence showing that Sox9 is a major 
downstream target of Sry that maintains Sertoli cell fate and directs testis 
development.  Appearance of abundant Sox9 transcript and protein expression 
mirrors that of Sry except with a slight delay (Kent et al., 1996; Wilhelm et al., 
2005) and occurs in the same pre-Sertoli cells that express Sry for ~90% of 
Sertoli cells (Sekido et al., 2004; Wilhelm et al., 2005).  Sox9 expression 
continues throughout embryonic gonad development in Sertoli cells, consistent 
with a gene that maintains Sertoli cell differentiation (Kobayashi et al., 2005).  
There is also compelling genetic evidence for Sox9 being the only required 
testis-determining gene downstream of Sry.  Artificial knockouts of Sox9 in mice 
show that Sox9 is required for development of testes and phenotypically male 
embryos (Barrionuevo et al., 2006; Chaboissier et al., 2004), while certain 
mutations in Sox9 cause campomelic dysplasia in humans, a developmental 
syndrome usually linked with sex reversal (Foster et al., 1994; Kwok et al., 
1995).  Conversely, Sox9 overexpression in the bipotential gonads of XX mice, 
due to the insertion of an ectopic enhancer or a Sox9 transgene, results in 
complete testis formation without Sry expression (Bishop et al., 2000; Vidal et 
al., 2001).  Recently, chromatin immunoprecipitation experiments have shown 
that Sry, in conjunction with SF-1, binds to a testis-specific region of the Sox9 
promoter in E11.5 XY gonads to drive Sox9 expression (Sekido and Lovell-
Badge, 2008).  Numerous studies have also reported testis-specific expression 
of Sox9 in a wide range of vertebrate species, ranging from turtles to chickens 




Sox9 in vertebrate testis formation despite diverse sex-determination triggers in 
these species. 
It is unclear how Sox9 ensures Sertoli cell differentiation and maintenance.  
Hundreds of genes have been identified as being sex-specifically-expressed in 
XY gonads after Sry expression (Cory et al., 2007; Nef et al., 2005), and many of 
these are expressed specifically in Sertoli cells.  Many of these genes are 
probably indirectly downstream of Sox9, and studies have identified some as 
direct Sox9 target genes.  For example, Sox9 and SF-1 work in concert to drive 
the expression of a variety of Sertoli cell-specific genes, as has been shown for 
Amh (Arango et al., 1999; De Santa Barbara et al., 1998) and Vanin-1 (Wilson et 
al., 2005).  Sox9 also binds directly to the Ptgds promoter in E11.5 XY gonads 
and drives testis-specific Ptgds expression in Sertoli cells from E11.5 (Wilhelm 
et al., 2007).  Also, it is known that autoregulation of the Sox9 promoter, also 
with the aid of SF-1, is probably what maintains Sox9 expression in Sertoli cells 
once they downregulate Sry (Sekido and Lovell-Badge, 2008).  Ptgds and Fgf9, 
both sex-specifically upregulated from E11.5/E12.5 in Sertoli cells in response 
to Sox9 expression, also have masculinisation properties that feedback 
positively upon Sox9 expression (Kim et al., 2006; Malki et al., 2005; Moniot et 
al., 2009; Wilhelm et al., 2005).  The masculinisation properties of these genes 
might reside completely in their ability to maintain Sox9 expression/Sertoli cell 
differentiation or might be due to triggering other downstream pathways (Kim 
et al., 2007). 
 
Fgf9 and Ptgds Maintain and Augment Sertoli Cell Differentiation 
Fgf9 and Ptgds are both expressed sex-specifically from E12.5 or E11.5, 
respectively, in the XY gonad in response to Sry and Sox9 (Kim et al., 2006; 
Wilhelm et al., 2007), and have independent positive effects on masculinisation 
of the E11.5 gonad.  Fgf9 is a member of the fibroblast growth factor of peptide 
signaling molecules and acts downstream of Sry to ensure testes development.  




Schmahl et al., 2004), and maintenance, rather than initiation, of Sox9 
expression (Kim et al., 2006) and Sertoli cell differentiation (DiNapoli et al., 
2006) in gonads of XY C57BL/6 mice.  This is known because Sox9 expression is 
initially upregulated in the Fgf9 knockout gonads at E11.5-E12.0, but is almost 
completely lost by E12.5 (Kim et al., 2006).  Fgfr2 appears to be the main 
receptor mediating these effects of Fgf9 in XY gonads, because knockout of Fgfr2 
results in a very similar phenotype (Bagheri-Fam et al., 2008; Kim et al., 2007).  
It is not completely clear whether the effects of Fgf9 are solely due to 
maintenance of Sertoli cell Sox9 expression and/or proliferation, which is 
required for testis formation (Schmahl and Capel, 2003), or whether Fgf9 has 
other masculinising effects, such as repression of female-specific genes like 
Wnt4, Follistatin and Bmp2, which are upregulated in Fgf9 knockout XY gonads 
(Kim et al., 2007). 
In the XX-XY chimera experiments by Palmer & Burgoyne approximately 10% of 
Sertoli cells in these mice were XX and therefore must have been induced by the 
masculinising environment rather than cell-autonomous Sry expression (Palmer 
and Burgoyne, 1991).  More recently Adams & McLaren found that Ptgds is 
expressed sex-specifically from E11.5 in embryonic XY gonads, and 
Prostaglandin D2 (PgD2), its enzymatic product, can partially masculinise 
cultured bipotential XX gonads (Adams and McLaren, 2002).  Further study 
showed that PgD2 induces Sertoli cell differentiation by enhancing Sox9 
expression and nuclear localisation (Malki et al., 2005), and could account for 
the small population of non-cell-autonomously induced Sertoli cells (Wilhelm et 
al., 2005).  Ptgds knockout on C57BL/6 background results in a delay rather 
than a complete block of testis development (Moniot et al., 2009), suggesting 








Genetic Pathways Controlling Ovary Development 
Expression screens examining sex-specific gene expression differences in 
gonads during the earliest stages of sex-specific gonad development have 
revealed that many genes are sex-specifically enriched in the somatic cells of the 
developing ovary (Bouma et al., 2005; Cory et al., 2007; Nef et al., 2005), 
showing that ovary development is an active process.  Furthermore, studies 
have shown that expression of these genes, such as Wnt4 (Kim et al., 2006), in 
the supporting cell lineage of XX gonads, actively represses testis formation by 
suppressing various aspects of testis development, such as Sertoli cell 
differentiation.  The prevailing current model is that the testis-determining 
genes, like Fgf9 (DiNapoli et al., 2006; Kim et al., 2006) and Sox9 (Qin and 
Bishop, 2005) counterbalance the ovary-determining genes like Wnt4 (Kim et 
al., 2006) and Rspo1 (Chassot et al., 2008), and vice versa, and that the testis-
determining switch, Sry, acts to initiate the male pathway (Hiramatsu et al., 
2009), which then feeds-back positively on itself, and feeds-back negatively on 
the ovary-determining genes.  In the absence of Sry expression, the ovary-
determining genes are not repressed and are automatically upregulated. 
Wingless-related MMTV integration site 4 (Wnt4) and R-spondin1 (Rspo1) are the 
two most prominent upstream positive regulators of ovary development that 
are currently known.  Wnt4 is expressed non-sex-specifically in the genital ridge 
at E10-E11, but is then downregulated in XY gonads from E11.5 and maintained 
in XX gonads (Vainio et al., 1999).  Knockout of Wnt4 results in dose-dependent 
increases in Fgf9 and Sox9 expression, resulting in partial masculinisation of XX 
gonads (Vainio et al., 1999).  This finding raises two important points for sex-
specific mouse gonad development.  Firstly, initiation of the male pathway can 
occur in the absence of Sry expression, and secondly, Wnt4 dose-dependently 
represses this initiation in XX gonads.  Wnt4 is also required in XX gonads to 
repress other aspects of gonad masculinisation such as mesonephric cell 
migration (Jeays-Ward et al., 2003), although some or all of these effects might 
be a consequence of inhibition of Sertoli cell differentiation.  Surprisingly, Wnt4 




differentiation and proper development of testes (Jeays-Ward et al., 2004).  
However, because Wnt4 is downregulated at E11.5-E12.5, this is seemingly due 
to a requirement for Wnt4 in the indifferent gonad, probably to prevent 
precocious masculinisation of the indifferent gonad. 
Mutation of Rspo1 in humans is linked with the development of XX males, also in 
the absence of Sry expression (Parma et al., 2006) and analysis in mice shows 
that Rspo1 is expressed much more highly in XX compared to XY gonads at 
E12.5-E14.5 in somatic cells (Chassot et al., 2008; Parma et al., 2006), suggestive 
of a role in promoting ovary development.  Knockout of the gene in mice results 
in partial masculinisation of embryos on a C57BL/6 background (Chassot et al., 
2008).  The XX gonads of these knockouts develop as ovotestes with varying 
degrees of masculinisation, in which meiotic entry and survival of oocytes is 
impaired, and male markers are slightly upregulated (Chassot et al., 2008).  
Rspo1 knockout also results in reduced Wnt4 expression in E11.5-E12.5 XX 
gonads (Tomizuka et al., 2008), so this could account for partial masculinisation 
of Rspo1 knockout XX gonads.  R-spondin signaling upregulates β-catenin and 
analysis of embryonic gonads showes that β-catenin reporters are sex-
specifically active in XX gonads from E12.5 in somatic cells (Chassot et al., 
2008).  β-catenin reporter activity is lost in the XX gonads of Rspo1 knockouts 
mice, while ectopic expression of a constitutively-active β-catenin driven by an 
SF-1 transgene was able to rescue normal ovarian development in surviving 
embryos (Chassot et al., 2008), showing that the feminisation activity of Rspo1 
involves downstream β-catenin signaling. 
Because XX sex-reversal is not complete in either the Wnt4 or Rspo1 knockout 
XX mice, Rspo1 and Wnt4 may be redundant and compensate for the loss of each 
other.  Nobody has yet carried out a Wnt4/Rspo1 double knockout.  β-catenin 
activation is also a common consequence of Wnt signaling, raising the 
possibility that Rspo1 and Wnt4 act in concert to maximally activate β-catenin 
expression in the XX gonad.  In support of this theory, one patient showing 
complete XY sex reversal was found with a duplication of the chromosomal 




studies are required to ascertain whether Wnt4 and Rspo1 work together to 
activate β-catenin to promote ovary development.  However, one recent study 
has shown that ectopic   expression of a stable form of β-catenin in SF-1-
expressing cells results in a complete block of testis formation in XY gonads, but 
does not impair ovary formation of XX gonads (Maatouk et al., 2008).  At E13.5, 
the transgenic XY gonads show loss of Sox9 protein expression, testis cord 
formation and coelomic vessel formation and an increase of female-specific 
markers, clearly displaying that active β-catenin is a potent inhibitor of testis 
formation. 
Other genes upregulated sex-specifically in XX gonadal supporting cells around 
the time of sex determination include Follistatin, Bmp2 and Foxl2, which are 
believed to act downstream of Wnt4 and Rspo1, after initiation of ovary 
development.  Follistatin is a member of the TGF-beta family of peptide 
signaling molecules and is downregulated in partially-masculinised Wnt4 
knockout XX gonads (Yao et al., 2004).  Follistatin knockout results in 
development of the coelomic vessel in XX gonads and eventual GC loss, but does 
not perturb expression of Bmp2 or absence of Sox9 expression (Yao et al., 2004).  
Bmp2 is another ovary-enriched gene that is also downregulated in XX gonads 
of Wnt4 knockout mice (Yao et al., 2004), and is upregulated in XY gonads of 
Fgf9 knockout mice (DiNapoli et al., 2006).  Its role in ovary determination has 
not yet been explored in much detail, but studies have shown that 
Decapentaplegic, the Drosophila Bmp2/4 orthologue, is required to maintain 
female germline stem cells in the Drosophila ovary (Xie and Spradling, 1998).  A 
similar ovary-specific role for Bmp2 is possible in mice but to find out its exact 
role will require a gonad-specific conditional knockout because Bmp2 knockout 
embryos die before E10.5 (Zhang and Bradley, 1996).  Foxl2 appears to 
represent a complementary ovary determination pathway (Garcia-Ortiz et al., 
2009), that genetically interacts with either absence of GCs in KitWv/Wv mice or 
with knockout of Wnt4, to produce partial or complete, respectively, 





Other Genes Involved in Sex-Specific Gonad Development 
It is not clear whether Dax1 is required for testis development, ovary 
development and/or both.  Dax1 knockout results in incomplete sex-reversal of 
XY gonads in 129Sv/J mice (Meeks et al., 2003a), and complete sex-reversal of 
XY gonads in C57BL/6 or XYPOS mice (Bouma et al., 2005; Meeks et al., 2003b).  
In completely sex-reversed knockout XY gonads, Sry upregulation is not 
affected, whereas the Sox9 upregulation is impaired (Bouma et al., 2005), 
suggesting that Dax1 is involved in the Sry-mediated stimulation of Sox9 
transcription, a critical event in male-specific gonad development.  On the other 
hand, female knockout mice appear to be unaffected and are fertile (Meeks et al., 
2003a), implying that Dax1 is not involved in female-specific gonad 
development in mice.  However, studies in humans (Swain et al., 1996) and mice 
(Swain et al., 1998) show that multiple copies of Dax1 can block, rather than 
augment, development of functional testes.  Swain and colleagues introduced 
multiple copies of Dax1 into mice and found that testis development was slightly 
delayed in mice with the highest transgenic Dax1 expression (Swain et al., 
1998).  Additionally, multiple copies of Dax1 were able to increase incidences of 
ovotestes and sex reversal in XYPOS mice, indeed suggesting that Dax1 does have 
an anti-testes effect.  The fact that a single extra copy of Dax1 in humans is able 
to cause sex reversal (Swain et al., 1996) suggests there are species-specific 
differences in the potency of the feminising effects of Dax1 and/or the way in 
which Dax1 interacts with other sex determining factors in mice and humans.  
Functional data of Dax1 suggest that Dax1 is able to inhibit SF-1-mediated gene 
transcription of genes such as Amh (Ludbrook and Harley, 2004), and this can 
explain the anti-testes effect of Dax1, but not necessarily why the removal of 
Dax1 predisposes mouse XY gonads towards ovarian development (Bouma et 
al., 2005; Meeks et al., 2003b).  
Signaling through insulin and Dhh receptors is also involved in testes 
development.  Knockout of all 3 insulin receptors results in complete XY sex-
reversal (Nef et al., 2003), which is characterised by massively reduced 




E12.5, a loss of the initiating pulse of Sry expression in E10.5-E12.0 testes and 
the absence of testis cord formation.  The percentage of Bromo Deoxyuridine-
stained cells was reduced in triple knockout testes and both XX and XY knockout 
gonads were smaller than controls, suggesting that insulin receptor signaling 
mediates proliferation of gonadal cells.  Blocking proliferation of gonadal cells 
by other means also blocks Sertoli cell differentiation (Schmahl et al., 2000), so 
this might explain the sex reversal in the triple knockout XY gonads.  Dhh on the 
other hand has a downstream role in stimulating Leydig cell differentiation and 
this occurs later than sex determination of the supporting and GC lineages 
(Pierucci-Alves et al., 2001).  Dhh knockout results in development of stunted 
testes and GC loss, but Sertoli cells still differentiate and testis cords still form 
(Bitgood et al., 1996).  
 
Effects of Genetic Background on Sex Determination 
The impact of spontaneous mutations or artificial knockouts of sex-determining 
genes on sex-reversal in mice depends upon the genetic background upon 
which it occurs.  For example, the inbred C57BL/6J mouse strain is known to be 
much more susceptible to XY sex-reversal than outbred mouse strains.  This 
phenomenon is typified by C57BL/6 mice carrying a Mus domesticus 
poschiavinus Y chromosome, whose gonads develop either as fully sex-reversed 
ovaries or ovotestes because of one or more C57BL/6 genetic determinants 
being incompatible with poschiavinus Sry-driven testis determination (Eckner et 
al., 1996).  As such, sex reversal in these mice is prevented by transgenic 
insertion of Mus musculus Sry (Eicher et al., 1995).  Variations of sex-reversal on 
these genetic backgrounds may be due to variations in expression levels of 
different Sry alleles, which is also affected by the genetic background it is found 
in due to upstream genetic determinants (Albrecht et al., 2003).  Additionally, 
Sry proteins between species and genetic backgrounds differ and vary in both 




1.4. GC Development in the Gonad 
1.4.1.  Colonisation of the Gonads by GCs 
 
The majority of GCs have colonised the genital ridges by E11.0 - E11.5 (Garcia-
Castro et al., 1997; Gomperts et al., 1994), and become more rounded in shape 
as they form tighter aggregates (Molyneaux et al., 2001).  Movements of the GCs 
once in the genital ridge slow significantly in both sexes, but the nature of their 
movements differs between male and female embryos (Molyneaux et al., 2001).  
with male GC movements being more directional and less random.  On reaching 
the genital ridges GCs non-sex-specifically begin to express certain post-
migratory GC markers.  These include Germ cell nuclear antigen (GCNA) (Enders 
and May, 1994), Mouse vasa homologue (Mvh) (Fujiwara et al., 1994) and Daz-
like (Dazl) (Seligman and Page, 1998). 
There are approximately 3000 GCs at E11.5 as the GCs are colonising the genital 
ridges (Tam and Snow, 1981).  Over the next 2 days the GCs proliferate with a 
doubling time of roughly 16 hours, similar to that of migratory GCs.  Despite the 
sex-specific differentiation of the surrounding gonadal cells and their own sex-
specific commitment events, proliferation rates of XY and XX GCs in E11.5-E13.5 
gonads are remarkably similar, resulting in roughly 10’000 GCs per gonad at 
E13.5 (Schmahl et al., 2000; Tam and Snow, 1981).  However, there are sex-
specific differences in post-migratory GC requirements for mitogenic/survival 
factors.  For example, XY GCs are responsive to GP130-mediated (Molyneaux et 
al., 2003) and FGF9 (DiNapoli et al., 2006) signaling, because knockouts of 
Gp130 or Fgf9 result in sex-specific deficiencies in XY GC numbers.  However, it 
is not completely clear whether this is due to a direct effect on the GCs or some 
indirect effect due to somatic cell dysfunction, especially in the Fgf9 knockout 
where Sertoli cell differentiation is perturbed (DiNapoli et al., 2006).   
Both Dazl and Mvh are also required sex-specifically for maximal post-migratory 




2005; Tanaka et al., 2000).  In Dazl knockout gonads male GCs are sex-
specifically lost due to apoptosis between E13.5-E15.5, and any surviving male 
GCs do not develop normally (Lin and Page, 2005).  Dazl is expressed GC-
specifically in the post-migratory gonad, indicating that Dazl provides some cell-
autonomous survival effect for male GCs.  However, widespread death of 
embryonic male GCs in Dazl knockout mice is specific to the C57BL/6 
background, therefore it is the combined effect of C57BL/6 testes development 
and Dazl loss that is responsible for this male-specific GC death.  Mvh is also 
expressed GC-specifically when GCs colonise the gonads (Fujiwara et al., 1994), 
and its knockout similarly results in a sex-specific defect in male GC 
development from E11.5-E12.5, on a mixed genetic background (Tanaka et al., 
2000).  A reduction in proliferation may be the cause of reduction in GC 
numbers in the Mvh knockout because the Mvh knockout GCs have less 
proliferative capacity in vitro.  So Mvh and Dazl, both of which encode RNA-
binding proteins, have sex-specific pro-survival and/or pro-proliferative role in 
embryonic male GCs in vivo. 
 
1.4.2. Sex-Specific GC Differentiation 
 
GCs remain bipotential until E12.5-E13.5, meaning they can commit to either 
spermatogenesis or oogenesis, and their choice depends upon the sex of the 
gonad in which they are in during a short time frame, rather than the 
chromosomal make-up of the GCs themselves (Ford et al., 1975; Palmer and 
Burgoyne, 1991).  At ~E12.5 both XX and XY GCs enter a post-mitotic state that 
represents the end of the last mitotic division and the beginning of meiosis I 
(McLaren, 1984; McLaren, 2003).  Concurrently with entry into this post-mitotic 
state, XY GCs commit to spermatogenesis between E11.5 and E12.5 and enter a 
reversible mitotic arrest in the G0 phase of the cell cycle (Adams and McLaren, 
2002; McLaren and Southee, 1997; Western et al., 2008) until just after birth, 







Figure 1.4.1.  Scheme showing the timeline of sex-specific GC development.  Before E11.5 XX and XY GCs are sexually bipotential, meaning they can 
commit to either spermatogenesis or oogenesis, depending upon the environment they find themselves in.  Masculinising signals from the 
developing testes cause either XX or XY GCs to commit to spermatogenesis and enter mitotic arrest.  In vivo this occurs between E11.5 and E12.5.  In 
the absence of these pro-spermatogenic signals, which we as yet do not know the identity of, both XX and XY GCs commit to oogenesis between 
E12.5 and E13.5 and prepare to enter meiosis.  Oogenic commitment might well be a latent ability of GCs that is triggered by intrinsic molecular 
events, or might be triggered by extrinsic signals from the ovary.  A candidate for the latter is retinoic acid.  Once committed, female GCs inhibit 





The XY GCs begin their mitotic arrest from E12.5, and by E14.5 there are almost 
no XY GCs in S phase (Western et al., 2008).  The masculinising environment of 
the embryonic testis is the developmental cue that causes the XY GCs to commit 
to spermatogenesis, and this must act on the GCs before E13.5 to cause them to 
commit to spermatogenesis (Adams and McLaren, 2002; McLaren and Southee, 
1997).  In the absence of exposure to these masculinising signals, either in vivo 
in the developing ovary or in re-aggregate culture with E12.5 XX genital ridges 
or embryonic lung cells, both XX and XY GCs commit to oogenesis between 
E12.5 and E13.5.  Oogenically-committed GCs enter into prophase I of meiosis at 
E13.5-E14.5 (Adams and McLaren, 2002; McLaren and Southee, 1997), proceed 
through leptotene, zygotene and pachytene stages of meiosis I then finally 
arrest in the diplotene stage of meiosis around the time of birth until oocyte 
maturation in the adult (McLaren, 2003).  Once XX or XY GCs are committed to 
oogenesis at E13.5, the GCs are refractory to masculinising signals (Adams and 
McLaren, 2002; McLaren and Southee, 1997).  Additionally, meiotic XX GCs have 
a negative effect on testes development, because XX gonads placed in between 
an E11.5 XY gonad and a mesonephros blocks mesonephric cell migration from 
the mesonephros into the XY gonad, but only when the XX gonad contains 
meiotic XX GCs (Yao et al., 2003).  It has not been shown whether this effect of 
oogenic female GCs is due to a direct effect of these oogenic GCs or an indirect 
effect of oogenic GCs on differentiation of the somatic cells of the gonad. 
Both male and female GCs upregulate meiotic markers such as Scp1 and Scp3 at 
E12.5-E13.5 (Di Carlo et al., 2000), indicating that both populations prepare to 
enter meiosis.  These markers are downregulated in the vast majority of 
spermatogenic XY GCs by E14.5 (Di Carlo et al., 2000; Yao et al., 2003), but 
remain expressed in leptotene and zygotene oocytes at E14.5-E15.5 (Di Carlo et 
al., 2000; Yao et al., 2003).  Bipotential GCs appear morphologically identical 
prior to these commitment events (McLaren and Southee, 1997).  However, the 
chromosomal conformations of spermatogenic and oogenic GCs differ markedly 
by E14.5 and provide an easy means of distinguishing the two fates after 




XX GCs that find themselves committed to spermatogenesis due to the 
masculinising effects of the developing testis are unable to form fully mature 
sperm (McLaren, 1981) presumably due to lack of spermatogenic genes found 
on the Y chromosome.  On the other hand, a small proportion of XY GCs that 
commit to oogenesis in an ovary do form functional oocytes able to contribute 
to viable offspring (Burgoyne et al., 1988).   
 
1.4.3. Control of Sex-Specific GC Differentiation 
 
Pro-Meiotic Signals or Cell-autonomous Meiotic Initiation? 
The fact that GCs commit to oogenesis and begin meiotic initiation outside of a 
masculinising environment, irrespective of their sex chromosome complement, 
suggests that commitment to the oogenic pathway and initiation of meiosis is 
the default pathway for GCs and is therefore under the control of some intrinsic 
mechanism.  However, it is possible that one or more pro-meiotic signals 
operate in the E12.5-E13.5 XX gonad to cause GCs to commit to meiosis.  These 
pro-meiotic signals would also be present in vivo in the adrenal gland (Zamboni 
and Upadhyay, 1983) and in the anterior region of wild-type embryonic testes 
(Yao et al., 2003); in cultures of re-aggregated E11.5 testes (McLaren and 
Southee, 1997), embryonic lung (McLaren and Southee, 1997) and Sl4-m220 
cells (Chuma and Nakatsuji, 2001); and in feeder-free cultures (Farini et al., 
2005); because all these environments support initiation of meiosis in 
embryonic GCs as shown by robust expression of meiotic markers.  
Intriguingly, the timing of meiotic entry of XX and XY GCs in these diverse 
conditions is very similar – within 1 day – of meiotic entry in vivo in the XX 
gonad at E13.5.  This suggests that either the intrinsic pro-meiotic signal is 
expressed by GCs at E12.5-E13.5, or that GCs become receptive to ubiquitous 




Any extrinsic pro-meiotic signals might originate from the anterior part of the 
mesonephros and diffuse into the anterior part of the E12.5-E14.5 XX gonad in 
vivo, because the appearance of meiotic markers, and presumably entry of XX 
GCs into meiosis, occurs in an anterior to posterior wave at E13.5-E15.5 
(Bullejos and Koopman, 2004; Menke et al., 2003; Yao et al., 2003).  Additional 
evidence for a pro-meiotic signal originating from the anterior mesonephros is 
that a small number of GCs at the anterior end of the E13.5-E14.5 testis in close 
juxtaposition to the mesonephros appear to enter into meiosis, as shown by 
meiotic marker expression, before degenerating by E15.5 (Yao et al., 2003).  
These GCs may encounter the pro-meiotic signal before they commit to 
spermatogenesis, and this is compounded by the delay in testis formation at the 
poles of the XY gonad.  However, this phenomenon and the observed pattern of 
meiotic entry in ovaries might instead be due to GCs colonising the anterior 
gonad first and therefore being more developmentally advanced.   
Recent work suggests that one candidate for an extrinsic pro-meiotic signal is 
Retinoic Acid (RA) (Bowles et al., 2006; Koubova et al., 2006).  However, the 
existence of an intrinsic pro-meiotic signal has not yet been disproven. 
 
RA as a Pro-meiotic Signal Opposed by Cyp26b1 
Recently, some have theorised that RA is the pro-meiotic signal operating in 
ovaries to induce XX GCs to enter meiosis.  The supporting evidence for this 
theory is as follows.  Aldh1a2, a major RA-synthesising enzyme, is expressed in 
the mesonephroi of both XX and XY genital ridges between E11.5 and E13.5 
(Bowles et al., 2006).  Consequently, there is very high RA receptor activity in 
the mesonephroi non-sex-specifically and moderate RA receptor reporter 
activity female-specifically in the gonads at E13.5-E14.5, measured by an RA 
response element-lacZ transgene (Bowles et al., 2006).  Lack of RA receptor 
activity in the male gonad at E13.5-E14.5 correlates with gonadal expression of 
Cyp26b1, an RA-metabolising enzyme, which becomes male-specific in gonads 




vivo in the gonads, there are sex-specific differences in RA activity and some 
observations suggest that this could account for meiotic entry of XX GCs. 
Treatment of cultured E12.5 XY gonads with RA or RA receptor agonists 
(Koubova et al., 2006) induces expression of Stra8, which is expressed female-
specifically in GCs from E13.5 (Menke et al., 2003) and is required for entry of 
female and male GCs into meiosis (Baltus et al., 2006).  In organotypic cultures, 
RA accelerates the entry of XX rat GCs into meiosis (Livera et al., 2000), while 
RA, RA receptor agonists or Am580, an artificial non-degradable retinoid, 
stimulate a proportion of mouse XY GCs to enter meiosis if treated before 
spermatogenic commitment at E12.5 (MacLean et al., 2007; Trautmann et al., 
2008).  All of this suggests that RA does have a pro-meiotic effect on some 
bipotential GCs, possibly by activating Stra8 expression, a well-documented 
consequence of RA treatment (Oulad-Abdelghani et al., 1996). 
Cyp26b1 appears to have a role in the male gonad in preventing excessive 
mesonephric RA, which is a potent mitogen for migratory and post-migratory 
GCs (Koshimizu et al., 1995), from interfering with mitotic arrest of the 
spermatogenic GCs.  Cyp26b1 knockout results in some of the GCs inside the 
cords entering meiosis (MacLean et al., 2007), probably due to widespread 
expression of Stra8 of the GCs in the knockout testes (Bowles et al., 2006).  Some 
have taken male-specific expression of Cyp26b1 as the primary mechanism by 
which GCs in testes are prevented from entering meiosis and stimulated to 
enter mitotic arrest.  
Despite this evidence, there are still major flaws in both the RA and Cyp26b1 
aspects of this theory.  Firstly, culture of E12.5 XY gonads with RA, or with the 
Cyp26b1 inhibitor ketaconazole, induces Stra8 expression but does not induce 
meiotic entry of the GCs (Best et al., 2008; Koubova et al., 2006), indicating that 
although RA often stimulates meiotic gene expression, this does not always 
result in meiotic entry.  One study has observed leptotene- and zygotene-like 
chromosome conformations in about ~20% of XY GCs when cultured with RA 




resulted in apoptosis of many of the GCs, and the pro-meiotic effect of RA in 
those gonads, and gonads in other studies (Livera et al., 2000), may have been 
an indirect effect on male somatic cell differentiation, because RA perturbs 
multiple aspects of testis development, including Sertoli cell differentiation 
(Cupp et al., 1999; Li and Kim, 2004).  One other study also observed 
widespread apoptosis and increased mitosis of GCs in XY gonads cultured with 
Am580 (MacLean et al., 2007).  Also in that study (MacLean et al., 2007), meiotic 
GCs were reported in testis cords of Cyp26b1 knockout XY gonads.  However, 
many of the GCs identified as meiotic in that paper appeared to be in fact 
apoptotic.  This suggests that RA might simply act as a mitogenic stimulus for 
the XY GCs in these artificial situations, preventing masculinising signals from 
arresting them mitotically and allowing meiotic entry, which is a latent ability of 
XY GCs (McLaren 1997).  Apoptosis of the majority of the GCs in the Cyp26b1 
knockout or in RA-treated XY gonads (MacLean et al., 2007), therefore, might 
occur due to the RA mitogenic stimulus conflicting with the as yet unidentified 
masculinising anti-meiotic/pro-mitotic arrest signal.   
Most notable is the fact that XY GCs found in the XY mesonephros still enter 
mitotic arrest (McLaren, 1983), and so are still able to receive masculinising 
signals from the XY gonad and commit to spermatogenesis despite the high RA 
levels in the mesonephros (Bowles et al., 2006).  Additionally, in some 
circumstances, such as in E11.5 cultured XY gonads transiently treated with 
brefeldin A, which reversibly inhibits secretion (Best et al., 2008), or in vivo in 
Nanos2 knockout XY testes in which Cyp26b1 expression levels are similar to 
wildtype (Suzuki and Saga, 2008), XY GCs are able to enter meiosis while they 
are still enclosed in the testis cords, which according to the Cyp26b1 theory 
would be sheltered from the effects of RA.  All of this evidence suggests that 
treatment of bipotential GCs with RA allows the automatic meiotic entry of some 
GCs, but RA is not the primary in vivo pro-meiotic signal in XX gonads.  
Furthermore, Cyp26b1 prevents RA from interfering with other masculinising 




meiotic signal inducing spermatogenic commitment and mitotic arrest of XY GCs 
in vivo. 
 
The Anti-meiotic Effect of the Developing Testis 
Before committing to meiosis, both XX and XY GCs are receptive to the 
masculinising environment of the developing testis (Adams and McLaren, 
2002), which causes them to commit to spermatogenesis.  The identities of the 
signal or signals that mediate spermatogenic commitment are not currently 
known but some characteristics can be determined from experimental 
observations.  Recently, some have hypothesised that instead of the developing 
testes providing a signal, the intact testis cords act as an epithelial barrier to 
diffusible pro-meiotic signals, such as RA (Koubova et al., 2006).  This 
hypothesis is supported by experiments in which cord formation was perturbed 
by dis-aggregation and re-aggregation of E11.5 XY gonads, which resulted in 
meiotic entry of the XY GCs (McLaren and Southee, 1997).  However, several 
other observations suggest testis cords are not required to either protect GCs 
from pro-meiotic signals or to transmit potential anti-meiotic signals.  
Spermatogenic GCs have been found in XY gonads in which cord formation was 
perturbed by cyclopamine treatment (Yao and Capel, 2002) or removal of the 
mesonephros (Buehr et al., 1993).  Others have observed spermatogenic GCs 
outside of the cords in the interstitial areas of the testes and even in the 
mesonephroi (McLaren, 1983).  Therefore, it appears that cord formation is not 
required for the anti-meiotic influence of the testis.  Furthermore, assuming that 
they originate from the XY gonad, any such anti-meiotic signals are probably 
diffusible, because GCs found in the male mesonephros are able to receive it and 
develop as spermatogonia, whereas GCs found in the female mesonephros enter 
meiosis (McLaren, 1984).  This fits nicely with the data indicating that 
masculinising signals from an XY gonad induce mesonephric cell migration, 




Recent work suggests that the masculinisation signals causing GC 
spermatogenic commitment are secreted by Sertoli cells into adjacent GCs.  
Sertoli cells are specialised secretory cells that express secretory markers and 
contain secretory granules (Best et al., 2008), and are known to actively secrete 
proteins such as Ptgds (Samy et al., 2000).  Re-aggregate culture of E11.5 XX 
genital ridges with a perinatal Sertoli cell line results in mitotic arrest of 75% of 
the observed GCs (Best et al., 2008), although this might be due to a detrimental 
effect of the Sertoli cell line on survival of meiotic GCs committed to oogenesis 
rather than sex-reversal of the GCs.  More compelling was data showing 
transient treatment of E11.5 XY genital ridges with brefeldin A, a reversible 
inhibitor of secretion, which resulted in meiotic entry of a proportion of the XY 
GCs (Best et al., 2008), despite them still being enclosed in testis cords 
surrounded by Amh-expressing Sertoli cells.  This work showed that secretion 
of masculinising factors in XY genital ridges at a specific time point is critical for 
mitotic arrest and spermatogenic commitment of bipotential GCs, and Sertoli 
cells, being specialised secretory cells and in direct contact with the GCs, are a 
likely source for it. 
In vitro evidence suggests that the cytokine LIF is a potential anti-meiotic 
signaling molecule.  In vitro treatment of E11.5 GCs with LIF or oncostatin M, 
another interleukin-6 cytokine, inhibits their expression of meiotic markers and 
progression through meiosis I (Chuma and Nakatsuji, 2001; Farini et al., 2005) 
and Lif mRNA is also expressed more highly in E13.5 male genital ridges 
compared to female genital ridges (Chuma and Nakatsuji, 2001).  However, LIF- 
and oncostatin M- treatment enhanced the proliferation of GCs rather than 
triggering mitotic arrest (Chuma and Nakatsuji, 2001), so the observed anti-
meiotic effect may simply be a consequence of a mitogenic effect of these 
growth factors.  Additionally, LIF transforms cultured GCs into ESC-like 
embryonic germ cells (Matsui et al., 1992), which actively proliferate in vitro, 
indicating that the anti-meiotic of LIF is probably due to diversion of GCs 
towards some other developmental state rather than commitment to 




in GCs are incompatible with meiotic entry, or it might be that the GCs do not 
enter meiosis because this IL-6 signaling does not allow them to enter a post-
mitotic state.  Whatever the case, Lif signaling is not required in vivo for male GC 
development, because Lif knockout male mice are fertile (Stewart et al., 1992).  
Additionally, knockout of Gp130, the shared interleukin-6 receptor, had no effect 
on fertility of male mice (Molyneaux et al., 2003).  However, these knockouts did 
have reduced numbers of male, but not female, GCs at E13.5, indicating that 
Gp130 signaling sex-specifically enhances in vivo survival and/or proliferation 
of male GCs, shortly after or during their spermatogenic commitment. 
 
Molecular Consequences of Sex-specific GC Differentiation 
Advances in molecular analysis techniques are now allowing us to probe in 
more detail what is occurring in mitotically arrested male GCs and early meiotic 
female GCs.  These sex-specific molecular differences not only allow rapid 
identification of spermatogenic or oogenic commitment, but also give us insight 
into both the upstream events triggering sex-specific commitment and the 
downstream mechanisms mediating meiotic initiation or mitotic arrest. 
Meiotic entry of XX GCs from E13.5 is followed by the expression of several 
meiotic markers.  Immunostaining for Sycp3, a component of the synaptonemal 
complex, is seen in both XX and XY E13.5 GCs as clumps of expression in the 
nucleus (Di Carlo 2000).  However, by E14.5, Sycp3 is expressed in XX GCs sex-
specifically, as XY GCs downregulate Sycp3 (Di Carlo et al., 2000), and high level 
immunostaining for Sycp1, another synaptonemal complex protein, appears in 
an anterior to posterior wave (Yao et al., 2003).  Sycp1 immunostaining at 
E14.5-E15.5 is seen as thread-like structures as the axial elements form along 
the condensed prophase chromosomes (Di Carlo et al., 2000; Yao et al., 2003).  
γ-H2AX, a marker for DNA double-strand breaks that occur in meiotic prophase 
I,  is detected in a similar dynamic wave of expression from E14.5 in XX GCs (Yao 




Stra8 and Nanos2 are required for the initiation of meiosis or maintenance of 
mitotic arrest, respectively.  Stra8 is expressed specifically in pre-meiotic GCs, 
including embryonic XX GCs from E12.5 to E16.5, in an anterior-posterior wave 
similar to and slightly preceding the waves of upregulation of the meiotic 
marker Dmc1 (Menke et al., 2003); and pre-meiotic and early prophase 
spermatogonia in postnatal testes (Oulad-Abdelghani et al., 1996).  Stra8 is 
required for meiotic initiation and/or progression into meiotic prophase for 
female GCs at E13.5-E15.5 (Baltus et al., 2006) and for meiotic prophase 
progression in male GCs in the adult (Mark et al., 2008), as displayed in Stra8 
knockout gonads.  In the embryonic Stra8 knockout ovary, XX GCs have pre-
leptotene nuclear morphology similar to wildtype GCs.  However, after E13.5 
the GCs fail to progress through further stages of prophase I.  At E14.5-E15.5 in 
the knockout ovaries, no GCs are seen with the typical leptotene or zygotene 
nuclear morphology that is seen after standard histological staining or Sycp3 or 
Rec8 immunostaining of wildtype GCs.  Additionally, an absence of intense γ-
H2AX immunostaining at E15.5 shows that DNA double-strand breaks do not 
occur in GCs in the knockout ovaries.  Finally, it was also suggested that the GCs 
in the knockout ovaries do not undergo pre-meiotic DNA synthesis because at 
E13.5-E15.5 the knockout GCs have DAPI staining intensity consistent with 2n 
rather than 4n nuclei, which is seen in wildtype meiotic GCs at E15.5.  RA is 
purported to be the upstream signal that stimulates Stra8 expression in 
embryonic XX GCs (Bowles et al., 2006), because of RA’s ability to stimulate 
Stra8 transcription in GCs (Best et al., 2008; Bowles et al., 2006; Oulad-
Abdelghani et al., 1996).  However, it is still not clear whether it is RA, an 
unidentified external signal or an intrinsic cell-autonomous trigger that 
operates in vivo to activate Stra8 expression and initiate meiosis in E12.5/E13.5 
XX GCs. 
Nanos is one of several RNA-binding proteins that have essential conserved 
roles in GC development.  In mice there are 3 Nanos genes, and Nanos2 is male-
specifically upregulated in GCs at E12.5/E13.5 shortly following spermatogenic 




but devoid of GCs, whereas females are viable and fertile (Tsuda et al., 2003).  
Loss of GCs in the testes of knockout XY mice begins after E14.5 when an 
increase in apoptotic GCs is observed, and a complete loss of spermatogenic GCs 
in postnatal testes ensues.  Apoptotic loss of GCs in the testes of Nanos2 
knockout mice prevented the analysis of the developmental state of these GCs.  
However, additional knockout of Bax2 prevented this apoptotic loss (Suzuki and 
Saga, 2008).  Molecular analysis of embryonic knockout testes in Nanos2/Bax2 
double knockout mice found that the GCs appeared to commit to 
spermatogenesis and did not enter meiosis, similar to wildtype XY GCs, at E12.5-
E13.5.  However, 2 days later they became positive for phospho-H3 
immunostaining at E15.5, indicating their re-entry into the cell cycle.  
Furthermore, the GCs also upregulated the early meiotic markers Stra8 and 
Sycp3 at E15.5 and had zygotene and pachytene Sycp3 immunostaining by 
E17.5, indicating their entry and progression through prophase I of meiosis.  
Conversely, ectopic expression of Nanos2 in XX GCs cell-autonomously 
prevented Stra8 transcription, Stra8 protein expression and synaptonemal 
complex formation and instead resulted in positive immunostaining for the 
male-GC-specific markers H3K9me2, Tudor-domain containing 1 (Tdr1d) and 
Dnmt3L, without affecting neighbouring XX GCs (Suzuki and Saga, 2008).  These 
experiments clearly show that Nanos2 prevents meiotic entry and maintains 
mitotic arrest of spermatogenic GCs in vivo, possibly by inhibiting Stra8 
expression.  Nanos2 must function downstream of any putative masculinising 
signals operating at E12.5 because the male GCs still appear to commit to 
spermatogenesis and arrest mitotically between E12.5 and E15.5 and because 
Nanos2 expression does not appear in wildtype XY GCs until after their 
spermatogenic commitment.   
By E13.5, GCs in male and female gonads are entering very different stages of 
the cell cycle.  One recent study looked at the expression patterns of certain cell-
cycle genes and proteins in purified spermatogenic XY GCs and compared that 
with expression in XX GCs for some markers (Western et al., 2008).  They found 




cell cycle except G0, concomitantly with their entry into mitotic arrest, 
suggesting that the XY GCs complete any initiated cell cycles when they receive 
the masculinising signals at E11.5-E12.5, before exiting the cell cycle in G0.  At 
E12.5 XY GCs have hyperphosphorylated retinoblastoma protein (Rb), which 
when hyperphosphorylated stimulates cells to enter S phase, but between E12.5 
and E13.5 Rb becomes dephosphorylated into its hypophosphorylated inactive 
form.  This is not surprising given the fact that XY GCs arrest mitotically at this 
time, but provides one possible mechanism by which XY GCs are induced into 
mitotic arrest.  In contrast XX GCs maintain their Rb in its hyperphosphorylated 
form.  By E15.5 XY GCs do not express detectable levels of Rb protein, 
suggesting that the XY GCs enter a more quiescent state, although presence or 
absence of the p107 and p130 pocket proteins, which can stimulate cell cycle 
entry in place of Rb, is not known.  XY GCs sex-specifically express the p21 and 
p27 cyclin-dependant kinase inhibitors at the protein level between E12.5 and 
E15.5, which might explain the rapid dephosphorylation of Rb and mitotic exit.  
The masculinising signals that cause XY GCs to commit to spermatogenesis 







Figure 1.4.2.  Summary of Expression of GC-expressed Genes Between E10.5 and E15.5.  Solid grey lines represent expression by bipotential GCs. 
When male GCs commit to spermatogenesis at E12.5, the solid lines split into blue and pink, representing expression by male or female GCs, 
respectively. Where solid lines begin at the top with a dashed line, this indicates expression turning on, and expression has been shown to be 
undetected at the stage(s) prior to this switching on. Conversely, dashed ends at the bottom of a line represent expression turning off, and 
expression has been shown to be undetected at the stage(s) following this switching off.  Where lines begin or end in a solid line, expression was 
either not studied for prior/following stage(s) or the data is not shown on this diagram. For example, pRB expression before E12.5 was not studied. 





Gene Known Function (if any) 
Nanog Maintains GC pluripotency 
Stella Maintains GC pluripotency 
Oct4 Maintains GC pluripotency 
Mvh Maintains proliferation and differentiation of 
GCs during embryogenesis 
Dazl Survival factor for GCs and promotes 
differentiation 
Nanos2 Spermatogenic GC survival and maintenance of 
mitotic arrest in embryonic spermatogonia 
Nanos3 Unknown 
Stra8 Meiotic induction of female GCs 
Sycp3 Component of the synaptonemal complex in 
meiotic GCs 
H2ax Marker for double-strand breaks in meiosis 
Rb Cell cycle control/unknown in GCs 
p27 Inhibits the cell cycle/unknown in GCs 
p21 Inhibits the cell cycle/unknown in GCs 
Table 1.4.1 Functions of GC-expressed Genes (where known). 
 
Concluding Remarks On the Control of Sex-specific GC Differentiation 
Despite recent advances there are still many questions that remain to be 
answered when it comes to our understanding of the intracellular mechanisms 
controlling the commitment of E11.5-E13.5 GCs to spermatogenesis or 
oogenesis.  Stra8 definitely appears to be required for the initiation of meiosis in 
female E13.5-E15.5 GCs (Baltus et al., 2006).  Many now believe RA induces 
Stra8 expression and meiosis in this system, but critical interpretation of all the 
available data suggests that RA is not the in vivo factor stimulating Stra8 




molecular events that do regulate sex-specific Stra8 expression in female GCs?  
Examination of the Stra8 promoter region and sex-specific expression analyses 
of transcription factors in E13.5 GCs may yield some candidates.  Another very 
large question that remains to be answered is how does Stra8 initiate meiosis in 
female GCs?  Stra8 appears to be confined to vertebrate species (Baltus et al., 
2006), contains a putative helix-loop-helix domain (Baltus et al., 2006), 
suggesting that it may be a transcription factor, and is a phosphoprotein (Oulad-
Abdelghani et al., 1996).  However, at present not much else is known in terms 
of the functional aspects of Stra8. 
On the other side of the coin, progress has been made towards understanding 
the signals mediating spermatogenic commitment and mitotic arrest of male 
GCs by E12.5.  The masculinising signals are likely to be secreted factors (Best et 
al., 2008), but the identity of those factors is not yet known.  Additionally, we 
know the consequences of those signals – mitotic arrest associated with Rb 
hypophosphorylation and CDKI expression (Western et al., 2008), but what are 
the intracellular events mediating these effects?  Much is known about the 
control of these cell cycle events in somatic cells (Satyanarayana and Kaldis, 
2009), and one class of proteins known to be involved are the tissue-specific 
basic helix-loop-helix transcription factors (Zebedee and Hara, 2001), which are 




1.5. Lipocalin-type Prostaglandin D2 Synthase 
(Ptgds) 
 
One particular gene known to be expressed in the GCs in a sex-specific manner 
shortly after sex-specific commitment is Ptgds, which is expressed male-
specifically in gonads from E11.5 in Sertoli cells and GCs (Adams and McLaren, 
2002)  Not only is Ptgds expressed sex-specifically, but Ptgds and its enzymatic 
product prostaglandin D2 (PgD2) have both been shown to have masculinising 
effects on bipotential gonad cells (Adams and McLaren, 2002; Moniot et al., 
2009; Wilhelm et al., 2005), but its role in spermatogenically-committed GCs has 
not been explored. 
 
1.5.1. Prostaglandin D2 (PgD2) 
 
PgD2 is an extracellular paracrine and autocrine signalling molecule with 
diverse roles in nociception (Eguchi et al., 1999), sleep control (Huang et al., 
2007), inflammation (Harris et al., 2002), reproduction (Saito et al., 2002) and 
embryonic testis development (Adams and McLaren, 2002; Wilhelm et al., 
2005).  Prostaglandin H2 is the general substrate for generation of 
prostaglandins, including PgD2, and COX1 and COX2 catalyse its production 
from arachidonic acid (Kostenis and Ulven, 2006; Urade and Hayaishi, 2000).  
PgD2 can itself be metabolised, both enzymatically and non-enzymatically, into 
various products (Kostenis and Ulven, 2006; Urade and Hayaishi, 2000), 
including the F and J prostaglandins, which have biological activity and possible 
in vivo roles (Urade and Hayaishi, 2000). 
PgD2 has 2 main receptors, both of which are G-protein-coupled (Kostenis and 
Ulven, 2006).  The first and most well-studied, DP1, is linked to Gs subunits, and 




in cellular cAMP levels, (Boie et al., 1995) which can activate PKA.  The DP1 
receptor is widely expressed in a variety of tissues (Kostenis and Ulven, 2006), 
and its in vivo roles include vasodilation and anti-inflammation effects (Kostenis 
and Ulven, 2006) as well as promoting Sertoli-cell differentiation in embryonic 
gonads (Adams and McLaren, 2002; Malki et al., 2005; Wilhelm et al., 2005).  
The second, less well-studied, receptor for PgD2 is the CRTH2 receptor, the 
expression of which is restricted to hematopoietic cells (Kostenis and Ulven, 
2006).  CRTH2 is coupled to Gi subunits and therefore CRTH2-mediated 
signalling results in decreased cellular cAMP and increased intracellular Ca2+ 
levels.  CRTH2-mediated signalling is heavily implicated in immune cell 
behaviour and is pro-inflammatory (Kostenis and Ulven, 2006). 
 
1.5.2. In Vivo Roles of Ptgds 
 
Ptgds, also known as Brain-type or glutathione-independent Prostaglandin D2 
Synthase or Beta-trace (human), is one of 2 enzymes that catalyses the 
production of PgD2 from PgH2.  Hematopoietic Prostaglandin D2 Synthase 
(Hpgds) is the other enzyme and is functionally and evolutionary diverse from 
Ptgds (Urade and Hayaishi, 2000).  Hpgds will not be discussed further. 
Ptgds is a bifunctional protein that binds to biologically active lipophilic 
molecules as well as catalyses the production of PgD2.  The catalytic functions of 
Ptgds require the presence of free sulfhydryl compounds such as glutathione, β-
mercaptoethanol, dithiothreitol, cysteine or cysteamine (Urade and Hayaishi, 
2000).  The lipophilic molecules Ptgds can bind to include retinoic acid (RA), 
thyroid hormone, bile acids and testosterone (Beuckmann et al., 1999; Tanaka 
et al., 1997), all of which have important biological roles.   
It is unclear, i.e. it has not been shown directly, when Ptgds functions as a PgD2-
producing enzyme and when it functions as a lipophilic molecule binding 




and the co-expression of certain genes. In certain cells, such as perivascular cells 
of the meninges, Ptgds is co-expressed with COX2 (Beuckmann et al., 1999), 
suggesting that in these cells Ptgds produce PgD2.  In arachnoid trabecular cells, 
Ptgds immunostaining localised to nuclear envelopes, Golgi and secretory 
vesicles, suggesting that these cells secrete Ptgds.  Secretion of Ptgds protein has 
also been detected in a number of cell types (Urade and Hayaishi, 2000), 
including Sertoli cells (Samy et al., 2000).  On the other hand, meningeal 
macrophages express Ptgds in lysosomes, so these cells may endocytose 
extracellular Ptgds.   
What is known is that binding of lipophilic molecules by Ptgds results in 
inhibition of Ptgds catalytic activity in in vitro assays (Beuckmann et al., 1999; 
Tanaka et al., 1997), suggesting that Ptgds cannot simultaneously perform both 
functions.    
Ptgds knockout mice are viable and fertile (Eguchi et al., 1999), but display a 
number of abnormal behavioural phenotypes, involved in sleep (Huang et al., 
2007) and nociceptive (Eguchi et al., 1999) behaviours.  PgD2 is involved in 
these behaviours (Urade and Hayaishi, 2000), suggesting that these behavioural 
phenotypes are caused by loss of PgD2-production by Ptgds.  Ptgds also has a 
role in augmenting mouse embryonic testis development, which becomes 
apparent when Ptgds is knocked out on a C57BL/6 genetic background (Moniot 
et al., 2009).  This role of Ptgds is also attributable to PgD2-production by Ptgds, 
as shown by the masculinising effects of PgD2 on bipotential gonad somatic cells 
(Adams and McLaren, 2002; Wilhelm et al., 2005).  Other reproductive and 
neuronal roles have been postulated for Ptgds, due to its high expression in 
certain tissues and fluids such as seminal plasma (Saito et al., 2002) and 
cerebro-spinal fluid (Hoffmann et al., 1993).  There are several papers showing 
that the lipocalin function of Ptgds does have in vivo roles, although these are 






1.5.3. Role of Ptgds in Embryonic Testis Development 
 
Ptgds is expressed in various parts of the mammalian male reproductive tract. 
The earliest observed expression in the mouse gonad occurs male-specifically in 
the early stages testis development at E11.5, shortly following the burst of Sry 
expression in the embryonic XY gonad (Adams and McLaren, 2002).  Ptgds 
expression continues in the embryonic gonad, with mRNA expression being 
clearly restricted to the testis cords in E13.5 testis (Adams and McLaren, 2002), 
and Ptgds immunoreactivity present in Sertoli cells and some GCs in E12.5 
testes (Moniot et al., 2009).  This early male-specific Ptgds expression following 
Sry induction is also observed at the same developmental time point in the 
developing chicken testis (Moniot et al., 2008), and Ptgds mRNA is also detected 
in embryonic testis and epididymis of sheep (Fouchecourt et al., 2003), 
suggesting conserved functions for Ptgds in embryonic testis development.   
Despite being expressed at high levels in embryonic testes from E11.5, Ptgds 
expression is limited to Sertoli cells and GCs (Adams and McLaren, 2002).  Ptgds 
protein expression is also limited to these cell types in the E13.5 testes (Moniot 
et al., 2009), with the highest expression in Sertoli cells, and only some GCs 
expressing detectable Ptgds protein.  Similarly, Ptgds mRNA expression is not 
always detected at high levels in GC cytoplasm (Wilhelm et al., 2007), and this 
suggests that mRNA expression levels in male GCs are lower than in Sertoli cells 
at E13.5.  This mirrors the situation in 20-day-old juvenile rats, in which Sertoli 
cells express roughly 3-fold higher levels of Ptgds protein than GCs from the 
same animals (Samy et al., 2000). 
Recent work by several groups has now more fully described the role Ptgds 
plays in embryonic testis development.  Adams & McLaren first demonstrated a 
role for PgD2 in embryonic gonad development when they partially 
masculinised XX bipotential gonads in organotypic culture with PgD2 (Adams 
and McLaren, 2002).  This partial masculinisation is characterised by Amh-




prospermatogonial germ cells and cells with Sertoli- and peritubular myoid-like 
characteristics arranged in disorganised testis cord-like structures (Adams and 
McLaren, 2002).  Further work by other groups showed that inhibition of PgD2 
signalling through the DP1 receptor prevents the recruitment of a small 
population of E12-E13.5 XX non-Sry-expressing cells to a Sertoli cell fate when 
they are cultured with identically-staged XY embryonic gonadal cells (Wilhelm 
et al., 2005).  A similar recruitment of non-Sry-expressing XX cells to Sertoli cell 
fate also occurs when XX embryonic gonadal cells are exposed to XY embryonic 
gonadal cells in embryonic XX-XY chimaeric gonads (Palmer and Burgoyne, 
1991), suggesting that PgD2 signalling through the DP1 receptor might be partly 
responsible for this in vivo phenomenon. 
The ability of PgD2/DP1 signalling to masculinise XX and probably XY non-Sry-
expressing gonadal cells to a Sertoli cell fate is due to at least 2 downstream 
effects.  Firstly, PgD2/DP1 signalling stimulates Sox9 mRNA and protein 
expression, and this has been shown for ovarian cancer cells (Malki et al., 2007), 
as well as cultured XX gonadal cells (Malki et al., 2005).  Secondly, PgD2/DP1 
signalling induces nuclear import of Sox9 protein, possibly by activation of PKA-
mediated Sox9 phosphorylation (Malki et al., 2005; Wilhelm et al., 2005).  
Increased expression and nuclear localisation of Sox9 protein in embryonic 
gonadal cells results in the differentiation of these cells as Sertoli cells, as shown 
by Amh expression (Adams and McLaren, 2002). 
Ptgds expression in Sertoli cells of E11.5-E13.5 testes is due to transcriptional 
activation by direct recruitment of Sox9 to the Ptgds promoter (Wilhelm et al., 
2007).  In C57BL/6 mice, which are more sensitive to perturbations in testis 
determination due to a delay in testis development (Eicher and Washburn, 
1986; Eicher et al., 1996), Ptgds knockout results in decreased Sox9 protein 
expression and nuclear localisation in E11.5-E13.5 testis (Moniot et al., 2009), 
identically to what occurs with DP1 antagonism of sex reversal of XX gonadal 
cells in organotypic cultures (Malki et al., 2005).  This suggests that PgD2, 
generated by Ptgds, induces a small proportion of Sertoli cells in embryonic 




This Ptgds/PgD2 masculinisation pathway is a secondary mechanism, at least in 
most, especially outbred, mouse strains (Moniot et al., 2009), and is conserved 
in non-mammalian chordates such as birds (Moniot et al., 2008).  The main 
pathway of testis-determination in mammals is cell autonomous Sox9 induction 
by Sry, which drives differentiation of the majority of Sertoli cells (Sekido et al., 
2004; Wilhelm et al., 2007).  Ptgds recruits a small number of non-Sry-
expressing somatic cells to a Sertoli cell fate (Wilhelm et al., 2005), and this 
small population of cells may correspond to the ~10% of XX Sertoli cells in the 
testes of XX-XY chimaeric mice (Palmer and Burgoyne, 1991).  This is why 
removal of Ptgds in C57BL/6 mice only results in a delay, rather than a complete 
block, in testis development (Moniot et al., 2009). 
 
1.5.4. Control of Ptgds Gene Transcription 
 
A variety of compounds and transcription factors positively or negatively 
regulate Ptgds expression in certain cell types.  Dexamethasone and other 
glucocorticoid receptor agonists are reported to stimulate Ptgds mRNA and 
protein expression in mouse neuronal cells, rat cardiomyocytes and in rat heart 
in vivo (Garcia-Fernandez et al., 2000; Tokudome et al., 2009), while estrogen 
increased Ptgds mRNA and protein levels in hearts of treated rats (Otsuki et al., 
2003).  Several groups have shown that thyroid hormone treatment in 
rhabdomyosarcoma cells increases Ptgds expression (White et al., 1997), while 
Ptgds expression is reduced in brains of hypothyroid rats (Garcia-Fernandez et 
al., 1998).  The actions of estrogen and thyroid hormone can be explained by the 
binding of activated estrogen (Otsuki et al., 2003) and thyroid hormone (White 
et al., 1997) receptors at specific  response elements in the Ptgds promoter.  The 
effects of dexamethasone and glucocorticoids may be indirect because direct 
receptor binding, or even the presence of a glucocorticoid response element, in 





TPA, an activator of PKC, has been shown to both negatively and positively 
regulate Ptgds expression, in conjunction with other factors.  TPA negates the 
positive effects of dexamethasone on Ptgds expression in mouse neuronal cells 
by unknown mechanisms (Garcia-Fernandez et al., 2000).  Conversely, PKC 
activation was shown to de-repress negative inhibition of Ptgds expression in 
human neuronal cells imposed by the Hes1 bHLH protein (Fujimori et al., 2005). 
Fujimori et al showed that Hes1 binds at an N-box in the Ptgds promoter to 
inhibit transcription (Fujimori et al., 2005), while transcriptional activation of 
Ptgds requires binding of AP2beta to an AP2 element in the Ptgds promoter 
(Fujimori et al., 2005; Fujimori and Urade, 2007).  A number of other 
transcription factors have been shown to regulate Ptgds expression, have 
binding sites in the Ptgds promoter and/or have been shown to bind directly to 
Ptgds promoter elements.  These include NF-κB (Fujimori et al., 2003) and Sox9 
(Wilhelm et al., 2007) and as well as several bHLH transcription factors such as 
Mitf (Takeda et al., 2006), Srebf1 (Fujimori and Urade, 2007) and Usf1 (Fujimori 
et al., 2008; Fujimori and Urade, 2007).   
Sox9 is believed to drive male-specific Ptgds expression in mouse embryonic 
gonads, because Sox9 binds to the Ptgds promoter in vivo in E11.5 male, but not 
female, gonads, while Ptgds expression begins at around E11.5 (Wilhelm et al., 
2007).  Because Sox9 is expressed specifically by Sertoli cells in embryonic 
testes, this drives Sertoli-cell-specific expression of Ptgds.  However, Ptgds 
mRNA is detectable in E13.5 male GC cytoplasm (Adams and McLaren, 2002) 
and Ptgds protein is also detected in GCs of embryonic male E12.5 gonads 
(Moniot et al., 2009).  Sox9 is not expressed in GCs, therefore, Sox9-independent 




1.6. Aims of the Research 
 
Until recently, sex-specific markers for GCs at the earliest stages of sex-specific 
differentiation (i.e. E12.5/E13.5) have been lacking.  In the last 10 years or so, 
this has changed.  We have discovered several sex-specific markers.  Using these 
markers, we can now begin to discern the molecular events that control and 
achieve the very diverse sex-specific cellular fates occurring in male and female 
GCs at his early stage.  It is likely that many more unidentified genes are also 
involved.  In order to discover some of these unknown genes I carried out an 
RtPCR expression screen comparing male and female E13.5 GC cDNA.   
I decided to analyse sex-specific gene expression at E13.5 for several reasons.  
Firstly, at E13.5, both male and female GCs are committed to their respective 
differentiation programs – spermatogenesis or oogenesis, respectively.  Analysis 
of differences at E12.5 would only identify gene expression changes that occur 
in male GCs as a result of male commitment.  I desired to identify bHLH genes 
involved in male and female commitment events, the latter of which would not 
likely be present at E12.5.  In addition, the increased numbers of GCs at E13.5 
make performing an expression screen much less problematic than analysis of 
E12.5 material.  The most upstream gene expression changes associated with 
spermatogenic commitment of male GC are likely to first occur at E12.5.  
Therefore, a limitation of analysing sex-specific expression differences at E13.5 
rather than at E12.5 is that some of these male-specific expression differences 
could be missed if they quickly decline by E13.5.  However, for the reasons 
stated earlier in this paragraph, I chose E13.5 as the time-point to study, and it 
was hoped that at least some of the earliest male-specific changes in gene 
expression persist until at least E13.5 and could be identified in the screen. 
Rather than carrying out a genome-wide screen, I decided to specifically analyse 
the 114 genes belonging to the bHLH family of transcription factors.  There 
were two reasons for this.  Firstly, previous studies have characterised the 




GC development so it is possible that other bHLH proteins are involved in the 
earliest stages of sex-specific GC development.  Secondly, we previously 
identified that female GCs sex-specifically express Id1 mRNA at E13.5.  Id1 is a 
dominant negative bHLH, so it was theorised that female GCs express Id1 
protein to ensure negative regulation of one or more unknown bHLH proteins 
that promote male-specific GC development.  Therefore, this screen might 
identify these bHLH proteins, if they are expressed male-specifically at the 
mRNA level in E13.5 GCs.  Another limitation of this screen is that it could not 
identify Id1-supressed bHLH proteins whose mRNA is expressed equally in both 
male and female GCs at E13.5. 
The screen identified a number of bHLH genes that were potentially sex-
specifically expressed by E13.5 GCs.  The second aim of the research was 
therefore to determine whether these potential genes, along with Ptgds, which 
was previously identified as being male-specifically expressed in E13.5 GCs, 
were in fact sex-specifically expressed by GCs, and not some other gonadal cell 
type contaminating the GC cDNAs used in the screen.  I used two methods to 
accomplish this.  Firstly, I carried out PCR on cDNA libraries prepared from 
single male and female GCs to identify whether Id1, Id2 and Id3 (female-specific)  
and/or Ptgds (male-specific)  mRNAs were expressed by E13.5 GCs.  Secondly, I 
used immunofluorescence staining against Id1 (female-specific) and Mnt and 
Ptgds (male-specific) to identify whether E13.5 GCs expressed these proteins 
sex-specifically. 
The third aim of the research was to use these sex-specific markers as a tool to 
discover potential upstream molecular events controlling the early stages of 
sex-specific GC development.  Towards this aim, I identified signalling pathways 
that previous studies have shown to affect Ptgds expression, either positively or 
negatively.  I then attempted to activate or repress Ptgds expression in female or 
male GCs, respectively, by treating genital ridges with compounds to activate 
these pathways.  If one or more of these compounds successfully activated Ptgds 




sex-reversal, thereby identifying potential signaling pathways controlling 
male/female GC fate commitment. 
Mnt protein was found to be male-specifically enriched in E13.5 GCs in this 
study.  Mnt belongs to the bHLH-ZIP class of bHLH proteins and suppresses Myc 
transcriptional activity.  Due to Myc’s involvement in activation of DNA 
synthesis, it was theorised that Myc could be acting in female GCs to activate 
genes for pre-meiotic S-phase and that male GCs expressed Mnt to suppress this 
activity and bring about mitotic arrest in male GCs.  Therefore, a potential fourth 
aim of this research was to analyse by cross-linking immunoprecipitation 
whether Myc and/or Mnt occupy certain cell cycle gene promoters differently in 
E13.5 male and female GCs.  Unfortunately, due to time constraints, the cross-






Chapter 2:  




2.1. Animals and Tissue Dissection 
 
Outbred CD1 mouse embryos were used unless otherwise stated.  CD1 mice 
were naturally mated with the day of appearance of a vaginal plug counted as 
E0.5 (0.5 days post coitum).  Generation of Oct4-GFP transgenic mice was 
carried out by others (Yoshimizu et al., 1999).  These mice possess a transgene 
consisting of an 18kb region of the Oct4 locus (GOF-18) containing EGFP 
(Enhanced Green Fluorescent Protein) in place of the Oct4 coding region and the 
critical upstream and downstream regulatory elements.  Expression of the 
transgene closely mimics the expression pattern of the endogenous Oct4 gene.  
Homozygous Oct4-GFP male studs of mixed genetic background were generated 
from embryos donated by Hans Scholer.  To confirm the homozygosity of the 
transgene in the studs, the studs were crossed with wildtype CD1 female mice 
and transmission of the transgene identified by green fluorescent GCs in E13.5 
genital ridges in the resultant heterozygous embryos.  To generate embryos for 
experimentation, the studs were crossed with CD1 female mice to produce 
heterozygote Oct4-GFP embryos, which were treated identically to wildtype 
embryos.  Wildtype and Oct4-GFP embryonic gonads were dissected into PB1 
media on ice.  E11.5 gonads were sexed by PCR as described below, while E12.5 
and older gonads were sexed according to the gonad appearance.   
XYTdym1 and XXSry embryos were generated as described previously (Durcova-
Hills et al., 2004).  Males with an MF1 random-bred (NIMR stock) background 
carrying the Sry deletion Tdym1 and complemented by an autosomally located 
Sry transgene were mated at the National Institute for Medical Research to MF1 
or 129/SvEv-Gpi1c to generate XX and XYTdym1 female and XXSry and XYTdym1Sry 
male embryos, from which gonads were dissected at E13.5 and processed for in 






2.2. Sexing of E11.5 Embryos 
 
For dissected E11.5 genital ridges, the corresponding heads of the embryos 
were sexed using PCR against the Uba1 and Ube1y1 genes as used previously 
(Chuma and Nakatsuji, 2001).  PCR against Uba1 on the X chromosome and 
Ube1y1 on the Y chromosome, using a common pair of primers, results in 2 
products that differ in length by 19 nucleotides.  The heads were boiled for 
10mins in 0.5ml dH2O, triturated and spun down at 13’000rpm in a 
microcentrifuge for 5mins to crudely isolate genomic DNA into the supernatant.  
2μl of the supernatant was added to PCR reactions with the final concentrations: 
1x PCR Buffer (Invitrogen), 2.0mM MgCl2, 0.4mM dNTPs, 1.0μM Ube1XA (5’-
TGGTCTGGACCCAAACGCTGTCCACA-3’) and Ube1XB (5’-
GGCAGCAGCCATCACATAATCCAGATG-3’) primers.  The samples were run on a 
PCR cycler with the following program: 95˚C for 2mins, followed by 30 cycles of 
95˚C for 30s and 68˚C for 1min.  Products were visualised by agarose gel 
electrophoresis. 
 
2.3. Oct4-GFP Gonad Microscopy 
 
E13.5 Oct4-GFP genital ridges were dissected the same as wildtype genital 
ridges.  Microscopy was performed on a stereo microscope equipped with a CCD 
camera.  Brightfield and GFP fluorescence image were taken of the same gonad.  







2.4. Generation of Purified GC PolyA+ mRNA 
 
E13.5 Oct4-GFP genital ridges were trypsinised and triturated, spun down at 
5’000rpm for 5mins in a microcentrifuge and the pellet resuspended in PB1 
media containing 4mg/ml BSA.  The cell suspensions were kept on ice until 
fluorescence-activated cell sorting using a FACSVantage SE Cytometer (BD 
Macrosort) operated by a PC running FACSDiva software (BD Macrosort).  GCs 
were sorted using 2 gates: 1 gate measuring GFP fluorescence and another gate 
measuring size/shape by side/forward scattering of light.  After sorting, small 
aliquots were processed for alkaline phosphatase staining and the remainder 
spun down at 5000rpm for 5mins, the supernatant aspirated and the pellet 
frozen on dry ice before storage at -20˚C. 
PolyA+ mRNA was prepared from the purified GC pellets using Dynabeads 
mRNA DIRECTTM Micro Kit (Invitrogen) as per the manufacturer’s instructions 
except taking the beads through the protocol one more time after the first 
elution.  The resulting mRNA was stored at -20˚C or reverse transcribed 
immediately.  cDNA was prepared as described for gonad cDNA. 
 
2.5. Alkaline Phosphatase Staining of Purified 
GCs 
 
Aliquots of freshly-purified GCs were allowed to attach to slides for 5mins 
before fixing with 4% formaldehyde at room temperature for 2mins and 
washing 3 times with PBS.  GCs were then equilibrated in NTMT (100mM NaCl, 
100mM pH9.5 TrisHCl, 50mM MgCl2, 1% Tween-20) for 10mins before addition 
of 4.5μl/ml of 50mg/ml 4-nitro blue tetrazolium chloride (NBT) and 3.5μl/ml of 
50mg/ml 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) stock solutions.  




washed several times with PBS once GCs showed obvious dark purple stain then 
incubated in PBS containing DAPI, washed with PBS and coverslips applied.  
 
2.6. Whole-gonad and Whole-Embryo cDNA 
Preparation 
 
E13.5 male and female gonads were trypsinised and triturated, spun down at 
5’000rpm for 5mins in a microcentrifuge and the pellet resuspended in TRI 
Reagent (Sigma).  Whole embryos were homogenised using a hand held 
electronic homogeniser, trypsinised and triturated then homogenised in TRI 
Reagent.  RNA was extracted according to the TRI Reagent manufacturer’s 
instructions (Sigma), resuspended in dH2O and RNA concentration measured 
using a spectrophotometer.  cDNA was prepared using Superscript III 
(Invitrogen) according to the manufacturer’s instructions. 
 
2.7. Generation of Single-cell cDNA Libraries 
 
Single-cell cDNA libraries were prepared as described previously (Brady and 
Iscove, 1993) with changes made to allow detection of expression by gene-
specific PCR.  E13.5 male and female gonads were dissected away from 
mesonephroi, trypsinised and triturated, spun down at 5’000rpm for 5mins in 
an Eppendorf microcentrifuge and the pellet resuspended in PB1 media 
containing 4mg/ml BSA.  An aliquot of this initial cell suspension was diluted 
into a large droplet of PB1 media, and single GC-like cells were aspirated from 
this droplet by fine glass pipette into a fresh 1ul drop of PB1 media containing 
4mg/ml Acetylated BSA (Sigma).  The single cells were then transferred into 4μl 




oligodT24, 0.5% Nonidet P-40 (Sigma), 300U/ml RNAguard (GE), 300U/ml 
Prime RNAse Inhibitor (Eppendorf)) in RNAse-free 0.2ml PCR tubes on ice.  The 
samples were incubated at 65°C for 1min then placed at room temperature for 
4mins before collecting to the bottom of the tube at 11’000rpm for 1min and 
placing on ice.  1.0ul Superscript III (Invitrogen) was added and samples 
incubated at 50°C for 15mins, placed on ice for 1min, then incubated at 70°C for 
10mins.  Samples were spun at 13’000rpm for 1min at 4°C then placed on ice. 
For polyA tailing of the cDNAs, 5.5μl 2x tailing buffer (2x Tdt Buffer 
(Invitrogen), 1.4mM dATP, 850U/ml Terminal Deoxynucleotidyl Transferase 
(Invitrogen)) was added to each sample.  Samples were then incubated at 37°C 
for 15mins and 65°C for 10mins, spun at 13’000rpm at 4°C for 2mins and placed 
on ice.  General amplification of tailed cDNAs was accomplished as follows.  4ul 
of the tailed cDNA was added to 16ul PCR buffer (1.25x PCR Buffer without 
MgCl2 (Invitrogen), 0.125μg/μl BSA (NEB), 1.25mN dNTPs, 0.125% Triton X-
100, 6.25μM Oligo dT24, 3.75μM MgCl2, 156.25U/ml Taq (Invitrogen)) and 
samples underwent the following PCR program: 94°C 2mins, followed by 20 
cycles of 94°C 1min, 42°C 1mins, 72°C 6mins, then a last step of 72°C for 5mins.  
Samples were then stored at -20°C. 
 
2.8. Gene-specific PCR Analysis 
 
PCR reactions were setup on ice as follows.  0.5μl of template cDNA was added 
into 19.5μl PCR buffer with final concentrations: 1x PCR Buffer without MgCl2 
(Invitrogen), 2mM dNTPs, 3.5mM MgCl2, 0.3μM primers, 25U/ml Taq 
(Invitrogen).  The following PCR program was used: 95°C 1min, followed by 
95°C for 30s, 52-62°C (standard 62°C but optimised for each primer set where 






2.9. Real-time PCR (RtPCR) Analysis 
 
For analysis of initial GC cDNA 15μl Real-time PCR reactions were setup by hand 
as follows. 5.0μl of template cDNA was added to 10μl PCR mix (one PCR mix was 
made per gene analysed), to give final concentrations of 1x SYBR Green PCR 
Master Mix (Applied Biosystems) and 0.3μM primers.  Reactions were prepared 
in 96-well plates that were then sealed, given a pulse spin to collect the liquid to 
the bottom of the wells and the reactions carried out on a Biorad CFX96 cycler 
(Bio-rad Laboratories) with the following program: 95°C 10mins, then 40 cycles 
of 95°C 15s, 60°C 1min.  The detector was set to measure SYBR green 
fluorescence at the end of each cycle.  After completion a melting curve program 
was carried out: 35°C for 30s then heating at 0.2°C/s to 85°C with continuous 
SYBR green fluorescence measurements.  Biorad CFX software (Bio-rad 
Laboratories) was used to analyse the results using a standard curve of serially 
diluted positive control cDNA. 
For the bHLH screen, one PCR mix was prepared per gene analysed, to give final 
reaction concentrations of 1x FastStart Taqman Probe Master Mix (Roche), 
0.3μM primers and 250nM Universal ProbeLibrary Hydrolysis Probe (Roche).  
Diluted cDNA was also prepared.  A Biomek 3000 (Beckman Coulter) automated 
pipetting robot was programmed to pipette first master mix then cDNA into 
384-well plates, which were then sealed and given a pulse spin before carrying 
out the reactions on a 7900HT Fast Real-Time PCR System (Applied Biosystems) 
with the following program: 95°C 10mins, then 40 cycles of 95°C for 15s and 
60°C for 1min.  Representative male, female, positive control and dH2O control 
reactions per gene were analysed by gel electrophoresis to ensure the presence 






2.10. Data Analysis for bHLH Screen Part 2 
 
Triplicate technical replicates were analysed for each gene in part 2 of the 
screen and for most of the genes another set of triplicates was analysed on a 
different biological sample. The data from these biological replicates was 
analysed separately.  Data was collected and analysed using SDS V2.0 (Applied 
Biosystems).  Standard curves were used only if they included triplicate 
reactions at 5 different dilutions.  The data was imported into Microsoft Excel, 
which was used to normalise the data according to the relative Gapdh and 
Tub1a1 levels in male and female GC cDNA.  All standard errors associated with 
mean averages were propagated.  The data was entered into Graphpad Prism 
4.0, for statistical analysis, as separate male and female means (converted 
relatively so that the lower mean had a value of one) with the propagated 
standard errors of the means (also converted relatively) and the number of 
replicates.  Unpaired 2-tailed t-tests were calculated from these figures to 
compare differences between male and female GC cDNA. 
   
2.11. Immunofluorescence of Embryonic Genital 
Ridges 
 
E11.5, E12.5 or E13.5 genital ridges were fixed for 1 hour in freshly-thawed 4% 
paraformaldehyde in PBS at 4°C with constant mixing.  After fixation, the genital 
ridges were washed 3 times with PBS for 5mins then stored at 4°C for up to 5 
days before wax embedding.  For wax embedding, the genital ridges were 
washed twice for 5mins in 70% ethanol, once in 90% ethanol, 3 times in 
absolute ethanol, then one rinse and one 5 minute wash in xylene before 3 5min 
washes in wax at 58°C.  Genital ridges were then embedded into blocks, which 




Blocks were sectioned into 6μm sections onto frosted slides, which were dried 
and incubated at 50°C overnight.  Sections were stored at 4°C until use. 
Wax-embedded sections were deparaffinised before use by washing twice in 
xylene, twice in absolute ethanol, once in 90% ethanol, twice in 70% ethanol 
then 3 times in PBS.  Antigen retrieval was accomplished by boiling for 20mins 
in a microwave oven on full power whilst immersed in 100mM pH6 sodium 
citrate buffer.  Sections were washed once in PBS, blocked (5/10% serum, 0.1% 
Tween-20, 0.05% sodium azide, in PBS) for one hour, incubated with primary 
antibodies for one hour, secondary antibodies and DAPI for one hour, each at 
room temperature in the dark, washed in PBS 3 times and mounted with 
Vectashield (Vector Labs) and cover slips.  Fluorescence staining was viewed 
using an Axioplan II fluorescence microscope (Carl Zeiss) outfitted with a 
Coolsnap digital camera (Photometrics) and operated by an Apple mac running 
IPLab software (BD Biosciences).  For each field, identical exposure times were 
used to capture an image for each channel, and these images were then 
recombined in Photoshop (Adobe).  Images of male, female and control sections 
were processed identically. 
The α-Id1 antibody used (BCH-1/37-2 from Biocheck Inc.) is a rabbit 
monoclonal IgG generated against recombinant full-length mouse Id1, is specific 
to mouse Id1 (Perk et al., 2006), and was used at 0.05μg/ml.  The α-Mnt 
antibody used (sc-769 from Santa Cruz Biotech.) is a rabbit polyclonal IgG 
generated against residues 226-361 of human Mnt, and was used at 0.4μg/ml.  
Generation of the Rat α-GCNA polyclonal antibodies was described previously 
(Enders and May, 1994) and these were used at 1:100, while mouse α-Dazl 
antibodies (kindly given by Howard Cooke) were used at 1:1000.  The Ptgds 
antibody used is a rabbit polyclonal IgG antibody generated against full length 
human Ptgds protein (sc-30067), which was used at 0.2μg/ml concentration.  
The Amh antibody used was a mouse monoclonal IgG (Abcam) used at 1:40 final 
dilution.  Alexa594 α-rabbit IgG secondary antibodies were used for α-Id1, α-
Ptgds and α-Mnt detection, Alexa488 α-rat IgM secondary antibodies were used 




α-Dazl and α-Amh detection.  All secondary antibodies were acquired from 
Molecular Probes (Invitrogen). 
For quantitative immunofluorescence analysis, the “Measure Regions” script of 
Fovea Pro 4.0 plugin (Reindeer Graphics) for Adobe Photoshop was used to 
measure the mean pixel intensity in the relevant channel for manually-
identified nuclei.  GC nuclei were identified by manual inspection of the GC 
marker channel.  Calculations were accomplished in Microsoft Excel and 
statistical analysis done using unpaired 2-tailed t-tests in Graphpad Prism. 
 
2.12. Culture of Embryonic Genital Ridges 
 
Sexed E11.5 genital ridges were placed on top of agar (2% agar in PBS) blocks in 
culture dishes containing PGC media (DMEM, 10% FCS, 2mM glutamine, 
100units/ml penicillin, 0.05mg/ml streptomycin, 1.5mM Sodium Pyruvate, 
0.1% Fungizone, 0.1μM β-mercaptoethanol, 1μg/ml Fungizone (Sigma)) with 
either a tested compound or equivalent vehicle added.  Levels of media were 
supplemented each day of culture.  After 2/3 days of culture, the genital ridges 
were washed in PBS then processed for in situ hybridisation. 
 
2.13. Wholemount In Situ Hybridisation 
 
Wholemount in situ hybridisation was accomplished using digoxigenin-labeled 
cRNA probes as previously described (Adams and McLaren, 2002).  PCR was 
performed on male gonad cDNA using primers against nucleotides 1-637 of 
Ptgds (AB006361 Genbank) and blunt-end cloned into pBluescript II SK+ 
(Stratagene).  The clones were checked by restriction digestion and sequencing 




insert.  The linearised clones were then used as templates for generation of 
digoxigenin-labeled sense and antisense cRNA probes using the DIG Probe 
Synthesis Kit (Roche) according to the manufacturer’s instructions.  Probe 
length was checked by RNAse-free gel electrophoresis and probe concentration 
was checked using a UV spectrophotometer. 
Wholemount in situ hybridisation was carried out as described previously 
(Henrique et al., 1995).  Briefly, genital ridges were fixed in fresh 4% 
paraformaldehyde, washed in PBS/0.1% Tween-20 then dehydrated into 
methanol, and stored for up to one month at -20°C.  Genital ridges were then 
rehydrated into PBS/Tween-20, treated with 10μg/ml proteinase K for 13mins, 
refixed in 4% paraformaldehyde and 0.1% gluteraldehyde, washed then 
equilibrated in hybridisation buffer (50% formamide, 1.3x SSC, 5mM pH8 EDTA, 
50μg/ml yeast RNA, 0.2% Tween-20, 0.5% CHAPS, 100μg/ml Heparin) at 70°C 
with constant mixing.  After equilibration, 1μg/ml of the cRNA probe was added 
and the genital ridges incubated overnight at 70°C with constant mixing.  After 
hybridisation, genital ridges were washed in hybridisation buffer at 70°C, 
transferred gradually to MABT (100mM maleic acid, 150mM NaCl, pH7.5, 0.5% 
Tween-20)  at 70°C then washed several times in MABT at room temperature, 
before blocking with Blocking Reagent (Roche) and 20% serum and incubating 
overnight at 4°C with 1/2000 Anti-digoxigenin-AP, Fab fragments (Roche).  
Excess antibody was washed away with several rinses and long washes in 
MABT, before NBT/BCIP staining as described for alkaline phosphatase staining 





Chapter 3:  
Real-time PCR Screen to Identify 
Candidate bHLH Genes Involved in 





3.1. Chapter Introduction and Aims 
 
This screen was prompted by the finding that Id1, which belongs to the basic 
helix-loop-helix (bHLH) family of transcription factors, is sex-specifically 
upregulated in E13.5 female GC cDNA (I. Adams unpublished data).  This finding 
was corroborated by real-time PCR (RtPCR) against Id1, which found a robust 
40-fold sex-specific enrichment of Id1 mRNA in E13.5 female GC cDNA (L. Lewis 
unpublished data).  Id1 itself is one of four Id proteins that make up a sub-class 
of bHLH proteins that are involved in the stimulation of the cell cycle and 
inhibition of differentiation (Yokota, 2001; Zebedee and Hara, 2001). 
The Id genes are upregulated in culture cells in response to stimulation by 
serum (Barone et al., 1994; Hara et al., 1994) or BMP (Hollnagel et al., 1999; 
Nakashima et al., 2001), and are required for efficient S-phase entry of various 
cultured cells in response to those signals, as shown by knockdown of Ids by 
antisense techniques, which results in delayed S-phase entry (Barone et al., 
1994; Swarbrick et al., 2005).  As well as stimulating the cell cycle, Ids inhibit the 
differentiation of cell types in vivo and in vitro.  Id1 expression is downregulated 
when cells differentiate, and forced expression of Id1 prevents differentiation 
(Desprez et al., 1995).  Similarly, ectopic expression of Id1 prevents neuronal 
differentiation of embryonic stem cells in the absence of BMPs (Ying et al., 
2003).  Expression patterns of Id1, Id2 and Id3 are overlapping (Yokota, 2001), 
and these genes have redundant roles in embryonic development (Fraidenraich 
et al., 2004).  However, double knockouts of Id genes are embryonic lethal 
(Fraidenraich et al., 2004; Lyden et al., 1999).  In Id1/Id3 double knockout 
embryos, many cells differentiate precociously, as shown by increased 
expression of differentiation markers, and some progenitor populations 
prematurely exit the cell cycle, resulting in a reduction in numbers of some cell 
types. 
The bHLH transcription factors comprise at least 114 genes in the mouse 




http://www.ensembl.org/index.html [Accessed 15/11/2007]).  Tissue-specific 
bHLHs promote cell-type-specific gene transcription and differentiation during 
embryonic development of many tissues (Massari and Murre, 2000).  bHLHs 
must dimerise to become transcriptionally active, and most tissue-specific 
bHLHs must heterodimerise with a ubiquitously-expressed Class A bHLH to 
form an active heterodimer.  Most tissue-specific bHLHs, therefore, rely on Class 
A bHLHs to affect transcription of their target genes.  The Id proteins possess a 
dimerisation domain but do not possess a DNA-binding domain and, therefore, 
they form inactive heterodimers with other bHLHs.  The Ids have particularly 
high affinity for Class A bHLHs (Yokota, 2001), and because of this the Id 
proteins sequester Class A bHLHs away from tissue-specific bHLHs, resulting in 
reduction of cell-type-specific gene expression and inhibition of differentiation. 
Several bHLHs have suspected or proven roles in various postnatal and late 
embryonic stages of GC development.  Sohlh1 and Sohlh2 have germ-cell-specific 
expression profiles and their knockout results in defects in the mitosis-meiosis 
transition of spermatogonia in adult testis (Ballow et al., 2006; Hao et al., 2008; 
Toyoda et al., 2009), as well as defects in oogenesis (Choi et al., 2008; Pangas et 
al., 2006; Toyoda et al., 2009).  Figla is expressed sex-specifically in female GCs 
undergoing oogenesis, and its knockout results in a female-specific defect in 
folliculogenesis shortly after birth (Soyal et al., 2000).  Ngn3 also has a 
suspected role in spermatogenesis, primarily because it is expressed in all 
spermatogonial stem cells that give rise to subsequent, more mature 
spermatogenic cells (Yoshida et al., 2004).  In addition, Tcfl5 has a GC-restricted 
expression pattern and is primarily expressed in spermatocytes and spermatids 
(Siep et al., 2004). 
Because bHLH genes are involved in later stages of sex-specific GC development, 
and the dominant negative bHLH Id1 is sex-specifically enriched in female GC 
cDNA between E11.5 and E13.5, it was theorised that bHLHs could have a role in 
the decision of embryonic GCs to commit to spermatogenesis or oogenesis, 
which occurs just before E13.5.  One plausible mechanism would be that female 




that initiates mitotic arrest in male GCs.  In fact, many bHLHs have the effect of 
promoting cell cycle exit at the same time as triggering cell-type-specific 
differentiation programs (Zebedee and Hara, 2001). 
An expression screen was carried out to find candidate bHLH genes that might 
be involved in this developmental decision.  The aim of the screen was to find 
candidate genes whose expression was consistently and significantly higher in 
one sex compared to the other in E13.5 GCs.  In the course of the screen, 21 out 
of 114 bHLH genes were found to be sex-specifically enriched in E13.5 GC cDNA.  
Experiments were then carried out on a number of these sex-specifically 
enriched genes to confirm that it is specifically GCs and not another 
contaminating cell types that express them.  Single-cell RT-PCR confirmed that 
Id1 and Id3 mRNA were expressed by female GCs.  Immunofluorescence staining 
for Id1 and Mnt confirmed that female and male GCs, respectively, sex-
specifically express higher levels of Id1 and Mnt at the protein level.  Further Id1 
and Mnt immunofluorescence analysis of E11.5 and E12.5 tissue was carried out 
in order to discover temporal changes in protein expression between E11.5 and 





3.2. Characterisation of FACS-purified E13.5 GCs 
 
In order sex-specific differences in E13.5 GC gene expression, E13.5 GC cDNA 
was prepared from male and female GCs.  Firstly, the GCs were purified by FACS 
of E13.5 male and female genital ridges from Oct4-GFP mice that contain a 
transgene consisting of Oct4 genomic sequences with GFP in place of Oct4.   The 
GFP transgene is expressed GC-specifically from E8.0 and this continues in male 
and female post-migratory GCs, resulting in GCs with fluorescent green signal 
(Yoshimizu et al., 1999).  Brightfield and green fluorescent images of E11.5, 
E12.5 and E13.5 transgenic male and female genital ridges were overlaid (E13.5 
tissue shown in Figure 3.2.1, A and B).  The pattern of GFP positive cells was 
consistent with GC expression.  For each FACS experiment, 3 litters-worth of 
male and female genital ridges (30-40 genital ridges per sex) were pooled and 
GCs were purified based on green fluorescence and shape and size.  This 
generally resulted in the collection of 100’000 to 200’000 GCs per sex, which 
was 3.5-4% of the parent population.  A GFP- cell fraction was also collected. 
To check the purity of these GC preparations, aliquots were fixed onto slides and 
stained by alkaline phosphatase (AP) staining and DAPI (Figure 3.2.1, C).  The 
number of AP+ nuclei was scored in 3 separate experiments and the percentage 
of AP+ nuclei calculated.  Both male and female GC preparations were very pure 





Figure 3.2.1. Characterisation of FACS-purified E13.5 GC Populations by Alkaline 
Phosphatase Staining.  GCs from E13.5 Testes, (A), and Ovaries, (B), from Oct4-GFP mice 
were purified by FACS using GC-specific expression of GFP.  Images (A) and (B) are a 
composite of brightfield images overlaid with green fluorescent signals of freshly-dissected 
E13.5 Oct4-GFP genital ridges.  Scales in (A) and (B) are 100μm.  After sorting, fresh cells 
were fixed and stained for alkaline phosphatase to identify GCs and DAPI to identify all 
cells, then blue fluorescence, (C), and brightfield, (C’), images taken to visualize DAPI and 
alkaline phosphatase staining, respectively.  Scale in (C’) is 50μm.  Each DAPI+ cell was 
counted and classified as either a GC or non-GC based on alkaline phosphatase staining 





3.3. bHLH Screen Part 1 
 
The bHLH screen was split into 2 parts.  In the first part, all 114 bHLHs genes 
were assayed non-quantitatively for sex-specific expression in E13.5 male and 
female GC cDNAs.  26 genes that had the highest sex-specific expression 
differences according to the results of the first part of the screen were 
quantitatively analysed in the second part of the screen. 
 
3.3.1. cDNA Normalisation 
 
This section describes the strategies employed to check and normalise the GC 
cDNAs for use in the first part of the bHLH expression screen.  
Male and female E13.5 GCs were purified as described in the previous section 
(section 3.2).  PolyA+ mRNA was extracted and GC cDNA prepared as described 
in Chapter 2.   An initial real-time PCR (RtPCR) experiment was carried out to 
quantitatively check the relative expression of the housekeeping genes 
Glyceraldehyde-3-phosphate Dehydrogenase (Gapdh) and α-tubulin (Tubala) in 
each fresh batch of male and female GC cDNA, and to allow pre-normalisation of 
the cDNA by dilution for this, the first part of the screen.  An example of one of 
these analyses is shown in Figure 3.3.1 (A-D) for Tuba1a.  All primers used in 
this screen for housekeeping and bHLH gene expression analysis are listed in 
appendix i. 
The purpose of the first part of the screen was to quickly identify which bHLH 
genes might be expressed differently in male and female GCs.  To do this quickly, 
non-quantitative RtPCR was used to measure and compare the mean threshold 






Figure 3.3.1.  α-tubulin (Tuba1a) Expression Analysis in GC cDNAs for the 1st Part of the 
Screen.  Real-time PCR (RtPCR) using primers for Tuba1a was used to measure the 
threshold cycles (C(t)) of serially-diluted standard cDNAs (green traces), in triplicate, (A), 
which were then used to produce a standard curve, (B).  Parallel RtPCR reactions of male 
GC (blue traces) and female GC (pink traces) cDNAs, in triplicate, were also carried out, (C), 
and the mean male and female C(t) values calculated along with standard deviations (“+/- 
SD”), (D).  Parallel dH2O negative control reactions (grey traces), in duplicate, were also 
carried out.  A “%” value, which was the % of starting quantity according to the standard 
curve (100% being the highest dilution of standard cDNA), was calculated for each male and 
female reaction.  “Mean %” was then calculated along with standard deviations, (D).  These 
Mean % values were used to calculate the relative male:female Tuba1a levels, which were 
used in conjunction with relative Gapdh levels to dilute the cDNAs to equivalence.  RtPCR 
reactions, (E), were run after each freeze-thaw of the GC cDNA, along with diluted positive 




remove the need for retrospective normalisation by quantitative analysis of 
housekeeping gene expression, the male and female GC cDNAs were diluted to 
equivalence before the experiments with respect to their Gapdh and Tuba1a 
levels.  Relative bHLH gene expression was then analysed in the male and 
female cDNAs after storage at -20˚C.  
Each subsequent experiment in the first part of the screen, after freeze-thaw of 
the GC cDNA, included analyses of C(t)s for both Gapdh and Tuba1a to ensure 
that the GC cDNAs were still equivalent (Figure 3.3.1E and F). 
 
3.3.2. bHLH Screen Part 1 Results 
 
In order to do identify which genes might be enriched sex-specifically in E13.5 
GC cDNA, each gene was analysed by comparing the mean C(t) of triplicate male 
and female GC cDNAs, and were analysed quantitatively in the second part of 
the screen if the mean C(t)s for male and female cDNAs differed by 2.0 cycles or 
more.  114 bHLH genes, as listed in Ensembl Genome Browser as having a bHLH 
domain (Ensembl Genome Browser [online], Release 47. Available from: 
http://www.ensembl.org/index.html [Accessed 15/11/2007]), were tested in 
total.  82 bHLH genes were either undetected in GC cDNA or had a mean C(t) 
difference between male and female GC cDNA of less than 2.0 cycles.  The mean 
male and female C(t)s for the remaining 32 genes differed by 2.0 cycles or more, 
and 26 of these genes, along with 1 other selected gene, were analysed 
quantitatively in the second part of the screen  (Section 3.4). 
Each analysis in this first part of the screen included 11 Real-time PCR reactions 
per gene – 3 replicates each containing male GC cDNA, female GC cDNA and 
positive control cDNA, and 2 replicates containing dH2O.  The positive control 
cDNA consisted of diluted cDNA generated from various embryonic tissues from 
E11.5, E13.5, E14.5 and E17.5 embryos.  As described in the previous section, 




an initial quantitative analysis of Tuba1a and Gapdh prior to analysis of bHLH 
genes.  During analyses of bHLH genes in this part of the screen, parallel 
reactions were also included for Tuba1a and Gapdh.  For both housekeeping 
genes, the male and female GC cDNAs consistently amplified within 0.3 cycles of 
one another, while the positive control cDNA amplified 3.0 +/- 0.6 cycles before 
male and female GC cDNAs.  The primers used for analysis of bHLH and 
housekeeping genes in this screen are listed in appendix i. 
A valid result for each cDNA (male GC cDNA, female GC cDNA and positive 
control cDNA) consisted of at least 2 out of the 3 reactions having C(t)s within 
±2.0 cycles.  Such replicates were deemed to concur and the mean of the 
concurring replicates was calculated and used as the result for that cDNA for 
that gene.  10.3% of the reactions did not concur in this way, and were 
disregarded.  A valid result for each gene consisted of valid mean C(t)s for each 
cDNA and no meaningful amplification in the dH2O reactions.  Two exceptions to 
these parameters are the analyses for Tcfeb and Tcfl5, which are explained 
below.  The decision to accept only 2 rather than all 3 concurring replicates was 
made to allow this part of the screen to progress in a timely fashion. 
3.5% of the reactions amplified with an abnormal, non-sigmoidal shape and/or 
were markedly different in appearance compared to the other 2 triplicates.  
These reactions were deemed anomalous and the data from them disregarded.  
The cause of these anomalous reactions is unknown.  For genes where replicate 
reactions showed similar non-sigmoidal reaction kinetics, different primers that 
did result in reliable sigmoidal reactions were used. 
For 30 out of the total 114 bHLH genes, no amplification was detected before 
the end of the reaction (40 cycles) in both male and female GC cDNAs (appendix 
v).  The positive control of embryonic tissue cDNA ensured that the primers 
were able to reliably detect transcript of known splice variants for these 30 
genes, with the exception of MycS, for which amplifications were detected in 




Sugiyama et al., 1989), and was undetected in positive control cDNA, as well as 
in GC cDNAs. 
Of the bHLH genes for which a PCR product was detected in GC cDNAs, 52 genes 
showed a sex-specific difference in mean C(t) of less than 2 cycles, and were not 
looked into further.  Figure 3.3.2 displays the data for these genes.   
No reaction was detected in positive control cDNA for Tcfeb or Tcfl5, whereas 
robust amplifications were detected in male and female GC cDNAs for these 
genes.  The amplification detected in the male and female GC cDNAs was 
considered acceptable for a valid result.  Previous studies found that both Tcfl5 
and Tcfeb have very restricted expression patterns, which would explain why 
amplification failed in positive control cDNAs.  Interestingly, Tcfl5 expression is 
spermatocyte-specific in adult mice with limited expression in embryonic 
tissues (Siep et al., 2004), while a testis-specific splice variant of Tcfeb is 
detected in adult tissues and high level embryonic Tcfeb expression is limited to 





























Figure 3.3.2.  bHLH Genes with Less Than 2.0 Cycle Sex-
specific Difference in E13.5 GC cDNA.  Triplicate Real-time PCR 
reactions were carried out containing male GC cDNA, female 
GC cDNA and positive control cDNA.  C(t)s for concurring 
reactions (within ±2.0 cycles) are shown for male GC cDNA 
(light blue bars), female GC cDNA (light pink bars) and positive 
control cDNA (light green bars) along with the calculated mean 
C(t) of the concurring reactions (bars in corresponding colours 
except dark).  “M” = male GC cDNA reactions, “F” = female GC 
cDNA reactions and “E” = Embryo (positive control) cDNA 































Figure 3.3.3.  bHLH Genes with 2.0 cycles 
or Greater Sex-specific Difference in 
E13.5 GC cDNA.  RtPCR reactions were 
carried out as explained in the legend for 
Figure 3.3.2 and in the text.  C(t)s for 
concurring reactions are shown for male 
GC cDNA (light blue bars), female GC 
cDNA (light pink bars) and positive control 
cDNA (light green bars) along with the 
mean C(t)s of the concurring reactions 
(bars in corresponding colours except 
dark), for the 7 genes with a lower mean 
C(t) in male GC cDNA, (A), and the 25 
genes with a lower mean C(t) in female GC 
cDNA, (B).  “M” = male GC cDNA 
reactions, “F” = female GC cDNA 
reactions and “E” = Embryo (positive 





For the 32 remaining bHLH genes, mean C(t)s for the male and female GC cDNAs 
were 2 or more cycles different from each other.  Figures 3.3.3 and 3.3.4 display 
the results for these genes.   
Interestingly, 25 out of 32 of the genes with a 2.0 cycles or greater sex-specific  
mean C(t) difference  had a lower mean C(t) in female GC cDNA compared to male 
GC cDNA, and therefore are potentially enriched in female GC cDNA.  
Furthermore, no amplification was detected at all in male GC cDNA for 15 of 
these 25.  Conversely, 7 genes had a lower mean C(t) in male GC cDNA, and no 
amplification detected in female GC cDNA for only one of these (Msc).  
Therefore, potentially many more bHLH genes are enriched in female GC cDNA 
compared to male GC cDNA.  This is interesting because most sex-specific 
expression screens in embryonic genital ridges find considerably more genes 
enriched in male genital ridges (McClive et al., 2003). 
26 of these 32 genes were assessed quantitatively in the second part of the 
screen, whereas the remaining 6 (Ascl1, Bhlhb5, Ebf3, Heyl, Tal1 and Tcf21) were 
not.  Although these 6 genes showed a sex-specific mean C(t) difference of 2.0 
cycles or greater, the lower mean C(t) of the GC cDNAs was also at least 5 cycles 
higher (i.e. occurred at least 5 cycles later) than the mean C(t) of the positive 
control cDNA.  This C(t) difference of at least 5 cycles make these genes less 
interesting candidates for several reasons.  Firstly, if the detected transcripts 
originate from GCs, rather than contaminating somatic cells, then the amount of 
transcript in the GCs is potentially very low.  Low amounts of transcript in the 
GCs make accurate quantification more problematic (especially here where GC 
cDNA was scarce) and could indicate a lack of significant sex-specific function in 
GCs.  Alternatively, this low-level amplification could originate from somatic 
cells transcripts contaminating the GC preparations, and therefore these genes 
are negligible for the main aim of this screen.  It must be remembered that one 
or more of these genes might still have important sex-specific functions 
specifically in GCs.  And, more likely, it is also possible that some of these genes 




number of potentials derived from the first part of the screen, an astute decision 
was made to concentrate on the more easily detectable genes. 
Epas1 is another gene having a greater than 2.0 cycle sex-specific difference in 
mean C(t), but with a very late mean C(t), so would ordinarily be removed from 
quantitative analysis in the second part of the screen.  However, Epas1 was 
previously shown to be expressed in E15.5 testis, but in somatic cells of the 
interstitium rather than in the testis cords where the GCs are located (Tian et al., 
1998).  As such, the lower relative mean C(t) observed with male cDNA 
compared to female cDNA is suspected to originate from transcripts of 
contaminating somatic cells.  It was therefore decided to include Epas1 in the 
second part of the screen, in order to observe how such a gene might behave in 
this analysis. 
Id2 was also specifically chosen for accurate quantification in the second part of 
the screen, even though the sex-specific mean C(t) difference was less than 2 
cycles.  Id2 was included because the closely related genes Id1, Id3 and Id4 did 





3.4. bHLH Screen Part 2 
 
3.4.1. cDNA Normalisation 
 
This section describes the strategies employed to check and normalise the GC 
cDNAs for use in the second part bHLH expression screen.  The second part of 
the screen accurately quantified the relative levels of the potentially-sex-
enriched bHLH genes in male versus female GC cDNA.  The GC cDNAs were not 
diluted to equivalence for these experiments.  Instead, normalisation was 
accomplished after analysis using the quantified relative male:female Gapdh or 
Tuba1a levels, which were analysed and calculated independently for each 
experiment, along with the bHLH genes.  
Relative male:female levels for each gene were quantified using a standard 
curve consisting of 5 concentrations of standard cDNA, and were then 
normalised using the relative male:female levels of Gapdh or Tuba1a, which 
were measured in identical fashion.  Therefore, the results of the second part of 
the screen are normalised to Gapdh or Tuba1a.  The Tuba1a-normalised data is 
shown in the following section, section 3.4.2.  Figure 3.4.1 shows a 
representative example of Tuba1a quantification data for an experiment from 









Figure 3.4.1.  α-tubulin (Tuba1a) Expression Analysis in E13.5 GC cDNAs for the 2nd Part of 
the Screen.  Relative Tuba1a levels in male and female GC cDNA were measured by RtPCR 
using a standard curve, (B), generated using 5 concentrations of standard cDNA, (A).  
Triplicate male (blue traces) and female (pink traces) were analysed in parallel, along with 
duplicate negative controls, (C), and the percentage of starting cDNA relative to the 
standard cDNA recorded and averaged (“Mean %”), (D).  This data was then used to 














3.4.2. bHLH Screen Part 2 Data  
 
The results of the first part of the screen identified 32 genes with 2.0 cycles or 
greater sex-specific difference in mean C(t) in E13.5 GC cDNA.  This second part 
of the screen aimed to accurately quantify the differences of 26 of those genes, 
along with Id2, by Quantitative RtPCR.  The remaining 6 genes were not 
analysed in this part of the screen due to their high C(t) values compared to 
positive control cDNA.  The primer sets used for this analysis are listed in 
appendix iv and were designed using the Roche UPL Assay Designer (Universal 
ProbeLibrary [online]. Available from: http://www.roche-applied-
science.com/sis/rtpcr/upl/ezhome.html [Accessed 04/03/2008]).  All primers 
were manufactured by Sigma and the sequences were checked against the 
mRNA sequence(s) of the relevant genes obtained from Ensembl (Ensembl 
Genome Browser [online], Release 47. Available from: 
http://www.ensembl.org/index.html [Accessed 15/11/2007 - 04/03/2008]) to 
ensure that they targeted the correct sequences.  The data was normalised to 
both Tuba1a and Gapdh.  However, the data shown in the tables and figures in 
this section are normalised to Tuba1a, which differs by only up to 25% 
compared to the Gapdh-normalised data (shown in appendix vi).  Therefore, 
statistical significance was retained across both sets of normalised data, and the 
analysis below does not differentiate between them, except where specified.  
A total of 15 genes were found to be significantly enriched sex-specifically – 4 
(Epas1, Helt, Mnt and Ngn3) male-enriched, and 11 female-enriched 
(A830053O21Rik, Bhlhb2, Ebf4, Figla, Id1, Id2, Id3, Mesp1, Mlxipl, Mxd4 and Scx) - 
in E13.5 GC cDNA (Tables 3.4.1 and 3.4.2, and Figures 3.4.2 and 3.4.3).  A further 
7 genes – one male-specific (Msc) and 6 female-specific (Ahrr, Atoh1, Bhlhb4, 
Hand1, Hes2 and Hes7) - were detected sex-specifically, with no amplification at 
all detected in the other sex (Table 3.4.3).  For all of these genes except 
A830053O21Rik and Hes2, the fact that statistically-significant fold enrichments 




makes these genes very good candidates for sex-specific expression in E13.5 
GCs.  The 5 remaining genes (Ascl2, Hey1, Id4, Max and Olig1) showed negligible, 
non-significant and/or non-replicated sex-specific differences (Table 3.4.4). 
In addition to the standards consisting of serially-diluted positive control cDNA, 
(mixed embryonic tissue cDNA for all except Figla, for which E15.5 female 
genital ridge cDNA was used), 9 reactions per gene were setup and analysed: 3 
sets of triplicate samples containing male GC cDNA, female GC cDNA or dH2O.  
Each set of triplicate samples consisted of 3 technical replicates containing an 
aliquot of the same cDNA sample.  The data from each experiment was used 
only if all three negative control reactions failed to show meaningful amounts of 
fluorescence.  The data from the standards was used to generate a standard 
curve, which was used to calculate the relative starting amounts of bHLH 
transcript per sample.  Reactions were run out on agarose gels to ensure that 
only one product was generated, the length of which corresponded to the gene 
under study. 
The reactions in this second part of the screen were only excluded if their 
overall reaction kinetics were not sigmoidal in shape, as would be expected of a 
normal PCR reaction.  4 reactions were excluded for this reason (one each from 
Helt, Ngn3, Id1 and Id4).  The assumed cause of these abnormal reactions 
kinetics are unwanted contaminations in the reaction or some other anomalous 
phenomenon or technical error, and as such do not represent normal variations 
in PCR reactions.  In the first part of the screen, a replicate was excluded if it 
disagreed from the other 2 replicates by a certain amount.  This approach is 
appropriate for an initial screening for potential target genes, but is 
inappropriate for quantitative measurement of expression levels.  Thus all 
replicates were included regardless of how much they disagreed.  A number of 













Fold Enrichment                                          
( / ) 
Biological Rep. 1 Biological Rep. 2 
Epas1 6 6 3.5 +/- 0.6 (**) 5.2 +/- 0.4 (***) 
Helt 6 5 3.3 +/- 1.1 (**) 3.8 +/- 0.4 (**) 
Mnt 6 6 2.6 +/- 0.4 (**) 3.8 +/- 0.8 (**) 

















Fold Enrichment                                          
( /  ) 
Biological Rep. 1 Biological Rep. 2 
A830053O21Rik 3 4 58.5 +/- 4.1 (***)  - 
Bhlhb2 6 6 16.5 +/- 3.8 (**) 14.4 +/- 8.6 (*) 
Ebf4 6 6 123.0 +/- 51.5 (*) 107.4 +/- 13.0 (***) 
Figla 6 6 84.1 +/- 21.8 (***) 79.3 +/- 12.9 (***) 
Id1 6 5 42.0 +/- 6.2 (***) 39.0 +/- 3.0 (***) 
Id2 6 6 32.0 +/- 10.9 (*) 34.6 +/- 3.5 (***) 
Id3 6 6 18.4 +/- 6.8 (*) 13.4 +/- 1.6 (**) 
Mesp1 6 6 15.2 +/- 4.0 (*) 10.7 +/- 1.4 (**) 
Mlxipl 6 6 12.9 +/- 4.5 (**) 26.4 +/- 10.4 (*) 
Mxd4 6 6 6.7 +/- 0.4 (***) 3.9 +/- 0.5 (**) 
Scx 6 6 31.0 +/- 9.4 (*) 32.6 +/- 12.4 (**) 
Table 3.4.1. bHLH Screen Part 2: Male-Enriched Genes (normalised 
to Tuba1a).  Each of the 2 biological replicate consisted of triplicate 
RtPCR reactions containing male or female GC cDNA.  The total number of 
technical replicates across both biological replicates is shown (“Total / 
 Reps.”).  In parallel, relative Tuba1a levels were also measured and 
used to normalise the relative bHLH levels, resulting in the mean fold-
enrichments shown.  The “+/-“ values shown here are the standard errors 
of the calculated and normalised means, which incorporates errors from 
both the bHLH and Tuba1a reactions by error propagation.  Statistical 
significances were calculated using unpaired 2-tailed t-tests and are 
displayed by bracketed asterisks (“ns” = not significant, “*” = P<0.05, “**” 
= P<0.005, “***” = P<0.0005). 
Table 3.4.2. bHLH Screen Part 2: Female-Enriched Genes (normalised 
to Tuba1a).  See legend for Table 3.4.1.  2 biological replicates were carried 





Figure 3.4.2. Male-enriched bHLH Genes 
(normalised to Tuba1a).  The data shown in Table 
3.4.1 represented as a bar chart.  The mean /  fold 
enrichments for both biological replicate 1 (blue 
diagonal hatched bars) and biological replicate 2 (blue 
dotted bars) are shown.  Standard Errors are shown as 







Figure 3.4.3. Female-enriched bHLH Genes (normalised to 
Tuba1a).  The data shown in Table 3.4.2 represented as a bar 
chart.  The mean /  fold enrichments for both biological 
replicate 1 (pink diagonal hatched bars) and biological 
replicate 2 (pink dotted bars) are shown.  Standard Errors are 
shown as solid lines and statistical significance as asterisks 
above each bar.  For clarity, genes with less than 30-fold 
enrichment are shown in (A), and those with greater than 30-





As can be seen in Tables 3.4.1 and 3.4.2 and Figures 3.4.2 and 3.4.3, the 2 
biological replicates of some of the sex-specifically-enriched genes differ greatly, 
and it was decided to keep the data for the biological replicates separate 
because of this.  These biological replicate variations are most notable for Ngn3, 
Mlxipl, and Mxd4.  This puts some doubt upon the precision of the fold-
enrichments for these genes.  Despite the difference in magnitude for the fold-
enrichments between the biological replicates, statistical significance is 
retained.  However, a third biological replicate for these genes would more 
accurately ascertain the true magnitude of the sex-specific enrichments. 
There are a number of possible causes of these variations between biological 
replicates.  It must be remembered that the purified GC preparations did contain 
a fraction of contaminating somatic cells, and the proportion of contaminating 
cells varied between different GC preparations by as much as 1-3%.  If the 
enrichment seen for these genes originated as high expression in one 
population of the contaminating somatic fraction as opposed to expression in 
GCs, then variations in the proportion of the expressing cell populations in the 
contaminating somatic fraction could drastically alter the overall enrichment 
seen.  For example, Epas1 expression is enriched in male GC cDNA over female 
GC cDNA in the second part of this screen, although to differing degrees in the 
two biological replicates (3.52-fold and 5.18-fold for biological replicate 1 and 2, 
respectively).  Somatic cells of the E15.5 mouse testis were previously shown to 
express Epas1 (Tian et al., 1998).  If the expression seen in this screen originates 
solely in somatic cells then an increase in the contaminating population from 
1% to 2% could cause as much as a two-fold difference between the two 
biological replicates.  In the reverse situation, a contaminating population of 
somatic cells in one GC cDNA that express the gene in question highly could 
mask or reduce an enrichment in the cDNA of the opposite sex that in fact does 
originate from GC expression.  These explanations would not hold true for GC-





Another possible explanation for the observed differences in biological 
replicates of the same gene could be that one replicate is invalid due to 
anomalous replicates.  Replicates were included in the analysis regardless of 
their variation from each other.  For the most part experiments were repeated if 
the replicates varied too greatly.  However, this was not possible for all genes, 
owing to the large number of genes analysed and the scarcity of GC cDNA.  This 
can be seen in the first biological replicate of Ngn3.  The magnitude of 
male/female enrichment may be overestimated in this biological replicate 
because of the large variations in the female replicates, the lowest of which had 
a value of 0.06, much lower than the other 2 female replicates that had values of 
0.24 and 0.36.  Once again, further biological replicates would help to more 
precisely measure the true magnitude of the sex-specific enrichments for these 
genes. 
Table 3.4.3 shows those genes that were detected in one sex only.  This sex-
specific amplification was observed over two biological replicates for male-
specific Msc, and for female-specific Ahrr, Atoh1, Bhlhb4, Hand1 and Hes7 and 
over one replicate for female-specific Hes2.  For the sex these genes were 
detected in, the reactions of both biological replicates amplified robustly and, 
apart from the second biological replicate of Hes7, all within 2.0 cycles of one 
another.  Conversely, all samples in the other sex completely failed to amplify 
before the end of the assay, and this was not due to poor quality male cDNA, as 
robust Gapdh and Tuba1a expression was detected in those cDNAs.  For Ahrr 
and Hes2, the female samples amplified quite late (~36 cycles), and it is possible 
that further optimisation of the RtPCR assays would result in robust detection in 
the male GC cDNA.  Therefore, Hes2 and Ahrr are at the very least female-
specifically enriched, while Msc, Atoh1, Bhlhb4, Hand1 and Hes7 are either very 
sex-specifically enriched or expressed sex-specifically, and are very interesting 


















Msc 6 6 2  
Ahrr 8 8 2  
Atoh1 6 6 2  
Bhlhb4 6 6 2  
Hand1 6 6 2  
Hes7 6 6 2  














Biological Rep. 1 Biological Rep. 2 
Ascl2 6 6 0.5 +/- 0.1 0.8 +/- 0.3 
Hey1 6 6 1. 8 +/- 0.2 2.0 +/- 0.2 
Id4 5 6 0.3 +/- 0.1 0.9 +/- 0.0 
Max 6 6 1.0 +/- 0.1 1.4 +/- 0.1 







For the remaining 5 genes, no convincing sex-specific enrichments that were 
sustained over 2 biological replicates were observed (Table 3.4.4).  The lack of 
robust sex-specific difference was very surprising for Max.  In the first part of 
the screen, Max transcripts were completely undetected in all triplicates of male 
GC cDNA (Figure 3.3.3), suggesting female-GC-specific expression.  To ensure 
this disparity was not caused by the different sets of primers used in the 2 parts 
Table 3.4.3. bHLH Screen Part 2: Genes Detected Sex-
Specifically.  RtPCR was carried out as described in the legend 
for Table 3.4.1.  The number of biological replicates carried out 
(“No. of Biological Reps.”) and the number of technical replicates 
over both biological replicates (“Total /  Reps.”) is shown for 
each gene. 
 
Table 3.4.4.  bHLH Screen Part 2: Genes With Negligible or No 
Sex-Specific Enrichment.  RtPCR was carried out as described in the 
legend for Table 3.4.1.  The calculated and normalised mean 
enrichments as well as the standard error (“+/-“) is shown for each 
biological replicate, and the total number of technical replicates 






of the screen, a quantitative RtPCR using the primers from the first part of the 
screen was carried out, and this resulted in similar normalised amounts of 
correctly-sized product in both male and female GC cDNA (data not shown).  
Additionally, a semi-quantitative PCR using a third primer set detected roughly 
equal amounts of both splice forms of Max (data not shown).  Therefore, it is 
likely that the lack of amplification in the male GC cDNA reactions in the first 
part of the screen was anomalous, and Max is not enriched sex-specifically in 
E13.5 GC cDNA.   
The data for Id4 and Ascl2, do suggest that these genes may be enriched in 
female GCs at E13.5.  However, more replicates are required to arrive at definite 
conclusions for these genes.  Hey1 is consistently enriched male-specifically in 
this screen, but these enrichments were lower than 2-fold. 
Why were the sex-specific differences seen in the first part of the screen not 
reliably replicated in the second part of the screen for Ascl2, Id4, Max and Olig1?  
The situation with Max suggests that the first set of data for Max is incorrect, 
and for the remaining 3 genes, there may be sex-specific differences, but these 
are probably not large or robust enough to result in a reliable result from more 
precise quantitative assays, as in the second part of the screen.  As such, these 5 
genes (including Hey1) are not as promising candidate sex-specific genes as the 
other 22 genes. 
In summary, 20 bHLH genes were found to be either sex-specifically enriched or 
sex-specifically expressed in E13.5 GC cDNA over 2 biological replicates, with 
another 2 bHLH genes over one biological replicate.  However, as suggested by 
Epas1, the enrichments may or may not be due to GC-specific expression The 
remaining sections of this chapter aim to confirm GC-specific and sex-specific 
expression for the female-enriched Id1, Id2 and Id3 and for the male-enriched 




3.5. Verification of Sex-Specific Germ Cell 
Expression of Id and Mnt 
 
3.5.1. Characterisation of cDNA Libraries Prepared 
From Single E13.5 Gonadal Cells 
 
The technique used was adapted from Brady and Iscove (Brady and Iscove, 
1993).  Only one round, rather than 2 rounds as stated in the original protocol, 
of PCR was carried out in the current study to amplify the tailed cDNAs non-
specifically and this change to the original protocol was made to enable 
subsequent expression analysis by gene-specific PCR.  This adaption may have 
changed the representivity of the final cDNA libraries compared to the original 
protocol.  Briefly, single cells were picked, their PolyA+ mRNA reverse 
transcribed and the resultant cDNA non-specifically amplified to generate a 
cDNA library of the original cell that was then analysed for the presence of 
multiple target genes.  Brady and Iscove suggest, and others have employed 
(Saitou et al., 2002), the use of Southern Hybridisation, while others have used 
quantitative methods (Yabuta et al., 2006), to assess the presence of genes of 
interest in the single-cell cDNA libraries.  In this study end-point PCR was used 
to assess gene expression using the amplified cDNA libraries as substrate. 
Male and Female samples were collected in 3 separate biological experiments 
per sex, with controls included in all biological replicates.  For the male analysis, 
38 RT+/cell+ libraries, which had a cell and reverse transcriptase (RT) added 
into them, 8 no-RT controls (i.e. had a cell but no RT added to them) and 11 no-
cell controls (i.e. had media instead of a cell, and RT, added to them) were 
generated.  For the female analysis, 49 RT+ cell+ libraries, 9 no-RT controls and 8 
no-cell controls were generated.  To increase the chance of only one cell being 
collected into each sample, the cell was collected first into a fresh drop of media, 




Exactly the same procedure was used for no-cell controls, except media instead 
of the cell was transferred into the tube for the second transfer. 
The amplified cDNAs were first tested for Glyceraldehyde 3-phosphate 
Dehydrogenase (Gapdh) expression by PCR in order to determine which cDNA 
libraries had amplified properly and had detectable transcripts.  All male and  
female no-RT and no-cell controls were negative for Gapdh expression, and cell-
type-specific expression as described below, with the primers and conditions 
used, indicating that products detected in the samples are likely dependent 
upon RT and represent mRNA expression of the cells added.  The absence of 
detected Gapdh expression in the no-cell controls implies that product detected 
in the RT+/cell+ libraries originates from RT expression of the added cell rather 
than from some contamination from the RT enzyme. 
Of the 38 male RT+/cell+ libraries, 27 were positive and 11 were negative for 
Gapdh expression and of the 49 female RT+/cell+ libraries, 21 were positive and 
28 negative for Gapdh expression.  Presuming that a cell was successfully placed 
into each sample, then the fact that Gapdh was not detected in some libraries 
suggests that reverse transcription or amplification failed to amplify the mRNA 
from these single cells.  Therefore, these libraries were not used in subsequent 
analyses.  
Those libraries that tested positive for Gapdh were then tested, along with the 
control samples, for expression of markers to identify the cell type of each 
library (Figures 3.5.1 and 3.5.2 and Table 3.5.1).  There are several bipotential 
cell lineages in the gonad, including GCs and at least 3 somatic cell lineages: 
supporting cells, steroidogenic cells and connective tissue cells (Swain and 
Lovell-Badge, 1999).  Dazl (Seligman and Page, 1998) and Stella (Bowles et al., 
2006) are GC-specific genes expressed by migratory and post-migratory GCs, 
including male and female E13.5 GCs.  Therefore, analysis of Dazl and Stella 
expression was used to identify GC libraries.  Primers against Sox9 and SF-1 
were used in order to identify male somatic cells.  Sox9 expression is restricted 




testis, whereas SF-1 is expressed by various somatic cell types in the testis 
shortly after sex determination (Hatano et al., 1994), including Sertoli cells, 
Leydig cells and peritubular myoid cells.  Importantly, neither Sox9 nor SF-1 are 
expressed in GCs.  Gata4 and SF-1, which are also not expressed by GCs, were 
used for the identification of female somatic cell libraries.  SF-1 is expressed in 
multiple somatic cell lineages in the embryonic ovary (Hatano et al., 1994), 
including granulosa cells and theca cells, the supporting and steroidogenic cells, 
respectively, of the mouse ovary.  Gata4 is expressed only at low levels in 
embryonic mouse ovary but highly in various somatic cells in the adult ovary, 
including theca and granulosa cells (Heikinheimo et al., 1997).  In this study, 
Gata4 transcripts were detected in 4 out of 6 libraries testing negative for GC 
markers, indicating that Gata4 is expressed in E13.5 female somatic cells at 
levels detectable by this single-cell PCR analysis. 
2 technical replicates of the cell-type-specific marker analysis PCR were carried 
out, and the same result obtained for each.  Assuming that only one cell was 
placed into each sample during the picking, each sample should test negative for 
both sets of markers or positive for either GC or somatic markers, but no sample 
should test positive for both somatic and GC markers.   
 No. of Positive Libraries 
  
GC-/-/SOM-/- 4 1 
GC+/+/SOM-/- 18 9 
GC+/-/SOM-/- 0 6 
GC-/-/SOM+/+ 2 1 
GC-/-/SOM+/- 3 3 
GC+/-/SOM+/+ 0 1 
TOTAL 27 21 
Table 3.5.1 Cell-type-Specific Expression Analysis of Single E13.5 








Figure 3.5.1. Cell-type Specific PCR Analysis of Male Gapdh+ Single-cell cDNA Libraries.  Single cells from E13.5 male gonads or blank media (“±Cell”) 
were reverse transcribed (“±RT”) and the cDNA amplified non-specifically to produce cDNA libraries.  The libraries were produced in 3 separate 
experiments (Batch 1 = samples 1 to 14, Batch 2 = samples 15 to 36, Batch 3 = samples 37 to 57), each of which included actual samples (Cell+/RT+), 
no-cell controls (Cell-/RT+) and no-RT controls (Cell+/RT-).  PCR was carried out on Gapdh+ samples, no-RT controls and no-cell controls using primers to 
somatic markers (Sox9 and SF-1) and GC markers (Stella and Dazl), along with a PCR negative control (“H2O”) and positive control (“POS”) consisting of 
mixed E13.5 male and female gonad cDNA.  For each marker analysed, all samples were run in the same PCR experiment, except for Sox9, for which 
the samples were run in 2 separate experiments (Experiment 1 = samples 1 to 36, Experiment 2 = sample 37 to 57).  The products from each PCR 
experiment were run out on multiple agarose gels (as denoted in separate boxes) and the gels shown above are from one of 2 replicates per gene that 
both gave the same result.  1kb ladder (Invitrogen) was run alongside reactions and the arrows and numbers to the left of the gels indicate the size of 







Figure 3.5.2. Cell-type Specific PCR Analysis of Female Gapdh+ Single-cell cDNA Libraries.  Single cells from E13.5 female gonads or blank media 
(“±Cell”) were reverse transcribed (“±RT”) and the cDNA amplified non-specifically to produce cDNA libraries.  The libraries were produced in 3 
separate experiments (Batch 1 = samples 1 to 22, Batch 2 = samples 23 to 44, Batch 3 = samples 45 to 66), each of which included actual samples 
(Cell+/RT+), no-cell controls (Cell-/RT+) and no-RT controls (Cell+/RT-).  PCR was carried out on Gapdh+ samples, no-RT controls and no-cell controls 
using primers to somatic markers (Gata4 and SF-1) and GC markers (Stella and Dazl), along with a PCR negative control (“H2O”) and positive control 
(“POS”) consisting of mixed E13.5 male and female gonad cDNA.  For each marker analysed, all samples were run in the same PCR experiment.  The 
products were run out on multiple agarose gels (as denoted in separate boxes) and the gels shown above are from one of 2 replicates per gene that 
both gave the same result.  1kb ladder (Invitrogen) was run alongside reactions and the arrows and numbers to the left of the gels indicate the size of 




Of the male libraries, 18 were positive for GC markers and negative for somatic 
cell markers, and were therefore male GC libraries.  Of those 18, all were 
positive for both GC markers (GC+/+/SOM-/-).  5 other male libraries were 
somatic cell libraries because they were negative for GC markers and positive 
for somatic markers.  Of the 5 male somatic cell libraries, 2 were positive for 
both somatic cell markers (GC-/-/SOM+/+) and the other 3 were positive for one 
somatic cell marker only (GC-/-/SOM+/-).  The 3 Sox9 positive male somatic cell 
libraries are likely to be Sertoli cells, because Sox9 expression is restricted to 
Sertoli cells (Sekido and Lovell-Badge, 2009).  4 libraries were negative for both 
GC and somatic cell markers (GC-/-/SOM-/-), and these libraries may have been 
generated from male gonadal cell types other than GC, Leydig, Sertoli or 
peritubular myoid cells.  Alternatively, the single-cell PCR procedure may not 
have been able to detect low level expression of cell-type-specific genes by GC, 
Leydig, Sertoli or peritubular myoid cells.  Finally, none of the male samples 
were positive for both somatic cell and GC markers, suggesting that it is likely 
that only GCs, or somatic cells, but not both were added into each male sample. 
Of the female libraries, 15 were positive for GC markers and negative for 
somatic cell markers, identifying these as female GC libraries.  Of those 15, 9 
were positive for both GC markers (GC+/+/SOM-/-) and 6 positive for only one GC 
marker (GC+/-/SOM-/-), which was Dazl in all 6 cases.  Another 4 female samples 
were GC marker negative and somatic marker positive, identifying these as 
female somatic cell libraries.  Of those 4, 1 was positive for both somatic 
markers (GC-/-/SOM+/+) and the other 3 were positive for one somatic marker 
only (GC-/-/SOM+/-).  One female library, library 29, was positive for both 
somatic markers and one GC marker, which was Dazl (GC+/-/SOM+/+).  The fact 
that none of the 19 male or female no-cell controls was positive for any gene 
tested suggests that it is unlikely multiple cells were added together into any 
one sample, including library 29.  Therefore, the presence of somatic cell and GC 
markers in the female library 29 is likely due to cross-contamination after cell 
picking.  2 female libraries were negative for both GC and somatic markers (GC-




be due to insufficient RT and/or amplification of those cells during the 
procedure, or because those cells do not express detectable levels of these 
genes, in which case they could be cells other than germ, granulosa or theca 
cells. 
Only 9 of 15 female GC libraries were positive for both GC markers.  The 
remaining 6 libraries were Dazl+/Stella-.  The difference in detection between 
Dazl and Stella in the female libraries might be due to the fact that Dazl remains 
expressed in female GCs past E13.5/E14.5 (Seligman and Page, 1998), whereas 
Stella expression is downregulated at E13.5-E14.5 in female GCs (Sato et al., 
2002; Yamaguchi et al., 2005) or might be due to differences in the efficiency of 
Dazl/Stella amplification during the protocol.  The fact that 18/18 male GC 
libraries were positive for both GC markers suggests that the differences 
detected in female GC libraries may be the result of true differences in Dazl and 
Stella expression by E13.5 female GCs.  A Fischer’s exact statistical test result of 
0.0045 indicates that this sex-specific difference is statistically significant.  
However, biological replicate variation was not tested here and might have 
resulted in this apparent ‘sex-specific’ difference, especially because 4 out of 6 
of these Dazl+/Stella- libraries were collected in biological replicate 2 while the 
other 2 were collected in biological replicate 3, with none collected in biological 
replicate 1. 
18/27 (67%) male and 14/21 (67%) female libraries were GC libraries.  This is 
high compared to the proportion of GCs identified in the total cell population 
during FACS (Chapter 4, Section 4.2.1), which was less than 5%, even when 
taking into account that mesonephric cells were removed before single cells 
were picked in these single cell assays.  The reason that the proportion of GCs 
identified in the male (and female) libraries was so high was that there was a 
bias towards GC-like cells during the picking.  Therefore, the proportion of GC 
compared to somatic cell libraries here does not represent the true proportions 




The 15 female GC libraries and 15 of the male GC libraries were analysed for 
expression of genes of interest in this Chapter and in Chapter 4 (Section 4.2.2). 
3.5.2. Analysis of Id1, Id2 and Id3 Expression in Single 
E13.5 GC cDNA Libraries 
 
The results from the bHLH screen indicate that a number of genes are enriched 
in a sex-specific manner in E13.5 GC cDNA.  However, because there was 1-3% 
contaminating cells in the GC preparations (Figure 3.2.1), it is unclear whether 
this sex-specific enrichment originates from GC or contaminating somatic cell 
expression.  In order to ascertain which gonadal cells might be expressing the 
genes, single-cell reverse transcription PCR was performed on individual 
gonadal cells.  The analysis assessed the expression of Id1, Id2 and Id3, which 
were sex-specifically enriched in female E13.5 GC cDNA.  These were chosen for 
further confirmation because of their involvement in the cell cycle and are 
therefore might be involved in initiating meiosis in female GCs.   The analysis 
suggests that Id1 and Id3 could be expressed female-specifically in E13.5 GCs.  
However, due to the low number of GCs analysed (15 per sex spread over 3 
biological replicates), the results are only slightly significant and firm 
conclusions cannot be drawn. 
cDNA libraries were generated from single E13.5 gonadal cells and analysed for 
GC and somatic cell markers to identify the cell type, as detailed in section 3.5.1.  
For each sex, 15 GC cDNA libraries, 3 no-RT control samples, 2 somatic cell 
libraries and 1 dH2O negative control, were analysed for Id1, Id2 and Id3 
expression.  At least one of the 15 GC libraries and one of the 3 no-RT controls 
originated from each of the 3 separate collection experiments. 
The first 5 GC libraries of the 15 from each sex are shown in Figure 3.5.3 below, 
together with control samples.  The results from all 15 GC libraries are shown in 
Figure 3.5.3B.  These results were verified by a technical repeat of each PCR, 





Figure 3.5.3. Single-cell reverse transcription PCR of Id Genes in E13.5 GCs.  Single-cell 
cDNA libraries were generated from single male or female E13.5 gonad cells and tested for 
expression of the GC markers Dazl and Stella and the somatic cell markers SF1 and Sox9 for 
male libraries, and SF1 and Gata4 for female libraries, to ascertain the original cell type (See 
Figures 3.5.1 and 3.5.2).  15 GC+/somatic- libraries (labeled as “GC” above the gel), the 
analysis for 5 of which is shown here, along with no reverse transcriptase (-RT) controls, 
H2O negative controls, genital ridge (GR) cDNA positive controls, and 2 GC
-/somatic+ (SC) 
libraries per sex, were tested for Id1, Id2 and Id3 expression analysis by PCR and gel 
electrophoresis, (A).  A summary of the results from all 15 GC+/somatic- libraries for Id1, Id2 
and Id3 is shown, (B).  Fisher’s tests were carried out to ascertain the statistical significance 
of the results.  The number of libraries showing different combinations of Id1 and Id3 
detection, (C), was used to calculate (using a Phi analysis) a correlation efficient of 0.2182 






Only 1 out of 15 male GC+/somatic- samples were positive for Id1, compared 
with 6 out of 15 female GC+/somatic- samples.  A Fisher’s Test result of 0.0352 
shows this difference to be significant.  For Id3, 2 out of 15 male GC+/somatic- 
samples were positive whereas 9 out of 15 female GC+/somatic- samples were 
positive.  A Fisher’s Test result of 0.0209 shows this difference to be significant 
also.  For Id2, the story is different - 1 out of 15 male GC+/somatic- samples were 
positive whereas 0 out of 15 female GC+/somatic- samples were positive for Id2.  
Once more, this result was verified by a replicate PCR that obtained the same 
results.  This difference was not significant using a Fisher’s Test.  Of the 15 
GC+/somatic- female cDNA libraries, 5 were positive, while 4 were negative for 
both Id1 and Id3.  Using a Phi test, a correlation coefficient of 0.2182 was 
calculated, indicating weak or no correlation between Id1 and Id3 detection in 
GC+/somatic- female GC libraries. 
These single-cell PCR analyses are not very robust due to the small number of 
GCs tested from each biological replicate.  More thorough analyses that test a 
larger number of GCs per biological replicate would yield more useful data.  
However, what can be said from these analyses is that firstly, both Id1 and Id3 
transcripts were readily detectable in multiple cDNAs derived from single cells 
that are very likely to be GCs due to the combined detection of GC markers Dazl 
and Stella, and the absence of somatic marker detection.  This suggests that 
female GCs do express both Id1 and Id3, lending weight to the argument that the 
female-specific enrichments seen in the bHLH screen indicate higher expression 
of Id1 and Id3 in female GCs compared to male GCs.  Furthermore, significantly 
more female than male GC cDNA libraries expressed detectable levels of both 
genes. 
The primers used in the Id2 single-cell PCR are able to detect transcripts, as 
shown by robust products in the positive control (female genital ridge cDNA) 
and the 2 female GC-/somatic+ samples.  The failure of the single-cell PCR to 
detect a sex-specific difference of Id2, and furthermore, that transcript was 
detected in only 1 out of all 30 GCs, is at odds with the bHLH screen data 




cell contamination in the purified GC preparations used in the screen could 
account for this disparity.  Alternatively, owing to the large magnitude (30-fold) 
and reliability of the screen result, a more likely explanation is that the different 
primers sets used in the screen and this single-cell analysis detect alternative 
splice forms of Id2.  Id2 splice variants are postulated (Mantani et al., 1998), but 
have not been detected.  Unfortunately, primers to detect alternative splice 
forms of Id2 would not be suitable for this single-cell analysis, but it should be 





3.5.3. Id1 Protein Expression in E11.5-E13.5 Gonads 
 
The results of the bHLH screen suggest that Id1 mRNA is enriched sex-
specifically in E13.5 female GC cDNA.  The current section describes the result of 
immunofluorescence experiments to ascertain sex-specific enrichment of Id1 
protein in E13.5 GCs.  E11.5 and E12.5 tissue was also examined by 
immunofluorescence to discover when sex-specific differences in GC Id1 protein 
expression arise. 
For all embryonic stages studied (except the quantitative study at E13.5), at 
least 2 separate experiments were carried out on separately processed tissue 
and a similar result obtained.  The data from one of these experiments is shown 
in each of the figures below.  For each experiment, tissue sections were stained 
with Id1 antibodies (Perk et al., 2006), along with DAPI and anti-GC-marker 
antibodies – against cytoplasmic Dazl for E13.5 tissue and predominantly-
nuclear GCNA for E11.5 and E12.5 tissue - to identify GC nuclei.  For E12.5 and 
E13.5 experiments, consecutive sections from the same genital ridges were 
processed in identical fashion in parallel using IgG instead of Id1 antibodies as 
negative controls for Id1 staining.  For the E11.5 experiments, sections from 
different genital ridges were processed in parallel as negative controls.  At least 
3 genital ridges from different embryos were examined in each experiment, and 
representative images recorded.   
The monoclonal mouse IgG α-Id1 antibody (37-2) used here was developed 
using recombinant full-length mouse Id1 and produces a single clear band at 
17kDa by Western Blot, which corresponds to Id1 and does not appear in 
Western Blots of Id1 null HeLa cell extract (Perk et al., 2006).  In addition, one 
very faint non-specific band is seen by Western Blot at 34kDa using this 
antibody.  The monoclonal rat IgM α-GCNA antibody was developed previously 
more than 15 years ago (Enders and May, 1994), is reactive to an unknown GC 
antigen and has since been used in many research papers to specifically identify 




developed previously, against the C-terminal 22 residues of mouse Dazl (Ruggiu 
et al., 1997) and produces a  clear band on a Western blot that is absent from 
Dazl null cell extracts (Ruggiu et al., 2000). 
Background fluorescence was evident in the negative controls, and consisted of 
2 types.  Firstly, low-level homogenous staining was evident in cytoplasm and 
nucleus of all cells, and was of much lower fluorescence than the Id1-antibody-
associated staining.  Secondly, particular cells that were possibly red blood cells 
exhibited uniformly high-level fluorescence in red, green and blue channels 
throughout each cell (see asterisk-marked cells in low power images in Figures 
3.5.4A, 3.5.7A and 3.5.8A).  This high-level fluorescence was found in both IgG- 
and antibody-stained tissue, and was visible immediately following processing, 
before application of antibodies.  Therefore, this auto-fluorescence was ignored 
with respect to analysis of antibody-associated fluorescence.  Additionally, these 
cells were avoided when selecting regions of tissue for high power images.  In 
comparison to both these types of background fluorescence, Id1-associated 
fluorescence was nearly always nuclear and punctate. 
Figure 3.5.4 shows immunofluorescence images from Id1- and IgG-stained 
E13.5 tissue.  A clear difference is visible in the Id1 fluorescence intensity 
between male and female GC nuclei that is evident even in low power images.  
Male GC nuclei have consistently very low intensity or undetectable levels of Id1 
fluorescence, and staining of the testes is mostly restricted to the interstitial 
region.  Conversely, female GCs have heterogeneous levels of Id1 fluorescence. 
A closer look at the E13.5 Id1-stained male tissue (high power images in Figure 
3.5.4B) shows that the only cells located in the testicular cords with detectable 
Id1 levels have Dazl- cytoplasm, whose shape and location at the perimeter of 
the testis cords suggests they are Sertoli Cells.  A very minor fraction of the GCs 
in E13.5 male tissue appear to have detectable levels of punctate Id1 
fluorescence that is higher than background IgG levels.  Interstitial cells, on the 




background levels comparable to male GC nuclei to higher Id1 fluorescence that 
is punctate. 
High power images of E13.5 female Id1-stained tissue confirm that female GC 
nuclei have heterogeneous Id1 fluorescence levels, and, where this staining is 
higher than background, is punctate.  An interesting pattern to the 
heterogeneous Id1 staining of E13.5 female GCs is evident.  Female GC nuclei 
with no Id1 fluorescence are usually grouped together, such as the group of 
female GCs in Figure 3.5.4.B pointed out by the white arrowhead, away from 
nuclei showing detectable levels of Id1 fluorescence. 
In summary then, nearly all Dazl+ GCs in male E13.5 gonads had undetectable or 
almost undetectable nuclear Id1 fluorescence while, conversely, Dazl+ GCs in 
female E13.5 gonads had heterogeneous levels of nuclear Id1 fluorescence that 







Figure 3.5.4. Id1 Immunofluorescence 
of E13.5 Genital Ridges. E13.5 male 
and female genital ridge sections 
underwent immunostaining against 
Id1 and Dazl.  Consecutive sections 
were stained in parallel for IgG and 
Dazl as negative controls for Id1 
staining.  Each image is displayed with 
red, green and blue channels split into 
separate panels as follows, top to 
bottom: mixed red (Id1) and green 
(Dazl) channels; red channel alone; 
green channel alone; blue channel 
alone (for high power images only) 
shows DAPI-stained DNA.  In the low-
power (x10) images, (A), scale bars are 
50µm; asterisks mark cells with high 
level autofluorescence in red, green 
and blue channels that appears 
yellow/orange in the topmost panel;  
“c”s mark a testis cord; and “i”s mark 
the interstitial region. In the high 
power (x40) images, (B), scale bars are 
10µm; white arrows mark a 
representative female GC nucleus with 
high Id1 fluorescence; white 
arrowheads mark representative male 
and female GC nuclei with 
undetectable Id1 fluorescence; and 
black arrows with white outline mark a 









Figure 3.5.5. Outline of Quantitative Immunostaining Protocol. Embryonic genital ridges were dissected and wax embedded and sectioned onto 
three slides. Half of the sections on each slide were stained with antibody (Ab) and the other half with IgG as negative control. One Image of a 
representative antibody-stained cell field and one of a representative IgG-stained cell field were recorded from each slide, (A). Average Id1 staining 
for each nuclei in these images was analysed in Adobe Photoshop CS in the following way, as in (B). For each image recorded, GCs (germ cells) were 
first identified by cytoplasmic Dazl immunostaining in the green channel, (a), and all GC nuclei delineated with the select tool in the DAPI/blue 
channel, (b). The Id1 staining level for each nuclei was then calculated by taking the mean red channel pixel intensity inside the selected area for each 




In order to quantify these sex-specific differences in Id1-antibody staining of 
E13.5 GCs and to quantifiably define the heterogeneous Id1 fluorescence levels 
in E13.5 female GCs, nuclear Id1 fluorescence levels were quantified in several 
images of male and female E13.5 gonads, as shown in Figure 3.5.5 and 3.5.6.  
Sections from genital ridges on 3 separate slides were processed for 
immunostaining.  Half of the sections on each slide were stained with Id1 and 
the other half with IgG as a negative control.  One high power image of a 
representative cell field from each slide was recorded.  The mean nuclear Id1 
(red channel) pixel intensity of nuclei of Dazl+ (green channel) cells was 
recorded and the mean of all Dazl+ nuclei from each image calculated.  The 3 
means were combined and the standard errors propagated to obtain the results 
shown in Figure 3.5.6A (Male Id1 = 20.8 ± 3.4; Male IgG = 27.3 ± 4.9; Female Id1 
= 43.2 ± 8.3; Female IgG = 21.5 ± 2.9; n = 3 for each).  The mean Id1 fluorescence 
levels for female GC nuclei were ~200% that of male GC nuclei.  This sex-specific 
difference is statistically significant (P=0.0117).  256 out of 400, or 64%, of 
female E13.5 GC nuclei had Id1 fluorescence levels that were higher than 
background levels in IgG-stained female nuclei.  Therefore, this 64% of female 
GC nuclei expressed detectable levels of Id1 protein.  The mean Id1 fluorescence 
in male GC nuclei was similar to that of background-level fluorescence in IgG-
stained male GC nuclei, and 0 out of 354 male GC nuclei had higher Id1 levels 
than IgG stained male GC nuclei.  Therefore, E13.5 male GC nuclei express 
undetectable levels of Id1 protein. 
It is surprising to find that female GCs on average have only 2-fold more Id1 
fluorescence than male GCs, considering that female GCs express 40-fold more 
Id1 transcripts than male GCs according to the results from the bHLH screen.  
This discrepancy is unlikely to be due to low-level translation of abundant 
transcripts in female GCs.  A more likely explanation for this discrepancy is that 
the Id1 fluorescence levels shown here are not corrected for background.  
Therefore, background levels of fluorescence, which are only 2-fold lower than 




probably masking the true extent of the difference in Id1 protein levels between 
male and female GCs.   
 
 
Figure 3.5.6.  Quantification of Id1 Immunofluorescence Intensity of E13.5 GCs. Sections 
from 3 separate genital ridges per sex were analysed quantitatively for anti-Id1 
immunostaining.  Consecutive sections from the same genital ridges were analysed in 
parallel for IgG as negative controls.  1 representative image per gonad was recorded and 
the mean red (Id1/IgG) pixel intensity for each GC nuclei measured.  GCs were identified by 
manual inspection of the cytoplasmic Dazl staining of each nucleus, and nuclei of GCs were 
manually delineated with reference to the DAPI staining signal.  The mean intensity from 
the 3 images was averaged to obtain the results represented by the bars in the chart, and 
the error bars represent the SD of these means, which was propagated throughout.  Data 
from Id1-stained sections is represented as a small red-and-white-checked bar, while data 
from IgG-stained sections is represented as large black-and-white-checked bars.   An 
unpaired, two-tailed t-test was calculated and the result displayed as an asterisk: “*”, 
P<0.05. 
 
In order to determine when the sex-specific difference in Id1 expression arises, 
Id1/IgG immunostaining was carried out on E11.5 and E12.5 genital ridge 
sections.  E11.5 embryos were sexed by PCR before processing for 
immunostaining.  Both male and female E11.5 GC nuclei have heterogeneous Id1 
fluorescence levels (Figure 3.5.7).  Some GCs have low Id1 fluorescence at or 
close to background levels, such as the GCs indicated by white arrowheads in 
the high power images in Figure 3.5.7B.  The majority have noticeably higher 




3.5.7B.  Some somatic nuclei have very high Id1 fluorescence and are the most 
highly-stained cells. 
At E12.5, there is a clear sex-specific difference in GC Id1 fluorescence (Figure 
3.5.8).  E12.5 male GC nuclei have undetectable levels of Id1 fluorescence.  
Female GCs, on the other hand, have heterogeneous levels of punctate Id1 
fluorescence that is higher than background IgG levels in the vast majority of GC 
nuclei.  Heterogeneous levels of punctate Id1 fluorescence are also seen in 
female somatic cells and in male somatic cells in the interstitial regions of the 
gonads.  The Id1 fluorescence of E12.5 female GC nuclei is generally high and it 
is difficult to find female GCs with comparatively low Id1 fluorescence.  This is in 
contrast to the Id1 fluorescence staining of E13.5 female GCs, which is more 
heterogeneous. 
Qualitative inspection of the data suggests that the ratio of high/low-level Id1 
fluorescent female GC nuclei decreases between E12.5 and E13.5, when female 
GCs commit to meiosis. However, the lack of quantitative analyses of the Id1 
fluorescence levels of E12.5 female GC nuclei here makes this impossible to 
confirm. 
So, in summary, male and female E11.5 GCs have heterogeneous levels of 
punctate Id1 fluorescence in their nuclei, proportionally more of which have 
higher fluorescence levels.  No sex-specific difference is obvious at E11.5.  This 
suggests that, at E11.5, male and female GCs express similar levels of Id1 
protein.  Between E11.5 and E12.5 a change occurs in male GCs, whose nucleic 
Id1 fluorescence drop to undetectable levels, whereas female GCs continue to 
have heterogeneous Id1 fluorescence.  According to this, male GCs sex-
specifically stop expressing Id1 protein, at a time when they also commit to 
spermatogenesis and enter mitotic arrest.  At E13.5, this pattern is continued: 
male GCs still do not express Id1, while female GCs continue to express 





Figure 3.5.7. Id1 Immunofluorescence 
of E11.5 Genital Ridges. E11.5 male 
and female genital ridge sections 
underwent immunostaining against 
Id1 and Dazl.  Consecutive sections 
were stained in parallel for IgG and 
GCNA as negative controls for Id1 
staining.  Each image is displayed with 
red, green and blue channels split into 
separate panels as follows, top to 
bottom: mixed red (Id1) and green 
(GCNA) channels; red channel alone; 
green channel alone; blue channel 
alone (for high power images only) 
shows DAPI-stained DNA.  In the low-
power (x10) images, (A), scale bars are 
40µm; asterisks mark cells with high 
level autofluorescence in red, green 
and blue channels that appears 
yellow/orange in the topmost panel. 
In the high power (x63) images, (B), 
scale bars are 10µm;  white arrows 
mark representative male and female 
GC nuclei with high Id1 fluorescence; 
and white arrowheads mark 
representative male and female GC 









Figure 3.5.8. Id1 Immunofluorescence 
of E12.5 Genital Ridges. E12.5 male 
and female genital ridge sections 
underwent immunostaining against 
Id1 and GCNA.  Consecutive sections 
were stained in parallel for IgG and 
GCNA.  Each image is displayed with 
red, green and blue channels split into 
separate panels as follows, top to 
bottom: mixed red (Id1) and green 
(GCNA) channels; red channel alone; 
green channel alone; blue channel 
alone (for high power images only) 
shows DAPI-stained DNA.  In the low-
power (x20) images, (A), scale bars are 
50µm; asterisks mark cells with high 
level autofluorescence in red, green 
and blue channels that appears 
yellow/orange in the topmost panel;  
“c”s mark a testis cord; and “i”s mark 
the interstitial region. In the high 
power (x40) images, (B), scale bars are 
10µm; white arrowheads mark a 
representative male GC nucleus with 
very low Id1 fluorescence; white 
arrows mark a representative female 
GC nucleus with high Id1 fluorescence; 
and black arrowheads with white 
outline mark a representative female 





3.5.4. Mnt Protein Expression in E11.5-E13.5 Gonads 
 
The results of the screen in Section 3.4.4 show that Mnt mRNA is sex-specifically 
enriched in E13.5 male GC cDNA.  In order to support this result and to see 
whether male and female E13.5 GCs specifically express different levels of Mnt 
protein, fluorescence immunostaining was carried out on paraffin-embedded 
E13.5 male and female gonad sections.  In addition, E12.5 and E11.5 gonad 
sections were also examined by fluorescence immunostaining in order to 
determine when sex-specific differences in GC Mnt staining first arise. 
For all embryonic stages studied (except the quantitative study at E13.5), at 
least 2 separate experiments were carried out and a similar result obtained.  For 
each experiment, tissue sections were stained with GCNA antibodies and DAPI, 
in addition to Mnt antibodies, to identify GC nuclei.  Consecutive sections from 
the same gonads and fixed onto the same slides were stained in parallel with IgG 
instead of Mnt as negative controls for Mnt staining.  At least 3 separate gonads 
were examined in each experiment, and representative images recorded. 
The rabbit α-Mnt polyclonal antibodies used for these immunofluorescence 
experiments was obtained from Santa Cruz Biotechnology, developed against 
residues 226-361 of human Mnt and produces a clear band on a Western of 
mouse cell extract that disappears when Mnt is knocked down by antisense RNA 
(Popov et al., 2005).  Verification and source of the GCNA antibodies was 
described at the beginning of Section 3.5.3. 
The majority of cells in the IgG controls, as shown in the figures below, had low, 
background levels of fluorescence in nuclei and cytoplasm.  A minority of cells in 
E12.5 and E13.5 tissue, believed to be red blood cells, had consistently highly 
intense autofluorescence in red, green and blue channels (see asterisk-marked 
cells in IgG controls in Figure 3.5.9A and Figure 3.5.12A).  The fluorescence in 
these cells appeared after processing of the tissue prior to addition of 




staining patterns.  Also, when fields for high power images were chosen, these 
cells were avoided. 
Throughout all embryonic stages examined, Mnt fluorescence overlapped 
strongly with DAPI and was therefore predominantly nuclear.  Figure 3.5.9 
shows representative images of Mnt immunostaining on E13.5 gonad sections.  
As shown in the low power images in part (A) of the figure, a difference in the 
pattern of Mnt immunofluorescence between male and female gonads is 
evident.  GCNA+ GC nuclei in the male gonad have relatively similar fluorescence 
levels to that of the majority of GCNA- somatic cells1.  Mnt fluorescence between 
GCs and non-GCs in the female gonad is more heterogeneous: regions of GCNA+ 
GC nuclei have low Mnt fluorescence in comparison to surrounding GCNA- 
nuclei. 
High-power images of E13.5 gonad tissue (Figure 3.5.9B) confirm this sex-
specific difference in staining patterns, and suggest that male GC nuclei have 
higher Mnt fluorescence than female GC nuclei.  For example, compare the male 
and female GCs marked by white arrows in Figure 3.5.9B.  Female somatic cells 
also have higher Mnt fluorescence than female GCs – compare the GCNA-  
somatic nucleus (black arrowhead with white outline) with the GCNA+ GC 
nucleus (white arrow). 
 
                                                             
1 There were also some unidentified GCNA- interstitial cells that had very high Mnt fluorescence 
levels but these are not discussed further.  Some of these can be seen in the male low power Mnt 





Figure 3.5.9. Mnt Immuno-
fluorescence of E13.5 Genital Ridges. 
E13.5 male and female genital ridge 
sections underwent 
immunofluorescence for Mnt and 
GCNA.  Consecutive sections were 
stained in parallel for IgG and GCNA 
as negative controls for Mnt staining.  
Each image is displayed with RGB 
channels split as follows, top to 
bottom: mixed red (Mnt) and green 
(GCNA) channels; red channel alone; 
green channel alone; blue channel 
alone (for high power images only) 
show DAPI-stained DNA.  In the low-
power (x20) images shown, (A), scale 
bars are 50µm; asterisks mark cells 
with high level autofluorescence in 
red, green and blue channels, that is 
orange in appearance in the top 
panels;  “c” marks a testis cord; and 
“i” marks the interstitial area, 
containing somatic cells with high 
Mnt signal.  In the high power (x63) 
images, (B), scale bars are 10µm.  
White arrows mark representative GC 
nuclei and black arrowheads with 
white outlines mark GCNA- somatic 




To ascertain the robustness of these observed differences, the staining 
intensities of Mnt-stained and GCNA-stained E13.5 tissue were analysed 
quantitatively (Figure 3.5.10).  The analysis was accomplished identically to the 
Id1 quantitative immunofluorescence (Figure 3.5.5), except two instead of three 
slides were analysed.  Therefore, the Mnt pixel intensities quoted below and in 
Figure 3.5.10 are the mean of two cell fields of GC nuclei.  Half the sections on 
each slide were stained for Mnt and GCNA, while the other half were stained for 
IgG and GCNA as negative controls.  Another difference between this analysis 
and the Id1 quantitative immunofluorescence is that both Mnt (red channel) 
and GCNA (green channel) pixel intensities were recorded (as opposed to Mnt 
alone) for both GCNA+ GCs and GCNA- somatic cells (as opposed to GCs alone).  
GCNA+ GC nuclei were identified by manual inspection of the GCNA staining 
pattern.  GCNA- cell nuclei were identified by definite absence of GCNA staining. 
The mean Mnt pixel intensity of male GCNA+ GCs was significantly higher than 
that of female GCNA+ GCs, with a P value of 0.0061 calculated using an unpaired 
2-tailed t-test (male GC Mnt  = 120.1 ± 3.06, n = 2, female GC Mnt = 77.85 ± 1.27, 
n = 2).  Background fluorescence of IgG-stained nuclei was much lower than the 
Mnt fluorescence of the tissue sections from the same gonads, which were 
handled in parallel, and these differences were also significant.  A P value of 
0.0020 (male GC Mnt = 120.1 ± 3.06, n = 2, male GC IgG = 24.46 ± 2.93, n = 2) 
was calculated comparing male Mnt-stained with male IgG-stained GCs, and a P 
value of 0.0035 (female GC Mnt = 77.85 ± 1.27, n = 2, female GC IgG = 25.22 ± 
2.85, n = 2) was calculated comparing female Mnt-stained with female IgG-
stained GCs.  Therefore, male GC nuclei have significantly higher Mnt staining 
levels than female GC nuclei at E13.5.  Also, the levels of Mnt staining in male 
and female GC nuclei were significantly higher than background staining due to 
IgG. 
Additionally, a P value of 0.0271 was calculated (female GC Mnt = 77.85 ± 1.27, n 
= 2, female somatic Mnt = 92.77 ± 2.16, n = 2) when comparing Mnt 
fluorescence levels of female GC nuclei and female somatic nuclei.  Conversely, 




nuclei and male somatic cell nuclei.  Therefore, Mnt staining levels of female GCs 
are significantly lower than those of female somatic cells, while male GCs and 
somatic cells have the same levels of Mnt immunostaining. 
                 
Figure 3.5.10.  Quantification of Mnt Immunofluorescence Intensity of E13.5 Gonadal 
Cells. Sections from 2 separate gonads per sex were analysed by quantitative 
immunofluorescence for Mnt and GCNA.  Consecutive sections from the same gonads were 
analysed in parallel for IgG and GCNA as negative controls.  2 images per gonad (a total of 4 
images per condition: Male Mnt/Female Mnt/Male IgG/Female IgG) were recorded and the 
mean red (Mnt/IgG) and green (GCNA) pixel intensity for each nuclei (demarcated by DAPI 
staining) measured.  The mean intensity from the 4 images was averaged to obtain the 
results represented by the bars in the chart and the error bars represent the SEM of these 
means.  Red (Mnt/IgG) pixel intensity is represented by small red and white checked bars; 
green (GCNA) pixel intensity is represented by large green and white checked bars.  GCNA+ 
nuclei (A) were identified manually by inspection of the GCNA staining pattern of each 
nuclei.  All other nuclei, which include true somatic cells and GCs with very low GCNA 
staining were classed as GCNA- (B).  An unpaired, two-tailed t-test was calculated and the 





Figure 3.5.11. Mnt Immuno-
fluorescence of E11.5 Genital Ridges.  
E11.5 male and female genital ridges 
were sexed by PCR then processed 
for immunofluorescence staining for 
Mnt and GCNA.  Consecutive sections 
were stained for IgG and GCNA as a 
negative control for Mnt.  Each image 
is displayed with RGB channels split 
as follows, top to bottom: mixed red 
(Mnt) and green (GCNA) channels; 
red channel alone; green channel 
alone; blue channel alone (for high 
power images only) displayed DAPI-
stained DNA.  In the low-power (x10) 
images shown, (A), scale bars are 
40µm.  In the high power (x40) 
images, (B), scale bars are 10µm and 
white arrows mark representative 
GCs, which in male and female have 








In conclusion, these Mnt fluorescence patterns suggest that E13.5 male GCs 
express higher levels of Mnt protein than E13.5 female GCs, at a stage when 
male GCs have committed to spermatogenesis and are entering mitotic arrest.  
To ascertain when this sex-specific difference in Mnt protein levels arises, 
immunofluorescence experiments were performed on E11.5 (Figure 3.5.11) and 
E12.5 (Figure 3.5.12) genital ridges. 
Gonads from several E11.5 embryos were sexed by PCR and processed for and 
analysed by Mnt or IgG immunofluorescence staining.  This analysis was 
repeated on one separate occasion, with similar results.  Figure 3.5.11 shows 
representative images from these analyses.  All GCNA+ GC nuclei in both male 
and female gonads stained strongly for Mnt, and were among the most strongly 
Mnt-stained nuclei. 
To conclude, male and female E11.5 GC nuclei had very similar levels of Mnt 
fluorescence, and these staining intensities were higher than the Mnt staining of 
the surrounding somatic nuclei. 
At E12.5, Mnt immunostaining in male and female GC nuclei is much more 
heterogeneous than that at E11.5 (Figure 3.5.12).  The general pattern and sex-
specific intensity differences of Mnt staining are similar to that observed at 
E13.5.  As shown in the high power images in Figure 3.5.12B, GCNA+ GC nuclei in 
the E12.5 female gonad have generally less intense Mnt staining than their 
surrounding GCNA- somatic nuclei, and furthermore appear to have less intense 
ttt 
Figure 3.5.12.  Mnt Immunofluorescence of E12.5 Genital Ridges.  E12.5 male and female 
genital ridge sections underwent immunofluorescence for Mnt and GCNA.  Consecutive 
sections were stained for IgG and GCNA as a negative control for Mnt.  Each image is 
displayed with RGB channels split as follows, top to bottom: mixed red (Mnt) and green 
(GCNA) channels; red channel alone; green channel alone; blue channel alone (for high 
power images only) displayed DAPI-stained DNA.  In the low-power (x20) images (A) shown, 
scale bars are 40µm; asterisks mark cells with high level autofluorescence in red, green and 
blue channels; “g” marks the gonad; and “m” marks the mesonephroi.  In the high power 
(x63) images, (B), scale bars are 10µm.  White arrows mark representative GC nuclei with 
relatively intermediate Mnt staining levels, while white arrowheads mark female GC nuclei 




Mnt staining compared to GCNA+ E12.5 male GC nuclei.  For example, compare 
the 2 male GCs indicated by white arrows with the 2 female GCs in the left 
female panel and the female GC in the right female panel indicated by white 
arrowheads.  Other female E12.5 GC nuclei, however, have Mnt fluorescence 
intensity similar to that seen in the majority of male GC nuclei and the 
surrounding female somatic nuclei.  2 such female GCs are indicated by white 
arrows in the right female panel in Figure 3.5.12B.   
Qualitatively therefore, Mnt staining of E12.5 tissue was similar to, but not as 
sexually different as that in E13.5 tissue.  Mnt levels were not quantified in 
E12.5 tissue. 
In conclusion to this section, at E11.5, both male and female GC nuclei have high 
Mnt immunofluorescence intensities and no sex-specific difference is seen at 
this early stage when GCs are sexually bipotential.   At E12.5, a time when male 
GCs have just committed to spermatogenesis, sex-specific differences in Mnt 
staining intensities arise.  GC nuclei no longer have such predominant Mnt 
staining intensity compared to the surrounding somatic cells, and this is most 
obvious for female GC nuclei, which have heterogeneous Mnt staining intensities 
that are in general noticeably lower than male GC nuclei.  By E13.5, when male 
GCs are entering a mitotic arrest and female GCs are entering meiosis, male GC 





3.6. bHLH Screen Discussion 
 
Previous studies have identified several bHLH genes as having functions at 
different stages of GC differentiation.  Both Sohlh1 and Sohlh2 are required for 
mitosis-meiosis transition of spermatogonia in testis (Ballow et al., 2006; Hao et 
al., 2008; Toyoda et al., 2009), while ablation of either gene results in sterility of 
female mice due to defects in oogenesis (Choi et al., 2008; Pangas et al., 2006; 
Toyoda et al., 2009).  Figla is also required for successful oogenesis, because 
Figla knockout results in defective folliculogenesis that begins perinatally and is 
associated with deficient oogenic expression (Soyal et al., 2000).  Additionally, 
both Ngn3 and Tcfl5 are believed to be involved in spermatogenesis – Ngn3 is 
expressed in both spermatogonial stem cells and  undifferentiated 
spermatogonial stem cells (Yoshida et al., 2004), whereas Tcfl5 has been shown 
to bind to the promoter of Calmegin, a gene first expressed in meiotic prophase, 
stimulate Calmegin transcription, and is expressed in primary spermatocytes 
and spermatids (Siep et al., 2004).  So bHLHs are known to have roles in 
postnatal stages of GC development.  The dominant negative bHLH Id1 was 
previously identified as being sex-specifically enriched in E13.5 female GC cDNA 
(Adams, I.R., unpublished data).  Id1 maintains cells such as embryonic stem 
cells (Ying et al., 2003) and myoblasts (Jen et al., 1992) in an undifferentiated 
state by preventing bHLH-mediated differentiation (Ruzinova and Benezra, 
2003).  Therefore, it was hypothesised that differential expression of Id1 and 
other bHLHs might be involved in sex-specific differentiation of E13.5 GCs.  This 
screen was carried out to find out which bHLHs are sex-specifically expressed in 
E13.5 GCs. 
 
Diverse Sex-specific Differences in bHLH Expression of E13.5 GCs 
The findings of this screen are very positive, in that 20 out of 114 genes were 




replicates.  14 genes were found to be enriched sex-specifically, while another 6 
genes were expressed sex-specifically over 2 biological replicates, suggesting 
that there may be striking differences in bHLH-mediated transcription between 
male and female GCs at E13.5.  Interestingly, 15 of those genes were 
enriched/specifically-expressed in female cDNA, while only 5 were in male 
cDNA, and additionally the fold-enrichments for female-enriched genes were 
generally much higher than those of the male-enriched genes.  This suggests 
that female GCs express higher levels of a variety of bHLH genes at a time when 
they are initiating meiosis (McLaren, 1984).   
Figla and Ngn3 were here found to be enriched in female, or male GC cDNA, 
respectively.  Previous studies show that both Figla (Soyal et al., 2000) and 
Ngn3 (Yoshida et al., 2004) are involved in sex-specific GC development, albeit 
at postnatal rather than embryonic stages.  Figla expression was first detected 
female-specifically at E13.0 by RNAse protection of whole gonads (Soyal et al., 
2000), confirming the female-specific expression detected in this screen in 
E13.5 GCs.  Defects in female GC development in Figla knockout mice are first 
seen at 1 or 2 days post partum, which is the same time that Figla expression 
peaks at roughly 30-fold of the levels detected at E13.0.  Therefore, the sex-
specific expression detected in this screen in E13.5 female GCs does not appear 
to be required for meiotic initiation and embryonic development of female GCs.  
Germline expression of Ngn3 was previously not detected at either E13.5 or 
E18.5 by in situ hybridisation, Northern hybridisation or reverse transcription 
PCR (Yoshida et al., 2004), although the results of these assays were not shown, 
and this is in disagreement with male-specific detection in this study at E13.5.  
The discrepancy of these previous findings with the current screen could be due 
to the use of more sensitive RtPCR assays using purified GC cDNA in this screen. 
Epas1, Helt, Mnt, Msc and Ngn3 were enriched sex-specifically in male E13.5 GC 
cDNA.  Helt expression in the adult is restricted to testis (Guimera et al., 2006a).  
However, GC expression of Helt has not yet been shown and the expression seen 
in purified GCs in this study could originate from GC or somatic cell expression.   




postnatally, and analysis of GC development in these mice has not yet been 
published.  Msc was detected sex-specifically in male GC cDNA, and could 
therefore be an interesting candidate gene.  Msc knockout results in only mild 
facial muscle defects and no fertility defect of male or female mice was reported 
(Lu et al., 2002) so a vital role for Msc in male-specific GC development is ruled 
out. 
The bHLHs enriched/detected sex-specifically in female E13.5 GC cDNA are 
spread across all bHLH classes except Class A.  Of those genes, Mesp1 (Saga et al., 
1999), Scx (Brown et al., 1999) and Hand1 (Riley et al., 1998) knockouts die 
embryonically before sex-specific GC differentiation, precluding straightforward 
examination of roles for these genes in sex-specific GC differentiation.  Math1 
(Ben-Arie et al., 1997) and Hes7 (Bessho et al., 2001) knockouts die postnatally 
before fertility could be assessed, while no knockouts have been carried out for 
Ebf4 and Mxd4.  Bhlhb2 (Sun et al., 2001), Mlxipl (Iizuka et al., 2004), Ahrr 
(Hosoya et al., 2008) and Bhlhb4 (Bramblett et al., 2004) knockouts are viable 
and fertile, which rules out critical roles for these genes in sex-specific 
differentiation of GCs. 
 
The Myc Antagonist Mnt is Enriched in Male E13.5 GCs 
The bHLH-Zip Mnt was enriched 3-fold in male GC cDNA.  Because of its role in 
suppressing the cell cycle by antagonising Myc activity (Hooker and Hurlin, 
2006), it was decided to look into GC expression of Mnt more closely and ask the 
question of whether Mnt could be involved in the developmental decision of 
male GCs to enter mitotic arrest at E12.5.  This male-specific Mnt mRNA 
enrichment was confirmed at the protein level by Mnt immunofluorescence, 
which found 2-fold higher Mnt immunofluorescence levels in E13.5 male GC 
nuclei compared to female GC nuclei.  According to this, male GCs express higher 
Mnt protein than female GCs at E13.5, but the actual sex-specific fold-
enrichment of male Mnt levels would be higher than 2-fold if corrected for 




(Hooker and Hurlin, 2006).  Firstly, Mnt competes with Myc for binding to Max, 
which is required for Myc function.  Secondly, Mnt-Max heterodimers compete 
with Myc-Max heterodimers for binding to the same promoter target sequences, 
and inhibits their expression.  Some of these Myc targets are Cyclins A1, B, D1, 
D2 and E1, Cdk4 and E2F2 (Walker et al., 2005), expression of which stimulates 
progression through various cell cycle transitions for example by 
phosphorylating retinoblastoma protein (Rb) and removing Rb-mediated 
inhibition of S-phase entry (Trimarchi and Lees, 2002).  Acute removal of c-Myc 
from murine embryonic fibroblasts by Cre-mediated recombination results in 
almost complete loss of S phase entry (Walker et al., 2005).  In these cells, 
simultaneous removal of Mnt restores S-phase entry to nearly wild-type levels, 
indicating that in the absence of c-Myc, Mnt prevents cell cycle entry.  A possible 
mechanism for this is hypophosphorylation of Rb, because acute removal of Mnt 
results in hyperphosphorylation of Rb.  Between E12.5 and E13.5, Rb in male 
GCs is completely converted from a hyperphosphorylated form into a 
hypophosphorylated form (Western et al., 2008) and this might contribute to 
mitotic arrest of male GCs.  Is higher Mnt protein in male GCs responsible for 
this? 
Mnt levels in male E13.5 GCs are not consistently high, and furthermore, Mnt 
immunostaining levels are very high at E11.5, when GCs are actively 
proliferating.  Therefore, it seems unlikely that a change in Mnt levels can 
account for mitotic arrest of male GCs at E13.5.  Instead, a theoretical role for 
Mnt in stimulating or augmenting mitotic arrest of male GCs would be that a 
drop in active Myc activity in E12.5-E13.5 male GCs allows cell cycle 
suppression by Mnt, among other mechanisms.  This is supported by data 
indicating that Mnt suppresses cell-cycle re-entry and proliferation of cells in 
which c-Myc is removed, because subsequent removal of Mnt rescues these cell 
cycle defects ((Nilsson et al., 2004; Walker et al., 2005).  Furthermore, many of 
the hallmarks of c-Myc or N-Myc gene removal, including delay of cell-cycle re-
entry and embryonic lethality, are phenocopied by Mnt overexpression (Hurlin 




could be that Mnt is not required for mitotic arrest of E13.5 male GCs and the 
sex-specific difference in Mnt levels is simply a consequence, rather than a 
cause, of sex-specific differentiation of GCs.  Similarly, high Mnt protein 
expression in E11.5 GCs might be a result of high Myc activity in E11.5 GCs, 
because Mnt levels are responsive to acute changes c-Myc expression (Walker et 
al., 2005). 
One interesting finding is that E11.5 GCs, both in male and female genital ridges, 
have very high nuclear Mnt immunofluorescence and are potentially the highest 
Mnt-expressing cells in the genital ridges at that stage.  This is surprising 
because E11.5 GCs are actively proliferating, and may indicate that proliferation 
of GCs at this developmental stage occurs through Myc-independent pathways.  
Alternatively, these high Mnt levels are insufficient to completely block GC 
proliferation, which is supported by the fact that ectopic expression of Mnt in 
fibroblasts slows but does not completely block cell cycle progression (Walker 
et al., 2005) and also that both migratory and post-migratory GCs have a 
doubling time of roughly 16 hours, which is slower than their proliferation 
before specification (Lawson and Hage, 1994; Tam and Snow, 1981).  
Comparing the consistently high Mnt levels at E11.5 with the low Mnt levels at 
E13.5 suggests that female GCs downregulate Mnt between E11.5 and E13.5 as 
they prepare for meiosis.  This might be a mechanism to prevent Mnt from 
interfering with meiotic entry.   
 
Multiple Id Genes are Enriched in Female E13.5 GCs 
The Id genes have very well-documented roles in stimulating S-phase and 
proliferation, which is why knockout of the Ids, especially Id1, Id3 and Id4, 
results in decreased proliferation of various stem cell populations in vivo.  In 
this screen, Id1 and Id3 were female-specifically enriched in E13.5 GC cDNA, by 
roughly 40-fold and 15-fold, respectively.  Id1 and Id3 expression was also 
detected in E13.5 female GC cDNA libraries by single-cell reverse transcription 




validating the female-specific Id1 and Id3 enrichments detected in the bHLH 
screen.  Immunofluorescence experiments also showed that female GCs express 
significantly higher levels of Id1 protein at E13.5 and probably E12.5 also.  
Could the Ids have roles in promoting meiotic entry of female GCs?  
Ids stimulate the cell cycle in a variety of ways, but in particular by inhibiting 
transcriptional activation of Cyclin-dependent kinase inhibitor (CDKI) genes 
mediated by Class A/B bHLHs (Garrett-Engele et al., 2007; Liu et al., 2004; 
Prabhu et al., 1997; Rothschild et al., 2006) and by increasing expression of 
Cyclins D1 and E1  (Jeon et al., 2008; Swarbrick et al., 2005), leading to increased 
CyclinD/E-Cdk activity (Swarbrick et al., 2005).  Meiotic defects in knockout 
animals of Cdk2 (Berthet et al., 2003; Ortega et al., 2003) and Cyclin A1 and 
expression of Cyclin A2 in E13.5-E15.5 female GCs (Persson et al., 2005) 
suggests that Id1 could affect the later stages of prophase I by stimulating 
expression of these genes.  However, no role has yet been shown for Cyclins or 
Cdks in meiotic initiation of mouse GCs (Satyanarayana and Kaldis, 2009), and 
the expression of Id1 was not assessed at later meiotic stages.  
Data from several studies suggests that Id1 and/or Id3 are dispensable for the 
initiation or progression meiosis.  Nuclear Id1 and Id3 immunostaining is absent 
in spermatogonial stem cells, differentiating spermatogonia and early 
spermatocytes in the adult testis (Sablitzky et al., 1998).  Additionally and more 
importantly, are the findings of one study that rescued the embryonic lethality 
of Id1/Id3 double knockout mice (Fraidenraich et al., 2004).  Double knockout of 
Id1 and Id3 results in embryonic lethality due to defects in cardiac development.  
However, the cardiac defects were rescued by injection of wildtype embryonic 
stem cells into the knockout blastocysts and the resultant chimaeric females 
were fertile and transmitted Id1-/Id3- alleles to offspring when mated with    
Id1-/-/Id3+/- male mice.  This indicates that neither Id1 nor Id3 are required cell-





Id2 was upregulated 30-fold in female GC cDNA but was not detected in female 
GC cDNA libraries by single-cell reverse transcription PCR, possibly due to a 
splice form not detected by the single-cell primers or because the single-cell 
PCR method was unable to detect Id2 transcripts from single cells.  GC 
expression of Id2 splice variants was not explored in this study, but should be 
investigated.  A role for Id2 in GC cell cycle control – either mitotic or meiotic – 
is attractive because of Id2’s unique ability to directly inhibit Rb (Lasorella et al., 
2000), in addition to the general mitogenic abilities of the Ids (Liu et al., 2004).    
However, Id2 knockout female mice are fertile and able to produce offspring, 
although are unable to wean them due to a lactation defect (Mori et al., 2000).  
Therefore, Id2 does not have a non-redundant role in female GC development.  
However, it is possible that only one of Id1, Id2 and Id3 is needed for any non-
redundant role of these three genes in triggering meiosis. 
 
Lack of Id Protein in Male GCs Could Facilitate Mitotic Arrest 
This study shows that the sex-specific difference of Id1 protein levels first 
appears between E11.5 and E12.5.  At E11.5, at a time when male GCs are 
actively proliferating at a high rate as shown by high BrdU incorporation 
(Western et al., 2008), male GCs express heterogeneous levels of Id1 protein, 
and this expression may relate to the phase of the cell cycle the GCs are in.  To 
show this would require a quantitative analysis of Id1 protein expression in 
male E11.5 GCs, which was not carried out in this study.  At E12.5 male GCs are 
committed to spermatogenesis and begin to enter mitotic arrest (Adams and 
McLaren, 2002; McLaren and Southee, 1997), and this coincides with almost a 
complete loss of detectable levels of Id1 protein in E12.5 male GCs.  The marked 
disappearance of Id1 protein in male GCs between E11.5 and E12.5 will serve as 
a useful marker for GCs committed to spermatogenesis, but also provides a 
plausible mechanism for augmentation of mitotic arrest of male GCs at E12.5.   
Loss of Id protein in male GCs would facilitate mitotic arrest of male GCs by at 




expression, both of which would lead to Rb hypophosphorylation and inhibition 
of S-phase entry.  Previous characterisation of cell cycle components in male 
GCs shows that Rb is present and hyperphosphorylated at E12.5, but by E13.5 
becomes hypophosphorylated, concomitantly with downregulation of Cyclin E 
(Western et al., 2008).  Downregulation of Id1 by siRNA expression in breast 
epithelial cells has previously been shown to result in reduced Cyclin E-Cdk2 
activity and pRB hypophosphorylation, and this was associated with decreased 
expression of Cyclin E and Cyclin D1 (Swarbrick et al., 2005).   
Western and colleagues found that male GCs express higher p21 and p27 
protein than female GCs at E13.5, and found that p27 protein levels increased 
between E12.5 and E13.5 in male GCs, concomitantly with Rb 
dephosphorylation (Western et al., 2008).  Previous studies utilising Id- 
knockdown or knockout strategies have demonstrated that Id proteins reduce 
proliferation and prevent differentiation by inhibiting expression of p21 in 
endothelial progenitors in vivo (Ciarrocchi et al., 2007) and  fibroblasts in vitro 
(Li et al., 2005a), p27 in cultured fibroblasts (Chassot et al., 2007) and human 
lymphomas (Garrett-Engele et al., 2007), and p16 in cultured human fibroblasts 
(Zheng et al., 2004).  Therefore, decreased Id1 in E12.5-E13.5 male GCs 
expression could result in increase p21 and p27 expression and this could 
translate into sex-specific increases in p21 and p27 protein expression, which 
could contribute to male GC mitotic arrest. 
Ids suppress CDKI expression by inhibiting the activity of various transcription 
factors, including ELK1 (Chassot et al., 2007), Ets1/2 (Ohtani et al., 2001; 
Stinson et al., 2003), Polycistins (Li et al., 2005b) and positively acting bHLHs 
(Garrett-Engele et al., 2007; Liu et al., 2004; Prabhu et al., 1997), all of which 
contribute to cell cycle arrest in cells in which they are expressed.  All 3 Class A 
bHLHs (E2A/Tcfe2a, E2-2/Tcf4 and HEB/Tcf12), were detected non-sex-
specifically in E13.5 GC cDNA, and Helt and Ngn3 were detected male-
specifically in the current study and, if they are expressed in male GCs, are 




Other bHLHs were detected non-sex-specifically but much more readily in E13.5 
GC cDNA than positive control cDNA, and are therefore promising candidates 
for GC-specific Class A bHLH heterodimer partners susceptible to Id1 inhibition.  
These include Sohlh1 and Sohlh2, which are required for male and female GC 
differentiation (Choi et al., 2008; Hao et al., 2008; Pangas et al., 2006; Toyoda et 
al., 2009).  Additionally, Tcfeb, which has a testis-specific splice form 
(Steingrimsson et al., 1998), and Tcfl5 (Siep et al., 2004), which is expressed in 
spermatocytes and controls Calmegin gene transcription, may have roles in GC 
development and might serve as targets for inhibition by Id1.  The male-
enriched Mnt would not be expected to interact with Id proteins as it belongs to 
the Max-network of bHLH-Zips, which generally do not interact with Ids and 
other non-bHLH-Zip bHLHs (Loveys et al., 1996; Murre et al., 1989). 
 
Sex-specific Signaling Could Affect GC Id Expression  
A variety of different signaling pathways stimulate Id expression.  Most notably, 
exposure of cells to serum (Barone et al., 1994; Hara et al., 1994) and BMPs 
(Hollnagel et al., 1999; Nakashima et al., 2001; Ying et al., 2003) results in 
increased Id gene activation.  BMPs are involved in multiple stages of GC 
development, such as primordial germ cell specification (Lawson et al., 1999; 
Ying et al., 2000; Ying and Zhao, 2001) and spermatogenesis (Zhao and Hogan, 
1996).  Knockout of Bmp7 results in reduced levels of proliferation of E10.5-
E11.5 mouse GCs according to phospho-Histone H3 staining, and the magnitude 
of the effect is more severe for GCs in male genital ridges (Ross et al., 2007), 
suggesting that there are sex-specific compensatory mechanisms in operation.  
The female genital ridge at E11.5 and E12.5 has higher Bmp2 and Bmp4 
expression (Ross et al., 2007; Yao et al., 2004), and this could compensate for 
Bmp7 knockout in female E11.5-E12.5 genital ridges.  The effect of lower BMP 
dosage on GC proliferation in the Bmp7 knockout might be mediated by a 
decrease in Id expression, because BMP stimulation of proliferation in other 




lower Bmp2 and Bmp4 expression in male gonads at E11.5-E13.5 could cause 
the lower Id expression seen in this screen and Id1 immunostaining in E12.5 
and E13.5 male gonads. 
Interestingly, a number of studies report that FGF signaling has a negative 
impact on Id expression.  FGF signaling through its receptors, such as Fgfr3, 
inhibits Id1 expression and induces mitotic arrest in chondrocytes (Rozenblatt-
Rosen et al., 2002), and also induces mitotic arrest of neuroblastoma cells that is 
associated with changes in Id1, Id2 and Id3 cellular localisation and enhanced 
p21 expression (Higgins et al., 2009).  FGF9 signaling serves as an essential 
reinforcement mechanism to ensure Sertoli Cell differentiation during the first 
stages of sex-specific testis development at E11.0-E12.5 (Colvin et al., 2001; Kim 
et al., 2006).  In Fgf9 knockout gonads, a direct effect of Fgf9 removal on GCs 
was not analysed, but E11.5-E13.5 GCs express multiple FGF receptors (Resnick 
et al., 1998; Schmahl et al., 2004) and are receptive to FGF signals (Resnick et al., 
1998), so it is possible that FGF9 signaling in the differentiating male gonad 






Chapter 4:  
Investigation of Sex-specific Ptgds 




4.1. Chapter Introduction and Aims 
 
Ptgds, a Prostaglandin D2 (PgD2) producing enzyme that is also a lipophilic 
molecule binding protein (Urade and Hayaishi, 2000), is sex-specifically 
upregulated in male gonads from E11.5 (Adams and McLaren, 2002).  In 
embryonic gonad development, Ptgds has a role in augmenting testis 
development, because Ptgds knockout in C57BL/6 mice results in a delay in 
testis development (Moniot 2009). 
This phenotype of C57BL/6 Ptgds knockout mice is probably due to the PgD2-
producing, rather than the lipocalin, function of Ptgds, for several reasons.  PgD2 
partially masculinises cultured bipotential XX gonads (Adams and McLaren, 
2002).  This masculinising effect of PgD2 is due to sex-reversal of XX supporting 
cells to a Sertoli cell fate via PgD2-mediated activation of intracellular cAMP and 
upregulation of Sox9 mRNA and protein expression in these cells (Malki et al., 
2005; Wilhelm et al., 2005).  PgD2 is also able to recruit non-Sry-expressing XY 
somatic cells to a Sertoli cell fate by an identical mechanism (Wilhelm et al., 
2005), and loss of this supplementary masculinising pathway probably accounts 
for the delay caused by Ptgds knockout in C57BL/6 mice.   
Ptgds mRNA has been detected in the cytoplasm of both Sertoli cells and GCs by 
in situ hybridisation (Adams and McLaren, 2002).  However, others dispute 
whether GCs express Ptgds mRNA (Wilhelm et al., 2007), even though Ptgds 
protein expression is detectable in GCs by immunostaining (Wilhelm et al., 
2007).   
The aim of the experiments in this chapter is to clarify whether E13.5 male GCs, 
which are committed to spermatogenesis, express Ptgds, whether they express 
any GC-specific isoforms of Ptgds, and whether they express Ptgds protein.  In a 
second set of experiments, this study aims to identify candidate signaling 
pathways controlling sex-specific commitment of GCs to spermatogenesis using 




4.2. Characterisation of Male-Specific Expression 
of Ptgds 
 
4.2.1. Ptgds PCR Analysis of E13.5 GC cDNAs 
 
PolyA+ mRNA was prepared from purified E13.5 male and female GCs and GFP- 
cells, which were purified and collected as described in the previous section, 
alongside E13.5 male and female genital ridge cells.  The GC, GFP- and genital 
ridge mRNAs were reverse transcribed, resulting in GC RT+, GFP- RT+ and GR 
RT+ cDNAs respectively.  Mock reverse transcribed GC mRNAs were generated 
simultaneously resulting in GC RT- cDNAs.   
GC RT+, GC RT- and GFP- RT+ cDNAs were checked by 30 cycles of end-point PCR 
for GC and somatic markers.  The GC marker Mvh was detected in GC RT+ cDNAs, 
but not in GC RT- cDNA or GFP- cDNAs.  Conversely, the somatic markers Gata4 
and Lhx9 were detected in GFP- cDNAs but not in GC RT+ cDNAs (Figure 4.2.1A).  
Therefore, the patterns of GC and somatic cell expression are preserved in the 
generated GC RT+ and GFP- cDNAs, and the lack of detection in GC RT- samples 
suggests that the detected products in the GC RT+ samples is RT-dependent and 
originates from GC mRNA expression.  In order to gauge the relative amounts of 
cDNA in the male and female GC RT+ cDNAs, these cDNAs were checked by semi-
quantitative PCR against the housekeeping genes Glyceraldehyde 3-phosphate 
Dehydrogenase (Gapdh) and β-actin (Actb) (Figure 4.2.1B).  Gapdh and Actb 
expression was always similar for the male and female GC cDNAs.   
Expression of somatic cell markers Amh and SF-1 was tested for male and 
female, respectively, GC RT+, GC RT- and GR RT+ cDNAs by semi-quantitative 
PCR at 25, 30, 35 and 40 cycles of PCR.  Detection of the somatic markers Amh in 






Figure 4.2.1. Characterisation of FACS-purified E13.5 GC Populations by Reverse 
Transcription PCR.  E13.5 male and female GCs were purified as described in Section 3.2 
(Figure 3.2.1).  PolyA+ mRNA was purified and reverse transcribed to make GC RT+ cDNAs.  
Mock reverse transcribed samples (RT-) were generated in parallel.  male and female GC RT+ 
and RT- samples, together with cDNA generated from the GFP- cell fraction obtained from 
FACS (GFP- RT+), were checked for expression of the GC marker Mvh, and the somatic cell 
markers Gata4 and Lhx9, by end-point PCR (30 cycles), (A). Semi-quantitative PCR, with 
aliquots removed for analysis at 25, 30, 35 and/or 40 cycles (as labeled above the gel in (B) 
and to the left of the gel in (C), was carried out on the male and female E13.5 GC RT+ 
samples for analysis of the housekeeping genes Gapdh and Actb, (B), and the somatic cell 
markers Amh for male cDNAs and SF-1 for female cDNAs, (C).  E13.5 genital ridge cDNA 
samples (GR RT+) were run alongside GC cDNAs for somatic cell marker expression in (C). 
Ptgds expression of GC RT+, GC RT- and male GR RT+ cDNAs was also assessed semi-
quantitatively, (D), at 30, 35 and 40 cycles, as labeled to the left of the gel in (C).  All these 
analyses were carried out on the same batch of GC cDNAs, and were replicated on 1 other 
batch of GC cDNA, with similar results.  PCR products were analysed by gel electrophoresis 
with 1kb ladder (Invitrogen) run in the left-most lane of all gels.  In all gels, black arrows 
with numbers indicate length of 1kb fragment, in nucleotides (nt).  Red arrows with 





shows that somatic cell gene expression is detectable in the GC cDNAs and likely 
originates from contaminating somatic cells in the purified GCs. 
Equivalent amounts of cDNA according to housekeeping gene semi-quantitative 
PCR were analysed by PCR using primers against part of the Ptgds coding region 
that are able to detect both known Ptgds splice variants, which differ by only 33 
nucleotides (nt) (Adams and McLaren, 2002).  Various products were detected 
in male cDNAs, but not in female cDNAs throughout the Ptgds expression 
analysis.  2 products were detected in male GC cDNA after 35 cycles of PCR 
(Figure 4.2.1D).  The larger product of roughly 260nt, which was more abundant 
than the smaller product of roughly 230nt, was also detected in male GR cDNA.  
This 260nt product corresponds to the larger splice form detected previously 
(Baker and O'Shaughnessy, 2001) and should give a product of 252nt using the 
current primers.  The 230nt product was not detected in male GR cDNA, and 
was therefore specific to male GC cDNA after 35 cycles.  The 230nt product 
corresponds to the shorter known splice form detected previously, which 
should give a product of 219nt with the current primers.  At 40 cycles, the 260 
and 230nt Ptgds products were more abundant in male GC cDNA, and a third 
product of roughly 200nt also appeared in male GC cDNA.  The 230nt product 
was also detected in GR cDNA after 40 cycles.    
A lack of detected product in the RT- samples suggests that the products 
detected in male GC cDNA originate from mRNA expression.  Additionally, Mvh 
and housekeeping gene transcripts were readily detected in the female GC 
cDNAs, indicating that RT of the female samples occurred as expected and 
female GC expression is detectable.  In summary, these data imply that 
detectable levels of Ptgds transcripts are expressed by cells in the male GC 
preparations, but not expressed by cells in the female GC preparations.  The 
longer splice form detected here at 260nt in male GC cDNA could be originate 
from GC expression of the longer Ptgds splice form, or might originate from 
expression by somatic cell contamination in the male GC preparations.  
However, detection of Amh, which is expressed highly by E13.5 Sertoli cells, in 




which is consistent with expression by a small contaminating population of 
cells.  On the other hand, expression of the 260nt splice form of Ptgds appeared 
at the same time (after 35 cycles) in male GC cDNA and male GR cDNA, albeit at 
a lower level in male GC cDNA, and this is consistent with low level expression 
by GCs rather than the contaminating somatic cells.  Therefore, the data do 
suggest that male GCs express the longer splice form of Ptgds. 
Similarly, the 230nt product appeared first in male GC cDNA at 35 cycles but did 
not appear in GR cDNA until 40 cycles, indicating that the shorter known Ptgds 
splice form might be expressed GC-specifically in E13.5 male genital ridges.  
However, although the same amount of RNA was input into the male GC and GR 
cDNAs, housekeeping gene expression of these cDNAs was not compared 
directly, putting this conclusion in doubt.  A more quantitative comparison of 
male GR cDNA with GC cDNA is required to make this a firm conclusion.  The 
200nt product detected only in male GC cDNA does not correspond to any 
previously identified splice form and could also represent a GC-specific splice 
form.  In summary therefore, the presence of multiple Ptgds splice forms that 
were not detected in male GR cDNA, and of Ptgds amplification consistent with 
expression by the majority of cells, in FACS-purified GC cDNA indicates that GCs 




4.2.2. Ptgds Expression in E13.5 Single Gonadal Cell 
cDNA Libraries 
 
15 E13.5 GC cDNA libraries from each sex that were generated and tested as 
described in the Section 3.5.1 (Figure 3.5.1 and 3.5.2 and Table 3.5.1) were 
selected for analysis of Ptgds expression, using different primers than those 
used for the Ptgds expression analysis of FACS-purified GC cDNAs in the 
previous section (Figure 4.2.1D).  The primers used here recognise both splice 
forms of Ptgds, which differ by 33 nucleotides (nt) in the 3’ un-translated region 
of the mRNA (Baker and O'Shaughnessy, 2001).  Ptgds expression analyses of 
the first 5 of the 15 GC cDNA libraries are shown in Figure 4.2.2, together with 
no-RT control samples and somatic cell libraries.  The male somatic cell libraries 
were Sox9 positive and therefore probable Sertoli cell libraries.  Ptgds 
transcripts were not detected in any of the 15 GC libraries of either sex.  
However, Ptgds transcripts were detected in male somatic cell libraries, 
indicating that Ptgds expression is detectable in the single-cell libraries.  A 
major product of roughly 175nt was detected in both male somatic cell libraries, 
and this corresponds to the longer known Ptgds splice form (Baker and 
O'Shaughnessy, 2001).  A minor product of roughly 150nt was also detected in 
one of the 2 male somatic libraries, and this corresponds to the shorter known 
splice variant.  Detection of the shorter splice form in this male Sertoli cell 
library suggests that Sertoli cells may express the shorter splice form in 
addition to the longer Ptgds splice form at detectable levels.  A second primer 
set, using primers designed specifically to recognise the longer Ptgds splice 
variant gave similar results – with products detected only in the male somatic 
cell libraries. 
This lack of Ptgds detection in E13.5 male GC cDNA libraries is in direct 
contradiction to the results of the previous section that detected 3 Ptgds splice 
forms after 40 cycles of PCR in FACS-purified E13.5 male, but not female, GCs 




detect the same Ptgds splice forms as the set used in the FACS analysis because 
they are designed to the same region of the Ptgds gene.  The results from the 
previous section attribute the detected Ptgds products to GC-specific 
expression; therefore, the most likely explanation for the lack of detection in the 
male GC libraries is because the Ptgds expression level in male GCs is below the 
detection limit of this single-cell assay. 
 
 
Figure 4.2.2. Ptgds PCR of Male and Female Single-Cell cDNA Libraries.  Germ cell (“GC”) 
and somatic cell (“SC”) cDNA libraries were generated, alongside no RT (“RT-“) control 
libraries, from single E13.5 male and female gonadal cells as described in Section 3.5.1, and 
were positive or negative for GC and somatic markers, as labeled (“+” or “-“), when tested 
by PCR.  5 of these libraries from each sex were analysed for expression of Ptgds, along with 
3 no–RT controls, 2 SC libraries and negative and positive PCR controls that consisted of 
H2O or mixed E13.5 male and female genital ridge cDNA (GR), respectively.  Products were 
run on agarose gels with 1kb DNA ladders run in the right- and left-most lanes.  The arrow 




4.2.3. Ptgds Immunostaining of E13.5 Testes 
 
In the previous sections, it was shown that male GCs sex-specifically express 
Ptgds mRNA.  To see whether male GCs express Ptgds protein, E13.5 testis 
sections were treated with Ptgds antibodies (Figure 4.2.3).  E13.5 testes were 
wax-embedded, sectioned then processed for immunostaining using antibodies 
against Ptgds and Amh to mark Sertoli cell cytoplasm.  Ptgds immunostaining 
was highest in cells in the testis cords, which agrees with in situ hybridisation 
Ptgds signal that is restricted to the cords in embryonic testis (Adams and 
McLaren, 2002).  In the cords, both Amh+ Sertoli cells and large, spherical Amh- 
GCs had roughly the same amount of Ptgds immunostaining signal, and that 
signal was higher in non-DAPI-stained cytoplasmic areas of stained cells.  No IgG 
negative control was carried out in this experiment, so it is impossible to say 








Figure 4.2.3. Ptgds Immunofluorescence staining of E13.5 Testes.  E13.5 testes were 
embedded in wax, sectioned then processed for immunostaining after antigen retrieval.  
Sections were stained with Ptgds antibodies, along with Amh antibodies to mark Sertoli cell 
cytoplasm and DAPI to mark cell nuclei.  Separate images were recorded for green 
fluorescence (Ptgds), red fluorescence (Amh) and blue fluorescence (DAPI) channels for 
representative areas of the gonad sections.  Channels from the same area are shown as 
stacked vertical images, in the order: Red/green combined, green, red then blue, top to 
bottom.  Images in the left column are x40 images of a gonadal section that intersects 2 
cords, scale bar 50μm.  Asterisks mark the interstitial area and white dashed boxes mark 
areas zoomed to in the images in the middle and right columns.  In the middle and right 
columns, scale bars are 10μm, white arrows mark GCs, black arrows with white outlines 




4.2.4. Ptgds Expression in XXSry and XYTdym1 Gonads 
 
The results from the previous sections in this chapter suggest that GCs do 
express Ptgds, but at a lower level than do Sertoli cells, which is in keeping with 
previous data showing that Ptgds mRNA expression is detected more readily in 
Sertoli cell cytoplasm (Wilhelm et al., 2007).  Recent data describes that Ptgds 
expression in E12.0-E14.5 XY gonads is dependent upon Sox9 expression, 
because Ptgds expression is heavily downregulated in XY gonads in which Sox9 
is conditionally knocked out (Moniot et al., 2009).  That study went on to show 
that Sox9 directly activates Sertoli cell Ptgds expression in XY gonads.  Because 
Sox9 expression in the embryonic gonad is dependent upon Sry expression 
(Sekido and Lovell-Badge, 2009), it is logical to assume that Sertoli cell Ptgds 
expression is also dependent upon Sry expression.   
In the current study, wholemount in situ hybridisation was carried out on XXSry 
transgenic and XYSry knockout gonads to find out whether Ptgds expression is 
in fact dependent upon Sry.  Gonads from XYTdym1 embryos develop as ovaries 
because of Sry deletion, while insertion of an autosomally located Sry transgene 
causes gonads from XXSry embryos to develop as testes (Durcova-Hills et al., 
2004).  Gonads from these mice were removed at E13.5 and Ptgds expression 
analysed by in situ hybridisation (Figure 4.2.4).  3/3 wildtype E13.5 XY testes 
were positive for Ptgds staining in the testis cords, while 4/4 E13.5 XYTdym1 
ovaries were negative for Ptgds staining.  Conversely, 4/4 wildtype E13.5 XX 
ovaries were negative for Ptgds staining, while 3/3 E13.5 XXSry testes were 
positive for Ptgds in the testes cords, identical to wildtype E13.5 testes.  These 
results indicate that Ptgds expression in the developing gonad is dependent 





Figure 4.2.4. Ptgds Expression in E13.5 XYTdym1 and XXSry Transgenic Gonads.  E13.5 testes 
were dissected, processed for in situ hybridisation against Ptgds and images captured by 
stereo microscopy.  Representative images are shown. Positive in situ signal appears as 
purple stain, as seen in the WT testis, and is not to be confused with blue precipitate on the 








4.3. Inducing/Suppressing Ptgds Expression in 
Cultured Genital Ridges (GRs) 
 
The previous sections in this chapter displayed that male GCs sex-specifically 
express Ptgds at E13.5.  Therefore, Ptgds expression is a marker for male-
specific differentiation of GCs.  The purpose of this study was to attempt to 
activate or repress Ptgds expression in E13.5 female or male GCs, respectively, 
in order to identify upstream pathways contributing to the sex-specific 
differentiation of GCs in vivo.  Previous studies show that treatment of cells with 
12-O-Tetradecanoylphorbol-13-acetate (TPA) can either activate (Fujimori et 
al., 2005) or repress (Garcia-Fernandez et al., 2000) Ptgds expression.   TPA 
treatment in these studies was shown to activate PKC to affect Ptgds gene 
transcription.  Dexamethasone (Garcia-Fernandez et al., 2000) and T3 (Garcia-
Fernandez et al., 1998; White et al., 1997) have also been characterised for their 
ability to activate Ptgds expression via glucocorticoid receptor activation and 
thyroid hormone receptor activation, respectively.  Therefore, TPA, 
Dexamethasone and Thyroid Hormone (T3) were tested for their ability to 
activate or repress Ptgds expression in embryonic female or male GCs, 
respectively.  ionomycin, a calcium ionophore that activates PKC in treated cells 
(Webb and Miller, 2003), was also tested for its ability to affect Ptgds 
transcription in embryonic GCs. 
E11.5 genital ridges (GRs) were sexed by PCR before being cultured for 48 
hours in their respective compounds or vehicles.  After this time, the genital 
ridges were processed for wholemount in situ hybridisation (WISH) against 
Ptgds to check for changes in expression of Ptgds.  In separate experiments, the 
cultured GRs were processed for immunostaining against GCNA to check that 
GCs had survived in the gonads. 
In total, 5 female GRs were cultured in TPA, 5 were cultured in ionomycin, 12 




negative for Ptgds detection by WISH (Figure 4.3.1A and C, and 4.3.1A and C), 





Figure 4.3.1. Ptgds Expression in Female GRs Cultured With TPA and Ionomycin.  Female 
E11.5 GRs were cultured for 2 days with 160nM 12-O-Tetradecanoylphorbol-13-acetate 
(TPA), 1μM ionomycin or vehicle (DMSO), as labeled.  After culturing, GRs were processed 
for wholemount in situ hybridisation, alongside E13.5 wildtype (WT) testes, using a probe 
against Ptgds, (A).  Scale bars in (A) are 100μm and the areas of the GRs enclosed by dashed 
lines, marked with “g” are the gonads.  Positive in situ signal appears as purple stain, as 
seen in the WT testis, and is not to be confused with blue precipitate on the surface of all 
GRs.  In separate experiments, identically cultured GRs were processed for immunostaining 
against GCNA (green signal) to assess GC survival, (B).  DAPI was included to stain all nuclei 
(blue signal).  Representative images were recorded and are shown here, scale bars are 
10μm.  The total number of GRs having negative Ptgds in situ signal or positive GCNA 
immunostaining, out of the number tested, is shown in (C), along with the number of 





Figure 4.3.2. Ptgds Expression in Female GRs Cultured With T3 and DEX.  Female E11.5 
GRs were cultured for 2 days with 100nM 3,3′,5-Triiodo-L-thyronine (Thyroid Hormone, 
T3), 100nM Dexamethasone (DEX) or their respective vehicles, NaOH or Ethanol, as labeled.  
After culturing, GRs were processed for wholemount in situ hybridisation, alongside E13.5 
wildtype (WT) testes, using a probe against Ptgds, (A).  Scale bars in (A) are 100μm and the 
areas of the GRs enclosed by dashed lines, marked with “g” are the gonads.  Positive in situ 
signal appears as purple stain, as seen in the WT testis, and is not to be confused with blue 
precipitate on the surface of all GRs.  In separate experiments, identically cultured GRs 
were processed for immunostaining against GCNA (green signal) to assess GC survival, (B).  
DAPI was included to stain all nuclei (blue signal).  Representative images were recorded 
and are shown here, scale bars are 10μm.  The total number of GRs having negative Ptgds 
in situ signal or positive GCNA immunostaining, out of the number tested, is shown in (C), 





Figure 4.3.3. Ptgds Expression in Male GRs Cultured With TPA and Ionomycin.  Male E11.5 
GRs were cultured for 2 days with 160nM 12-O-Tetradecanoylphorbol-13-acetate (TPA), 
1μM ionomycin or vehicle (DMSO), as labeled.  After culturing, GRs were processed for 
wholemount in situ hybridisation using a probe against Ptgds, (A).  Scale bars in (A) are 
100μm and the areas of the GRs enclosed by dashed lines, marked with “g” are the gonads.  
Positive in situ signal appears as purple stain, as seen in the cultured male gonads, and is 
not to be confused with blue precipitate on the surface of some GRs.  In separate 
experiments, identically cultured GRs were processed for immunostaining against GCNA 
(green signal) to assess GC survival, (B).  DAPI was included to stain all nuclei (blue signal).  
Representative images were recorded and are shown here, scale bars are 10μm.  The total 
number of GRs having negative Ptgds in situ signal or positive GCNA immunostaining, out of 
the number tested, is shown in (C), along with the number of biological replicates carried 




WISH staining, showing that the probe and protocol were able to detect Ptgds 
transcripts.  Therefore, under the culture conditions used, the concentrations of 
TPA, ionomycin, T3 and Dexamethasone tested failed to induce detectable levels 
of Ptgds expression in female GRs. 
It is possible that one or more of the compounds did in fact induce Ptgds 
expression in GCs, but the treatments caused the GCs to die, resulting in loss of 
detection of the induced Ptgds expression.  To rule this possibility out, GCNA 
immunostaining of identically cultured GRs showed that, in a vast majority of 
cases (7/9 for TPA, 3/3 for ionomycin, 4/4 for T3 and 5/5 for dexamethasone), 
treated GRs contained many GCNA+ GCs, comparable in number to that in 
vehicle-cultured GRs (Figure 4.3.1B and C, and 4.3.2B and C).  2/9 GRs cultured 
in TPA contained very few GCNA+ GCs after culturing (0-5 per 6μm section).  
However, GC loss also occurred in 1/10 cultured in DMSO vehicle, indicating 
that these occurrences were probably not due to addition of TPA.  The absence 
of Ptgds expression in the treated female GRs also indicates that these 
compounds were unable to stimulate Ptgds expression in female somatic cells in 
the gonads.  In summary, this data suggests that, at the concentrations tested, 
TPA, ionomycin, T3 and dexamethasone were unable stimulate detectable levels 
of Ptgds expression in surviving female GCs or somatic cells. 
Because PKC activation has also been shown to inhibit Ptgds gene induction 
(Garcia-Fernandez et al., 2000), E11.5 male GRs were similarly cultured in TPA, 
ionomycin or vehicle DMSO, to see if these treatments could inhibit Ptgds 
expression in male GCs.  The results from this analysis are shown in Figure 4.3.3.   
All 10/10 and 9/9 male GRs cultured in TPA and ionomycin, respectively, were 
positive for Ptgds WISH staining and had similar levels of Ptgds WISH staining 
as male GRs cultured in vehicle.  5/5 and 4/6 of the TPA- and ionomycin-
cultured GRs were also positive for GCNA immunostaining showing that 
numerous GCs survived, similar to 8/10 DMSO-cultured GRs that also had 
numerous GCNA+ GCs.  The nature of this WISH protocol means that WISH 




levels.  Therefore, quantification could not be carried out, and it cannot be ruled 
out that Ptgds expression dropped in one particular cell type, e.g. GCs.  However, 
the data do suggest that culture of male GRs with TPA or ionomycin, at the 
concentrations tested here, does not overtly affect Ptgds expression of male GRs 




4.4. Chapter Discussion 
 
Male GCs Sex-specifically Express Ptgds 
A role for Ptgds in embryonic testis development was first shown when Adams 
& McLaren (Adams and McLaren, 2002) found that Ptgds is enriched sex-
specifically in male GC cDNA, and that exogenous PgD2, Ptgds’s catalytic 
product, partially sex-reverses cultured female gonads.  Since then, further 
studies have shown that Ptgds augments male-specific gonad development by 
reinforcing Sertoli cell differentiation.  Ptgds accomplishes this by increasing 
Sox9 transcription (Moniot et al., 2009; Wilhelm et al., 2005) and enhancing 
nuclear localisation of Sox9 protein (Malki et al., 2005; Moniot et al., 2009), at 
least partially via PgD2/cAMP/PKA signaling (Malki et al., 2005). 
Ptgds expression in E13.5 testes is restricted to the testis cords (Adams and 
McLaren, 2002; Wilhelm et al., 2007).  There are conflicting data with respect to 
which cell type in embryonic testis cords - GCs or Sertoli cells, or both - express 
Ptgds.  Ptgds transcript has been detected by in situ hybridisation in apparent 
Sertoli cell and GC cytoplasm (Adams and McLaren, 2002).  Others describe 
Ptgds in situ hybridisation signal, using probe generated from the same cDNA 
sequence as Adams & McLaren (Adams and McLaren, 2002), as having an 
opposite pattern to Oct4 expression in E13.5 testes (Wilhelm et al., 2007), and 
therefore conclude that Sertoli cells but not GCs express Ptgds.  However, in the 
Wilhelm paper, Ptgds in situ hybridisation signal that is slightly higher than 
background can be seen in GC cytoplasm in the images in that paper, albeit at a 
lower level than in Sertoli cell cytoplasm.   
The current study aimed to clarify whether E13.5 male GCs express Ptgds.  Ptgds 
transcripts were sex-specifically detected in purified male E13.5 GC cDNA by 
end-point PCR after 35 cycles of PCR, which was the same number of cycles 
after which Ptgds expression was detected in male genital ridge cDNA that was 




study similarly detected Ptgds transcripts in cDNA generated from SSEA-1-
purified E13.5 male GCs, but to a lesser degree than in the somatic fractions 
(Tanaka et al., 2002).  The male GC cDNA used in the previous study (Tanaka et 
al., 2002) and the current study (Figure 3.2.1) contained roughly 5% and 3%, 
respectively, of contaminating somatic cells.  This raises the question of whether 
the Ptgds expression detected in male GC cDNA originates from Sertoli cell or GC 
mRNA expression.  Amh expression was also detected in the male GC cDNA in 
the current study (Figure 4.2.1), indicating that somatic cell transcripts are 
represented in the male GC cDNA.  However, Amh expression was detected 10-
15 cycles later in male GC cDNA than in male genital ridge cDNA that was 
prepared from the same amount of mRNA, and this late appearance of PCR 
product is consistent with expression by a small contaminating population of 
cells.  On the other hand, Ptgds expression was detected at the same time – after 
35 cycles of PCR – but with a lower amount of product.  This is consistent with 
expression by the majority of cells in the male GC cDNA at a lower level than 
that of Sertoli cells in the genital ridge cDNA.  Therefore, this PCR data suggests 
that Ptgds mRNA is expressed by GCs. 
PCR was also used in the current study to see whether Ptgds transcripts were 
detectable in cDNA libraries prepared from single E13.5 male GCs, which do not 
contain contaminating somatic cell transcripts.  However, Ptgds was not 
detected in 15 out of 15 E13.5 male GC single-cell cDNA libraries, whereas it 
was robustly detected in Sertoli cell cDNA libraries (Figure 4.2.2).  This lack of 
Ptgds detection contradicts the detection of GC Ptgds expression in male GC 
cDNA, as described in the previous paragraph.  There are several possible 
explanations for this discrepancy.  Firstly, it is possible that Sertoli cells and GCs 
express different splice forms of Ptgds that were not detected by a particular 
primer set.  However, this cannot explain the discrepancy because the primer 
sets used in the single-cell library analysis and the FACS GC cDNA analysis, 
although different, were designed to the same region of the Ptgds 3’ 
untranslated region and are therefore able to detect all known Ptgds splice 




originated as contaminating Sertoli cell expression does not hold up due to the 
conclusions made in the previous paragraph.  A third explanation for the 
discrepancy would be that E13.5 male GCs do express Ptgds, but the level of 
expression is below the detection limit of the single-cell procedure, and that is 
why Ptgds was not detected in the male GC cDNA libraries.   
Previous studies have detected 2 splice forms of Ptgds (Baker and 
O'Shaughnessy, 2001), and both were detected in male FACS-purified GC and 
male genital ridge cDNA.  However, the shorter known splice form was more 
abundant in the male GC cDNA, with the 230nt product appearing first in male 
GC cDNA.  Additionally, an even shorter 200nt product was also detected in 
male GC cDNA.  This product does not correspond to any known Ptgds splice 
form and was not detected in male genital ridge cDNA, suggesting that E13.5 
male GCs may express a GC-specific splice form of Ptgds. 
Ptgds immunostaining was also carried out on E13.5 testes sections and             
Ptgds protein was readily detected in male E13.5 GC cytoplasm (Figure 4.2.3).  
Unfortunately, no negative control was carried out for this immunostaining, so 
the detected immunostaining might signify background staining only.  On the 
other hand, the immunostaining levels were only slightly less intense than high 
level staining in Sertoli cell cytoplasm, and much higher than in the interstitial 
area, which is in agreement with previous detection of Ptgds mRNA that is 
restricted to the testis cords as shown in previous studies (Adams and McLaren, 
2002; Wilhelm et al., 2007) and in the current study (Ptgds-in situ-stained E13.5 
wildtype testes in Figures 4.3.1 and 4.3.2).  Therefore, the immunostaining 
might represent the actual presence of Ptgds protein in E13.5 GC cytoplasm, and 
this is confirmed by a recent study detecting Ptgds immunostaining in the 
cytoplasm of some, but not all, Mvh+ E12.5 male GCs (Moniot et al., 2009).   
To conclude the Ptgds GC expression analysis, Ptgds was detected sex-
specifically in male E13.5 GC cDNA, suggesting that male GCs sex-specifically 
express Ptgds mRNA.  Expression was not detected in cDNA libraries generated 




is lower than the detection limit of the single-cell analysis.  Immunostaining 
experiments confirmed that GCs also express Ptgds protein, which was 
predominantly cytoplasmic. 
 
Possible functions for Ptgds Expression in Male GCs 
What could be the function of Ptgds protein in E13.5 male GCs?  Ptgds knockout 
C57BL/6 mice are fertile but show a delay in Sertoli cell differentiation and 
testis cord formation due to a delay in Sox9 transcription and Sox9 protein 
mislocalisation (Moniot et al., 2009).  Ptgds is a multifunctional protein, being a 
lipocalin able to bind to small lipophilic molecules such as retinoic acid (RA) 
with high affinity (Tanaka et al., 1997), and a PgD2-producing enzyme.  The 
PgD2-producing function of Ptgds is relevant to gonad development because 
PgD2 partially masculinises cultured XX genital ridges (Adams and McLaren, 
2002) by recruiting Sertoli cells non-cell-autonomously (Wilhelm 2005).   
Could PgD2 signaling cause bipotential GCs to commit to spermatogenesis?  The 
answer to this is probably no, because the vast majority of GCs in PgD2-treated 
XX gonads develop as oocytes so are not sex-reversed (Adams and McLaren, 
2002).  However, PgD2 production by Ptgds expressed in male GCs would 
endow committed male GCs with potential to masculinise the surrounding 
somatic cells, via augmentation of Sertoli cell differentiation.  This might 
contribute to the enhanced masculinisation due to the presence of GCs in 
gonads with ‘weak’ Sry alleles, as opposed to reduced masculinisation in the 
absence of GCs due to concurrent Kitl knockout or Kit mutation in these same 
gonads (Nagamine and Carlisle, 1996).  This means that once embryonic GCs are 
committed to spermatogenesis, they express Ptgds and produce PgD2 to help 
ensure that the surrounding tissue is also masculinised.  Ingenious experiments 
will be required to assess whether this is the case. 
Ptgds can bind to lipophilic molecules, such as RA, with affinity similar to other 




and this is of interest because RA promotes meiosis, as well as apoptosis and 
mitosis, in embryonic GCs (Koubova et al., 2006; MacLean et al., 2007; 
Trautmann et al., 2008).  RA is produced in the mesonephros of both male and 
female genital ridges.  However, sex-specific expression of Cyp26b1, an RA-
metabolising enzyme, in the E11.5-E14.5 gonad prevents RA signaling in the 
male gonad at that time (Bowles et al., 2006), thereby preventing RA from 
interfering with mitotic arrest and spermatogenic commitment of male GCs.  
Ptgds expression in male GCs, and in Sertoli cells, could be another mechanism 
to ensure that RA does not interfere with GC spermatogenic commitment. 
 
TPA, Ionomycin, Dexamethasone and T3 failed to Affect GC Ptgds Expression 
Experiments were also carried out in this study to identify signaling pathways 
that might affect Ptgds expression in bipotential GCs.  A recent study found that 
Sox9 is able to bind to the Ptgds promoter and activate its transcription 
(Wilhelm et al., 2007), while another study showed that the majority of Ptgds 
expression in developing embryonic testes depends on Sox9 (Moniot et al., 
2009).  Therefore, it is likely that Sox9 activates Ptgds transcription in Sertoli 
cells during Sertoli cell differentiation.  However, other pathways may activate 
Ptgds transcription in male E13.5 GCs.  The pathways that activate GC Ptgds 
transcription also may overlap with the pathways that ensure commitment of 
GCs to spermatogenesis.  Therefore, experiments were carried out in the current 
study to try to activate or repress Ptgds expression in female or male GCs, 
respectively, in the hope of identifying pathways contributing to sex-specific 
differentiation of GCs. 
Active PKC (Fujimori et al., 2005), glucocorticoid signaling (Garcia-Fernandez et 
al., 2000; Tokudome et al., 2009) and thyroid hormone signaling (Garcia-
Fernandez et al., 1998; White et al., 1997) can all stimulate Ptgds transcription 
in various cell types.  In this study, organotypic culture of female GRs from E11.5 
to E13.5 with TPA or Ionomycin, Dexamethasone or T3, which activate PKC, 




activate detectable Ptgds expression in GCs, despite survival of most of the GCs.  
The concentrations of the compounds used were similar to those used to elicit 
Ptgds expression in other studies, but may not have been sufficient for 
activation of the pathways in the GCs in this organotypic culture system.  
Alternatively, the GCs themselves, or Ptgds transcription, may simply not have 
been receptive to those particular signals.   
PKC activation has also been reported to repress Ptgds expression (Garcia-
Fernandez et al., 2000), so TPA and Ionomycin were tested for their ability to 
inhibit Ptgds expression in E13.5 male GCs.  Neither TPA nor Ionomycin 
treatment noticeably affected Ptgds expression in male GRs cultured from E11.5 
to E13.5, indicating that Ptgds expression in the majority of expressing cells was 
unaffected.  GC Ptgds expression was not looked at specifically, so it is possible 
that the treatments may have reduced male GC Ptgds expression, and this 
reduction was masked by continued expression in Sertoli cells.  In summary 
then, no changes in GC Ptgds expression were identified due to treatment of 
cultured male or female gonads with any of the compounds tested.  Therefore, 












The first part of this study – the bHLH expression screen – was successful.  In 
total, 22 bHLH genes are now potential candidate genes for controlling the 
developmental decision of mouse GCs to commit to spermatogenesis or 
oogenesis, and enter mitotic arrest or meiosis, respectively.  Further work is 
needed to corroborate which of these candidate genes are in fact sex-specifically 
expressed by GCs, rather than some other contaminating gonadal cell 
population.   
In most screens studying sex-specific expression differences in E12.5-E14.5 
gonadal cells, many more genes are discovered as being enriched in male 
gonads compared to female gonads (e.g. Bouma et al., 2004).  This might be due 
to the fact that masculinisation of the gonad, which is more morphologically 
complex than ovary development at this early stage of gonad development, 
requires expression of more genes.  Conversely, this study found many more 
bHLH genes sex-specifically enriched or expressed in E13.5 female GC cDNA.  
What is the significance of this?  This finding could indicate that a number of 
bHLHs are actively involved in promoting meiosis-specific differentiation 
programs in female GCs.  A survey of temporal changes in the expression of 
these bHLHs during spermatogonial development, as male GCs enter meiosis, 
could indicate a corresponding role for these bHLHs in promoting meiotic entry 
of male GCs.  Alternatively, or additionally, the higher number of female-
enriched bHLHs might indicate that male GCs at E13.5, as they are beginning 
mitotic arrest, generally reduce their transcriptional activity.  This could easily 
be corroborated by a genome-wide microarray analysis of male and female 
E13.5 GCs. 
Previous studies indicate that Epas1 is expressed in E15.5 embryonic testis, but 
in somatic cells not GCs (Tian et al., 1998), suggesting that the male-specific 
enrichment detected in this screen might also be due to somatic cell, not GC, 
expression.  Similarly, some of the bHLHs found to be enriched in female GC 
cDNA here might also represent bHLHs expressed by somatic cells rather than 




might be involved in early ovarian somatic cell differentiation, an area that has 
recently been shown to be an active process (Nef et al., 2005), but is currently 
vastly under-researched.  To confirm which of these bHLHs might have such 
biological functions will require more detailed expression analysis of all the 
candidate bHLH genes to determine precisely which cell types are expressing 
them, further highlighting the need for this type of analysis. 
One of the rationales of the screen was to find a male-specific bHLH that acts 
within committed male GCs to promote mitotic arrest.  This is a well-
documented and common function for differentiation-inducing bHLHs (Zebedee 
and Hara, 2001).  In this study five male-enriched/specific bHLHs were 
identified.  Due to reasons discussed in the Chapter 3 discussion, Epas1, Msc and 
Ngn3 are the most unlikely to have this biological activity.  Of the remaining 
two, Mnt was confirmed as being male-specifically enriched at the protein level 
in E13.5 GCs and might contribute to, but is probably not the primary 
mechanism for, mitotic arrest of male GCs.  Helt was not corroborated beyond 
the screen data, but interestingly in the adult its expression is restricted to the 
testis (Guimera et al., 2006a), indicating that Helt might be involved in adult 
spermatogonial differentiation.  This identifies Helt as a very promising 
candidate for involvement in spermatogonial differentiation and its expression 
and biological functions should be studied further.  Knockout of Helt has been 
accomplished (Guimera et al., 2006b) and results in post-natal death, so an 
analysis of the testis of knockout embryos could well shed light upon this. 
Helt belongs to the bHLH-O class of bHLHs, which includes the Hes genes.  The 
Hes genes are well-established as downstream effectors of Notch signaling 
(Kageyama et al., 2005).  The bHLH-O class bHLHs are generally negative 
transcriptional regulators and have complex dimerisation and functional 
properties (Fischer and Gessler, 2007), being able to dimerise with, augment 
and repress various classes of bHLH, such as the Id proteins.  The Hey genes also 
belong to the bHLH-O class.  Interestingly, this study found that Hey1 was 




and female GC Hey1 expression was very high compared to control cDNA 
comprised of mixed embryo tissue.  Furthermore, Hey1 is expressed during 
multiple stages of adult spermatogenesis (Van Wayenbergh et al., 2003).  This 
evidence, together with the fact that Notch signaling is a key regulator of the 
meiosis/mitosis switch in C. elegans GCs (Kimble and Crittenden, 2005), 
indicates that Hey1 and other bHLH-O genes such as Helt are interesting 
candidates for controlling aspects of GC development, including mitotic arrest of 
spermatogenically-committed GCs.  Because the dimerisation properties of 
bHLH-O proteins are so complex, and the functional properties of Helt are 
mostly unknown, it would be prudent to discover Helt’s dimerisation 
properties, especially with the ubiquitous E-protein class A bHLHs, Hey1, the Id 
proteins and other candidate genes identified in the current screen.  This might 
shed light upon the functional role, if any, of Helt in GC development.  
Mnt belongs to the bHLH-Zip class of bHLH genes and interacts specifically with 
the bHLH-Zip Max, but not with other bHLHs, including Ids, E-proteins and 
bHLH-Zips other than Max (Hooker and Hurlin, 2006).  Mnt counteracts Myc 
transcriptional activity by competing for Myc’s obligatory partner Max, and by 
binding as repressive Mnt-Max heterodimers to Myc transcription targets.  
Knowing that E13.5 male GCs express greater Mnt protein than E13.5 female 
GCs prompts the theory that the purpose of this higher Mnt expression could be 
to counteract a potential pro-meiotic activity of Myc.  Phase 1 of the screen 
identified N-Myc as being the only one out of three Myc genes to be expressed in 
E13.5 GCs.  However, N-Myc PCR amplification occurred at roughly equal times 
for both female and male GC cDNA, and therefore N-Myc was not studied further 
in this study.  A closer examination of N-Myc, for example by immunostaining in 
E13.5-E15.5 gonadal tissue might reveal a role for N-Myc in promoting meiosis 
in female GCs.  Greater Myc activity in female GCs could also explain greater Id 
gene expression in female GCs, because previous studies have noted that Id1 
expression is responsive to Myc activity (Swarbrick et al., 2005), and that Id2 is 




Induction of a meiotic pathway in female GCs by Myc activity would be a novel 
role for Myc, but its expression has been noted before in type B spermatogonia 
and primary spermatocytes undergoing prophase I (Wolfes et al., 1989).  In 
another previous study, investigators ectopically-expressed a c-myc transgene 
in rats under the regulatory influence of the metallothionein IIA promoter, 
which the authors claim results in c-myc expression in primary spermatocytes 
through to spermatid stages in adult spermatogenesis (Kodaira et al., 1996).  In 
rats that expressed the transgene in their testes, spermatogenesis failed at 
prophase I and the spermatocytes underwent apoptosis.  Thus, ectopic c-myc 
prevented successful meiotic entry of the spermatocytes and this may have 
been caused by deleterious effects of excessive Myc activity.  Another way to 
study the possible effects of Myc activity on meiotic initiation would be to 
knockdown c-myc/N-myc expression in female GCs at E12.5/E13.5 and see 
whether this would prevent meiotic entry of female GCs. 
Ptgds was previously identified as being male-enriched in E13.5 gonads (Adams 
and McLaren, 2002), but some have disputed whether GCs contribute to this 
enrichment (Wilhelm et al., 2007).  Experiments in this study were also able to 
confirm that male E13.5 GCs probably express Ptgds mRNA at low levels, and 
have Ptgds immunostaining.  A recent study also found that male GCs express 
Ptgds protein by immunostaining (Moniot et al., 2009).  Now that we know that 
GCs express Ptgds, we can ask the question of whether this GC-specific Ptgds 
expression has biological significance.  Any study of this will be complicated by 
the fact that Sertoli cells express higher levels of Ptgds mRNA and protein than 
male GCs.  However, it should be possible to answer this question.  For example 
by comparing the ability of committed male GCs from wild-type and Ptgds 
knockout embryos to sex-reverse female somatic cells.  It is very likely that sex-
reversal of female somatic cells due to GC-expressed Ptgds will be due to 
Prostaglandin D2 (PgD2) production, owing to the well-documented ability of 
PgD2 to partially masculinise female gonads (Adams and McLaren, 2002; 
Wilhelm et al., 2005).  In mice, this is a minor testis determination pathway, 




mice (Moniot et al., 2009).  However, this pathway might be more important in 
other species because the ability of PgD2 to partially masculinise embryonic 
gonads is conserved in other animals such as chickens (Moniot et al., 2008). 
Ptgds is a bifunctional protein that can also bind to lipophilic molecules, such as 
retinoic acid (RA), with high affinity (Tanaka et al., 1997).  Owing to RA’s ability 
to induce meiosis in some GCs (Livera et al., 2000; MacLean et al., 2007; 
Trautmann et al., 2008), we can also ask whether the ability of Ptgds to bind to 
lipophilic molecules is of biological relevance to this system.  Ptgds in 
spermatogenically-committed GCs might act to scavenge free RA to prevent RA 
from interfering with mitotic arrest.  Because binding of lipophilic molecules 
inhibits the catalytic activity of Ptgds (Tanaka et al., 1997), the presence of RA 
would counteract PgD2 production and thus could be another mechanism 
whereby RA interferes with testis development and spermatogenesis.  A 
biochemical analysis of Ptgds extracted from spermatogenically-committed GCs, 
in particular whether it is bound by lipophilic molecules like RA, would be a 
good way to test this hypothesis. 
To conclude, this study has made excellent progress in identifying candidate 
bHLHs involved in the spermatogenesis/oogenesis switch and some progress in 
corroborating the GC-specific expression of some of these genes and also Ptgds.  
Further corroboration is needed for most of the candidate bHLHs identified, and 
once this is completed we can begin to study their functional relevance to early 










Primers used for analysis of FACS-purified GC cDNAs 
Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) 
Mvh AGGAGCTTGCAGAGATGTTCAGCAGAC CAACTGGATTGGGAGCTTGTGAAGAAG 
Gata4 ATGCGCCCCATCAAAACAGAG TGCAGTGATTATGTCCCCGTGA   
Lhx9 CCAAGGACCTCAAACAGCTTGC CCAAGGACCTCAAACAGCTTGC 
Gapdh CCTGCGACTTCAACAGCAACTCCCAC TGAGGTCCACCACCCTGTTGCTGTA 
Actb CTGGTGGTACCACCATGTACCCAGG AGTGAGGCCAGGATGGAGCCAC 
Amh CACCCTGAGCATCGATCAGCTGCAAG ACCTCTGACCCAGGCTTCGAACACG 
SF-1 TCCCTCGCCACTACCCTTGAAGCTG GGAGACAGCCTTGTCCAGTTGGGTG 






Primers used for analysis of Single-cell cDNA Libraries 
Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) 
Gapdh CCTGCGACTTCAACAGCAACTCCCAC TGAGGTCCACCACCCTGTTGCTGTA 
Sox9 CTTACTCACTGCTGTGGCTGGAGAGT AAGAAAGGCAGGGTGCACAAAGAAGG 
SF-1 CTTTCCTGCTTTCGCGTCAGAT GCACTTCTTGTCTTGGGGCTGT 
Gata4 TTCCTTGTCCTCATCACCCACA CCTTGAGGGAGAAACAGCGAAA 
Stella AAAAAAGGCTCGAAGGAAATGAG AGTTAAGATTTCCCAGCACCAG  
Dazl CAGACAGTGGTCTCTTGTCTGTTT TTAAGCACTGCCCGACTTCT 
Id1 AGGGGATCTCTGGGAAAGAC ATTTTCAGCCAGTGATCATTGTAA 
Id2 TGATCGTCTTGCCCAGGTGTCGTTCT TGGGTCCTTCTGGTATTCACGCTCCA 
Id3 GCCTGAGGGCATGGATGAGCTTCG GCTGACCAGCGTGTGCTAGCTCTTCA  












Ensembl Code MGI Symbol UPL No. Forward Primer Reverse Primer 
ENSMUSG00000044243 A830053O21Rik 073 GAGGCTGGCAGGAATTTTG TGCCTCTTCTGCCTCGTC 
ENSMUSG00000019256 Ahr 027 GCACAAGGAGTGGACGAAG AGGAAGCTGGTCTGGGGTAT 
ENSMUSG00000021575 Ahrr 101 ACCCCAAGGGGACTTCAG GGGGATCTCCTTAGTATGTGCTT 
ENSMUSG00000015522 Arnt 049 TCCACTGCACAGGCTACATC TCATCATCTGGGAGGGAGAC 
ENSMUSG00000015709 Arnt2 040 CACCAACACCAATGTCAAGC CTCGCTGATGTACCTCCAGTT 
ENSMUSG00000055116 Arntl 074 TCAGATGACGAACTGAAACACC CGGTCACATCCTACGACAAA 
ENSMUSG00000040187 Arntl2 084 AAGGAACTCAGTCACTTAATCCTCA GCATCCAACCACAAACAGG 
ENSMUSG00000020052 Ascl1 038 GCTCTCCTGGGAATGGACT CGTTGGCGAGAAACACTAAAG 
ENSMUSG00000035951 Ascl3 060 GAACAATTACGGGGATCCATAC CAGCGCCTGTAGTTGGTGTA 
ENSMUSG00000073043 Atoh1 069 TGCGATCTCCGAGTGAGAG CTCTTCTGCAAGGTCTGATTTTT 
ENSMUSG00000037621 Atoh8 038 CAAAGCCCTGCAGCAGAC AGAGCTTCTGCCCATAGGAGT 
ENSMUSG00000030103 Bhlhb2 050 TCTCCTACCCGAACATCTCAA AATGCTTTCACGTGCTTCAA 
ENSMUSG00000030256 Bhlhb3 070 CCTGCCCTTCTATCTGCTGT TCTTGTCTAGCCAGGGCTGT 
ENSMUSG00000045493 Bhlhb4 081 CGCTTGGTAGCATACCTCAAC CCGAGAACGGGTAAATCG 
ENSMUSG00000025128 Bhlhb5 034 ACACTTGCAGGGCAAACAA GAATGTCCGGTTTGTCTCTGA 
ENSMUSG00000052271 Bhlhb8 110 GGCTAAAGCTACGTGTCCTTG GGTGAGGCCCTTCCAACT 
ENSMUST00000016399 Btub 055 GGGACGTCTGCTCTCCAG GCGGCACATACTTCTTACCG 
ENSMUST00000016399 Btub 055 GGGACGTCTGCTCTCCAG GCGGCACATACTTCTTACCG 
ENSMUSG00000029238 Clock 069 TCATCTCACACCGCAGTCTC GGAGGAGTGCTAGTATCAGTAGGG 
ENSMUSG00000024140 Epas1 003 GGAGCTCAAAAGGTGTCAGG CAGGTAAGGCTCGAACGATG 
ENSMUSG00000030001 Figla 068 CTGGAAGAAGCGAAGGTCTC GGACACATGAGGGTCAGAGG 
ENSMUSG00000068284 Gm608 020 TCAGCCAAACGTCAGAAGC TCAGGGGCATACTTTCAAGC 










UPL No. Forward Primer Reverse Primer 
ENSMUSG00000038193 Hand2 055 CTTCAAGGGCCCAAGATTC TCAGCGCATCCATTTTCTAA 
ENSMUSG00000047171 Helt 080 GTTCCGGGAAACTGGAGAA TTGGCAAATTCTGCTAAAAGC 
ENSMUSG00000022528 Hes1 099 ACACCGGACAAACCAAAGAC CGCCTCTTCTCCATGATAGG 
ENSMUSG00000028940 Hes2 067 AGCTGCGCAAGAACCTAAAG TTCGAAGAGCGGGAAGTCT 
ENSMUSG00000028946 Hes3 078 TGGAGAGACACTACTCACATCAGA TGTACTTAACACTCAGCTCCAGGATA 
ENSMUSG00000048001 Hes5 022 CCAAGGAGAAAAACCGACTG TGCTCTATGCTGCTGTTGATG 
ENSMUSG00000067071 Hes6 066 ACGGATCAACGAGAGTCTTCA TTCTCTAGCTTGGCCTGCAC 
ENSMUSG00000023781 Hes7 078 GAGAGGACCAGGGACCAGA TTCGCTCCCTCAAGTAGCC 
ENSMUSG00000040289 Hey1 017 CATGAAGAGAGCTCACCCAGA CGCCGAACTCAAGTTTCC 
ENSMUSG00000019789 Hey2 001 ATTGCAAATGACAGTGGATCAT AGCATGGGCATCAAAGTAGC 
ENSMUSG00000032744 Heyl 025 CTGAATTGCGACGATTGGT GCAAGACCTCAGCTTTCTCC 
ENSMUSG00000021109 Hif1a 018 CATGATGGCTCCCTTTTTCA GTCACCTGGTTGCTGCAATA 
ENSMUSG00000042745 Id1 093 GCGAGATCAGTGCCTTGG CTCCTGAAGGGCTGGAGTC 
ENSMUSG00000020644 Id2 089 ACAGAACCAGGCGTCCAG AGCTCAGAAGGGAATTCAGATG 
ENSMUSG00000007872 Id3 019 GAGGAGCTTTTGCCACTGAC GCTCATCCATGCCCTCAG 
ENSMUSG00000021379 Id4 092 AGGGTGACAGCATTCTCTGC CCGGTGGCTTGTTTCTCTTA 
ENSMUSG00000034041 Lyl1 041 GCAGGACCCTTCAGCATCT CCACCTTCTGGGGTTGGT 
ENSMUSG00000059436 Max 050 ACCTCAAGCGGCAGAATG AGTTGGGCACTTGATCTTGC 
ENSMUSG00000030544 Mesp1 089 CCCATCGTTCCTGTACGC TCTAGAAGAGCCAGCATGTCG 









UPL No. Forward Primer Reverse Primer 
ENSMUSG00000030543 Mesp2 047 CCCAGAGCCTAGGAACAAGAC GGTTCTGGAGACACAGAAAGACTC 
ENSMUSG00000033943 Mga 083 CTACATCTGGGCTTATCCAGGT AACAGGGTGCGTGGTTTC 
ENSMUSG00000035158 Mitf 062 AAGCTGGAGCATGCGAAC GCGCTCTAGCCTGCATCT 
ENSMUSG00000017801 Mlx 100 GTGTCTTCAGCTGGATTGAGG GATGAAGGACACCGATCACA 
ENSMUSG00000038342 Mlxip 020 GCCCAACCCACGAGAAATA GGGTTGCAAAGGGATCAG 
ENSMUSG00000005373 Mlxipl 069 TGGAGAGCCTGGTACATTCA GGTCACGAAACCACACACTG 
ENSMUSG00000000282 Mnt 001 AAGCGCAGCAACAACAGAG CTCCTGCTCTCTCTCACGTTC 
ENSMUSG00000025930 Msc 011 AGCTTTCCAAACTGGACACG GTCCAGAGACCACGAATGG 
ENSMUSG00000047002 Msgn1 106 AATTACCTGCCGCCTGTCT TGAGTGTCTGGATCTTGGTGA 
ENSMUSG00000001156 Mxd1 098 ACAATGAAATGGAAAAGAACAGG GCGGTACCAATCCCTTTAGC 
ENSMUSG00000021485 Mxd3 025 CCAGGGTGCATATCCAGAA TGCGAAGCTTTTCCTTGAG 
ENSMUSG00000037235 Mxd4 015 GAAGCGTGCTAAGATGCACA CGCTGAAGCTGTTCCTTGAT 
ENSMUSG00000025025 Mxi1 055 AGCCAAAGCACACATCAAGA GCCGCTTTAAAAACCTCTGTT 
ENSMUSG00000022346 Myc 077 CCTAGTGCTGCATGAGGAGA TCCACAGACACCACATCAATTT 
ENSMUSG00000028654 Mycl1 045 ACGGCACTCCTAGTCTGGAA CCACGTCAATCTCTTCACCTT 
ENSMUSG00000037169 Mycn 069 CCTCCGGAGAGGATACCTTG TCTCTACGGTGACCACATCG 
ENSMUSG00000044597 Mycs 031 CAGGCTGATGAGTCCAAGC AGCAACTGCTGTTGTCTTTCAT 
ENSMUSG00000000435 Myf5 010 CTGCTCTGAGCCCACCAG GACAGGGCTGTTACATTCAGG 
ENSMUSG00000035923 Myf6 012 GGGCCTCGTGATAACTGCT AAGAAAGGCGCTGAAGACTG 
ENSMUSG00000009471 Myod1 042 AGCACTACAGTGGCGACTCA GGCCGCTGTAATCCATCA 
ENSMUSG00000026459 Myog 063 CCTTGCTCAGCTCCCTCA TGGGAGTTGCATTCACTGG 









UPL No. Forward Primer Reverse Primer 
ENSMUSG00000020647 Ncoa1 084 TGGCATGAACATGAGGTCAG GCCAACATCTGAGCATTCAA 
ENSMUSG00000005886 Ncoa2 002 GAATGTCCCGACCAGCTC TCGGCCAGCTCCTCTATGTA 
ENSMUSG00000027678 Ncoa3 110 GCAGCTGAGAATGCAGCTT CCTGCCGGCTCTGATTTA 
ENSMUSG00000034701 Neurod1 001 CGCAGAAGGCAAGGTGTC TTTGGTCATGTTTCCACTTCC 
ENSMUSG00000038255 Neurod2 027 ACAGCCCACCACGAATCT TCCGTGAGGAAGTTACGAGAG 
ENSMUSG00000048015 Neurod4 022 ACTACTCGCGGGAGCTGAC CCATCCAGGATTGTGTGTTG 
ENSMUSG00000037984 Neurod6 080 TCCTTCGAGGAAAGAGCATT TCCTCCTCTTCTTTCTCGGTTT 
ENSMUSG00000048904 Neurog1 101 GACCTGTCCAGCTTCCTCAC TGGAGGCTAGGGGCTGTAG 
ENSMUSG00000027967 Neurog2 069 ACATCTGGAGCCGCGTAG CCCAGCAGCATCAGTACCTC 
ENSMUSG00000044312 Neurog3 108 ACTGCTGCTTGTCACTGACTG ATGGTGAGCGCATCCAAG 
ENSMUSG00000051251 Nhlh1 001 GATCCCTTGGCAGAGTCCTT CTTCAAAGTTCCATGGTCAAGA 
ENSMUSG00000048540 Nhlh2 063 AATATTGGCTGCTTTTAATATTTGC GGACTCAGCATCATTTTGGAG 
ENSMUSG00000070623 NOVEL1 010 AGTGCGTGAATGAGGGCTAC TGAGCCGCTTCTCAGTCAG 
ENSMUSG00000057741 NOVEL2 017 GCCATCAGCTACATCAAGCA TGCTTTGGACTCGCCATC 
ENSMUSG00000075157 NOVEL3 032 GAGCCGGCACAGAAACAT GTGTAGATCTGTTGGCAGTGCT 
ENSMUSG00000001988 Npas1 074 TCTACCTGGGTCTCTCACAGG TCCCCAGGATGGATGTAGTC 
ENSMUSG00000026077 Npas2 076 GGAGTTCCCACAAGTCCTCA ATCAGCTTGGTTGGAGTGGA 
ENSMUSG00000021010 Npas3 107 GGGCATCACCTCCTACCAG ATTCTGATTGGTTGGGCAGA 
ENSMUSG00000046160 Olig1 020 GGCCCAGTTCTCCAAGTG GGGAAGATTGGCTGAGGTC 
ENSMUSG00000039830 Olig2 021 AGACCGAGCCAACACCAG AAGCTCTCGAATGATCCTTCTTT 
ENSMUSG00000045591 Olig3 025 CAGGAGAGTCGTCTGAACTCG TGGCATCTTCTGGACCATATC 









UPL No. Forward Primer Reverse Primer 
ENSMUST00000090749 Ppia 046 GACGCCACTGTCGCTTTT CTGCAAACAGCTCGAAGGA 
ENSMUST00000090749 Ppia 046 GACGCCACTGTCGCTTTT CTGCAAACAGCTCGAAGGA 
ENSMUSG00000026735 Ptf1a 073 GGGACGAGCAAGCAGAAGTA CGCGGTAGCAGTATTCGTG 
ENSMUSG00000030259 Rassf8 079 CTGTGGCGTCACGGAAGT GGGTGTACCTTCCAGTTCGAC 
ENSMUSG00000034161 Scx 029 ACACCCAGCCCAAACAGAT TCTGTCACGGTCTTTGCTCA 
ENSMUSG00000019913 Sim1 049 CGGCTCTCATCTACTCCAGAC TGAAATGTACATGATCTTCCCATC 
ENSMUSG00000062713 Sim2 109 CCAGCCTTGACCTGAAGC CATAGCCCGTAAGCTCTGTCA 
ENSMUSG00000059625 Sohlh1 011 GAGCGCGTTGTCATTCAGT CTGGCTGCCATGAGTGAG 
ENSMUSG00000027794 Sohlh2 005 CATCGAGCTGTTCCTTCCAT CTGGTCAGCATGGCATCTT 
ENSMUSG00000020538 Srebf1 077 ACAAGATTGTGGAGCTCAAAGAC GCGCAAGACAGCAGATTTATT 
ENSMUSG00000022463 Srebf2 074 ACCTAGACCTCGCCAAAGGT GCACGGATAAGCAGGTTTGT 
ENSMUSG00000030255 Sspn 026 AGCCCCTCCCTGCTAGTC AGTCCAAGGTAAGCCACCAC 
ENSMUSG00000028717 Tal1 060 CGCCTCACTAGGCAGTGG CTCTTCACCCGGTTGTTGTT 
ENSMUSG00000028417 Tal2 017 TGCGACAGCTACCTTGACTG GCTCCCTGGTATTTGTGAAGA 
ENSMUSG00000032228 Tcf12 100 AACCAGAGGGAATGCTGCT TTGTGTGGTCAGGGGAATAAA 
ENSMUSG00000068079 Tcf15 080 GTGTAAGGACCGGAGGACAA GATGGCTAGATGGGTCCTTG 
ENSMUSG00000045680 Tcf21 049 CATTCACCCAGTCAACCTGA CCACTTCCTTCAGGTCATTCTC 
ENSMUSG00000006642 Tcf23 051 CCAGAGCTAGGGGAACAGC CTTCACCCGAGTCCGTTC 
ENSMUSG00000053477 Tcf4 002 TAGGGAAAGCCCTAGCTTCG TGAAGGATTGGAGGAAAAGC 
ENSMUSG00000005718 Tcfap4 016 CGGGAACAGCAGCACCTA CGATCACTGTGGGGTGGT 
ENSMUSG00000020167 Tcfe2a 079 GTGGGCTCTGACAAGGAACT ACAGGTAGCGGGAACATCA 









UPL No. Forward Primer Reverse Primer 
ENSMUSG00000000134 Tcfe3 080 GGAACAGCAACGCTCCAA GGGCCTGCAGTTCTAGCTC 
ENSMUSG00000023990 Tcfeb 085 GAGCTGGGAATGCTGATCC CTTGAGGATGGTGCCTTTGT 
ENSMUSG00000029553 Tcfec 009 AGCTTAGGCTCCGGATTCA TTCCTCTCAGGATGGGTCTG 
ENSMUSG00000038932 Tcfl5 002 CTTCACGACCACCGACCT TGCAGCTGCGTGTACTCC 
ENSMUSG00000035799 Twist1 058 AGCTACGCCTTCTCCGTCT TCCTTCTCTGGAAACAATGACA 
ENSMUSG00000007805 Twist2 010 CATGTCCGCCTCCCACTA GGTGCCGAAAGTCACAGC 
ENSMUSG00000026641 Usf1 074 CCCCCTCACAGAGAGATGAA CACTGTTCCCTCTTCGGTTT 
ENSMUSG00000058239 Usf2 070 GTCTGGATCCCGCTTCCT GCCTTCCTGCAGCTCAAC 










Forward Primer Reverse Primer 
Epas1 3 GGAGCTCAAAAGGTGTCAGG CAGGTAAGGCTCGAACGATG 
Helt 81 CGAGCTGGGCAAGACAGT ATCTCCGCCTTCTCCAGTTT 
Mnt 72 ACCATCGAGGTGGAAAAGG CTTCTCGATGATGCCTCTCC 
Msc 1 AAGCGCAGCAACAACAGAG CTCCTGCTCTCTCTCACGTTC 
Ngn3 12 GCAGCTTGTTTATGGGGTCT AGCACATGTCCCCAAATAGG 
A83005
3O21Rik 73 GAGGCTGGCAGGAATTTTG TGCCTCTTCTGCCTCGTC 
Bhlhb2 50 TCTCCTACCCGAACATCTCAA AATGCTTTCACGTGCTTCAA 
Ebf4 70 CCTCACCTTTCGCCATCA AGGAGAAGACGCTGGTGGT 
Figla 68 CTGGAAGAAGCGAAGGTCTC GGACACATGAGGGTCAGAGG 
Id1 93 GCGAGATCAGTGCCTTGG CTCCTGAAGGGCTGGAGTC 
Id2 89 ACAGAACCAGGCGTCCAG AGCTCAGAAGGGAATTCAGATG 
Id3 19 GAGGAGCTTTTGCCACTGAC GCTCATCCATGCCCTCAG 
Mesp1 12 CCAGACTGTACCATTCCAACC TGCCTGCTTCATCTTTAGAGC 
Mlxipl 69 TGGAGAGCCTGGTACATTCA GGTCACGAAACCACACACTG 
Mxd4 15 GAAGCGTGCTAAGATGCACA CGCTGAAGCTGTTCCTTGAT 
Scx 66 GCCTCAGCAACCAGAGAAAG CCTTCACTAGTGGCATCACCT 
Ahrr 101 ACCCCAAGGGGACTTCAG GGGGATCTCCTTAGTATGTGCTT 
Atoh1 24 TCTGATGAGGCCAGTTAGGAA AGGGCATTTGGTTGTCTCAG 
Bhlhb4 16 AAAATTACGCCGAGGTCCTT TCACCTCCTGGGATCTTCC 
Bhlhb5 34 ACACTTGCAGGGCAAACAA GAATGTCCGGTTTGTCTCTGA 
Hand1 51 CAAGCGGAAAAGGGAGTTG GTGCGCCCTTTAATCCTCTT 
Hes7 78 GAGAGGACCAGGGACCAGA TTCGCTCCCTCAAGTAGCC 
Hes2 68 GAAATGACTGTGCGCTTCC ACCCTCGAGGTAGCTATTCAAA 
Max 52 AGGACGCCTGCTCTACCA TCACAAAGTCCACCAAACAGA 
Ascl2 71 AAAGTGTGGACCGGTTGG GCCAAACATCAGCGTCAGTA 
Id4 92 AGGGTGACAGCATTCTCTGC CCGGTGGCTTGTTTCTCTTA 
Olig1 20 GGCCCAGTTCTCCAAGTG GGGAAGATTGGCTGAGGTC 
Hey1 25 CTGAATTGCGACGATTGGT GCAAGACCTCAGCTTTCTCC 






Additional Results for bHLH Screen Part 1 
Gene 
Positive Control 
 N  N 
N Ct 
Ascl3 3 32.1 +/- 1.9 3 3 
Ascl4 2 35.8 +/- 0.9 2 3 
Atoh7 3 32.7 +/- 1.3 2 3 
Bhlhb8 3 32.2 +/- 0.7 2 2 
Ebf2 2 33.9 +/- 1.8 3 3 
Ferd3l 2 35.5 +/- 0.8 3 2 
Hand2 3 28.1 +/- 1.9 2 3 
Msgn1 3 33.2 +/- 0.5 3 3 
Mycs (A) 2 23.7 +/- 1.3 3 3 
Mycs (B) 3 24.7 +/- 0.2 3 3 
Myf5 2 27.7 +/- 0.6 2 3 
Myf6 2 30.1 +/- 0.2 3 3 
Myod1 3 30.9 +/- 1.2 3 3 
Neurod1 2 28.2 +/- 0.4 3 3 
Neurod2 2 28.8 +/- 0.0 3 3 
Neurod4 3 35.0 +/- 1.4 3 3 
Neurod6 2 28.5 +/- 0.3 3 2 
Neurog1 2 34.0 +/- 0.3 2 2 
Neurog2 3 31.2 +/- 0.8 3 3 
Nhlh1 2 34.4 +/- 0.1 3 3 
Nhlh2 3 28.3 +/- 0.7 3 2 
Npas1 3 36.1 +/- 1.9 3 3 
Npas3 2 36.2 +/- 0.4 3 3 
Npas4 3 33.2 +/- 1.3 2 2 
Olig2 3 31.4 +/- 0.5 3 3 
Ptf1a 2 37.3 +/- 0.2 3 3 
Sim1 3 35.3 +/- 0.5 3 3 
Sim2 2 31.6 +/- 0.3 2 3 
Tal2 3 31.7 +/- 1.4 2 2 
Tcf23 3 28.6 +/- 0.6 3 3 
Tcfec 2 31.5 +/- 0.6 3 3 










Positive Control Male Female 
Ct 
N Ct N Ct N Ct 
Ahr 3/3 29.9 +/- 0.4 3/3 31.2 +/- 0.5 3/3 31.2 +/- 1.2 0.0 
Arnt 3/3 27.8 +/- 0.9 3/3 29.9 +/- 0.7 2/3 30.2 +/- 0.3 -0.3 
Arnt2 3/3 28.2 +/- 1.1 3/3 31.9 +/- 1.0 3/3 31.7 +/- 1.3 0.2 
Arntl 3/3 28.8 +/- 1.6 3/3 31.5 +/- 2.0 3/3 31.9 +/- 0.5 -0.4 
Arntl2 3/3 30.2 +/- 1.5 3/3 30.4 +/- 0.1 3/3 32.0 +/- 0.5 -1.6 
Bhlhb3 3/3 35.5 +/- 0.5 2/3 36.9 +/- 0.6 3/3 34.9 +/- 1.5 1.9 
Clock 3/3 32.9 +/- 0.3 3/3 34.3 +/- 1.0 3/3 33.3 +/- 0.5 1.0 
Ebf1 2/3 27.7 +/- 1.0 3/3 34.8 +/- 1.4 3/3 34.8 +/- 0.8 0.1 
Gm608 2/3 34.2 +/- 1.4 3/3 33.4 +/- 0.5 3/3 32.6 +/- 0.9 0.7 
Hes3 2/3 33.9 +/- 0.4 2/3 38.8 +/- 0.6 3/3 38.0 +/- 1.4 0.9 
Hes5 3/3 29.3 +/- 0.5 3/3 33.2 +/- 0.6 3/3 31.7 +/- 0.8 1.5 
Hes6 3/3 30.8 +/- 0.9 2/3 34.7 +/- 0.4 3/3 34.3 +/- 2.0 0.4 
Hey2 2/3 31.6 +/- 1.0 3/3 34.3 +/- 0.6 2/3 36.0 +/- 1.0 -1.7 
Hif1a 3/3 25.0 +/- 1.0 3/3 27.4 +/- 1.2 2/3 26.8 +/- 0.6 0.7 
Lyl1 2/3 27.2 +/- 0.0 2/3 37.6 +/- 0.5 2/3 36.8 +/- 0.6 0.8 
Mesp2 3/3 32.7 +/- 1.2 3/3 31.8 +/- 1.2 3/3 30.7 +/- 1.2 1.1 
Mitf 3/3 29.6 +/- 0.4 2/3 35.5 +/- 2.0 3/3 35.4 +/- 1.1 0.1 
Mlx 3/3 28.5 +/- 1.0 3/3 28.8 +/- 0.3 3/3 28.1 +/- 0.5 0.7 
Mlxip 3/3 28.4 +/- 0.4 3/3 29.5 +/- 0.3 3/3 29.8 +/- 0.4 -0.3 
Mxd1 3/3 31.2 +/- 0.4 3/3 32.6 +/- 0.4 3/3 31.6 +/- 0.5 1.0 
Mxd3 3/3 26.6 +/- 1.3 2/3 32.4 +/- 0.8 3/3 31.7 +/- 0.7 0.7 
Mxi1 3/3 25.9 +/- 0.9 3/3 29.0 +/- 2.0 3/3 28.2 +/- 0.5 0.9 
Myc 3/3 24.3 +/- 2.0 3/3 32.0 +/- 1.4 2/3 33.0 +/- 0.2 -1.0 
Mycl1 3/3 32.2 +/- 2.0 3/3 32.1 +/- 2.0 3/3 32.2 +/- 1.2 -0.1 
Mycn 3/3 31.1 +/- 1.6 3/3 30.3 +/- 1.0 3/3 30.8 +/- 0.8 -0.6 
Myog 3/3 25.5 +/- 0.7 2/3 33.2 +/- 0.4 2/3 32.8 +/- 1.2 0.4 
Ncoa1 3/3 31.7 +/- 0.2 3/3 33.3 +/- 1.7 3/3 32.0 +/- 2.0 1.3 
Ncoa2 3/3 30.3 +/- 0.8 3/3 29.6 +/- 0.4 3/3 29.7 +/- 1.4 -0.1 
Ncoa3 3/3 28.5 +/- 0.5 2/3 29.5 +/- 1.2 3/3 29.0 +/- 1.2 0.5 
Npas2 3/3 31.7 +/- 0.5 2/3 34.4 +/- 0.8 3/3 34.3 +/- 1.4 0.1 
Olig3 3/3 30.5 +/- 0.9 2/3 31.7 +/- 1.7 3/3 31.7 +/- 1.1 -0.1 
Sohlh1 2/3 36.9 +/- 0.0 2/3 34.1 +/- 1.0 3/3 33.1 +/- 1.5 1.0 
Sohlh2 2/3 30.6 +/- 0.0 3/3 25.8 +/- 0.3 2/3 25.5 +/- 0.4 0.3 
Srebf1 3/3 25.4 +/- 1.4 3/3 27.8 +/- 0.3 3/3 28.1 +/- 1.1 -0.3 
Srebf2 3/3 27.8 +/- 0.0 2/3 29.6 +/- 0.6 3/3 29.7 +/- 1.4 0.0 
Tcf15 3/3 28.8 +/- 0.7 3/3 32.9 +/- 1.3 2/3 31.7 +/- 0.4 1.2 
Tcf4 3/3 28.9 +/- 0.8 3/3 30.7 +/- 0.4 3/3 32.6 +/- 0.4 -1.9 
Table v.2. Genes with  <2.0 cycles difference between male and female E13.5 GC cDNA in 





Positive Control Male Female 
Ct 
N Ct N Ct N Ct 
Tcfap4 3/3 27.7 +/- 1.3 2/3 29.7 +/- 0.3 2/3 31.5 +/- 0.3 -1.9 
Tcfe2a 3/3 24.2 +/- 0.9 3/3 25.5 +/- 1.0 3/3 25.1 +/- 1.0 0.4 
Tcfe3 3/3 29.3 +/- 0.6 3/3 31.5 +/- 0.7 3/3 31.2 +/- 0.8 0.3 
Twist1 2/3 29.4 +/- 0.6 2/3 38.4 +/- 1.7 3/3 38.4 +/- 0.9 0.1 
Twist2 3/3 28.5 +/- 1.5 3/3 37.0 +/- 1.4 2/3 37.8 +/- 0.3 -0.9 
Usf2 2/3 27.5 +/- 1.9 3/3 30.7 +/- 0.8 3/3 30.4 +/- 0.8 0.2 
Table v.2. Genes with  <2.0 cycles difference between male and female E13.5 GC cDNA in 























Positive Control Male Female Ct 
(M-F) N Ct N Ct N Ct 
Ascl2 2/3 28.4 +/- 0.1 2/3 26.3 +/- 0.1 2/3 29.1 +/- 0.5 2.8 
Epas1 2/3 23.0 +/- 1.0 2/3 28.5 +/- 0.0 3/3 31.4 +/- 1.2 2.9 
Helt 3/3 34.1 +/- 1.8 3/3 30.5 +/- 0.4 2/3 34.5 +/- 1.5 4.0 
Hey1 3/3 28.7 +/- 0.5 2/3 29.5 +/- 0.2 3/3 32.0 +/- 1.5 2.5 
Mnt 2/3 27.2 +/- 0.3 3/3 28.9 +/- 1.0 3/3 30.8 +/- 0.5 2.0 
Msc 2/3 27.4 +/- 0.3 3/3 31.3 +/- 1.3 3/3 0.0 +/- 0.0 M 
Ngn3 2/3 36.2 +/- 0.3 3/3 35.1 +/- 1.3 2/3 37.2 +/- 0.5 2.1 
A830053
O21Rik 
3/3 32.2 +/- 0.4 3/3 0.0 +/- 0.0 3/3 32.3 +/- 0.8 F 
Ahrr 3/3 33.4 +/- 0.5 3/3 0.0 +/- 0.0 3/3 35.4 +/- 0.7 F 
Ascl1 2/3 27.3 +/- 0.6 3/3 0.0 +/- 0.0 2/3 34.9 +/- 0.1 F 
Atoh1 3/3 32.3 +/- 1.3 3/3 0.0 +/- 0.0 2/3 34.8 +/- 1.6 F 
Bhlhb2 2/3 27.5 +/- 0.3 2/3 32.7 +/- 2.0 2/3 28.2 +/- 0.3 4.6 
Bhlhb4 3/3 33.1 +/- 0.7 2/2 0.0 +/- 0.0 3/3 35.4 +/- 1.1 F 
Bhlhb5 3/3 28.1 +/- 0.5 2/3 0.0 +/- 0.0 3/3 33.6 +/- 1.8 F 
Ebf3 2/3 29.3 +/- 0.5 2/3 0.0 +/- 0.0 3/3 34.7 +/- 0.8 F 
Ebf4 2/3 30.6 +/- 0.7 2/3 0.0 +/- 0.0 3/3 30.0 +/- 1.4 F 
Figla 3/3 36.0 +/- 1.5 3/3 31.5 +/- 0.7 3/3 27.6 +/- 0.2 3.9 
Hand1 3/3 25.3 +/- 0.6 2/3 0.0 +/- 0.0 2/3 29.0 +/- 1.1 F 
Hes2 3/3 35.0 +/- 0.7 2/2 0.0 +/- 0.0 2/3 36.8 +/- 0.9 F 
Hes7 3/3 34.0 +/- 1.6 3/3 0.0 +/- 0.0 2/3 35.0 +/- 0.7 F 
Heyl 3/3 28.6 +/- 1.2 2/3 0.0 +/- 0.0 2/3 35.9 +/- 1.1 F 
Id1 2/3 23.8 +/- 0.8 3/3 27.4 +/- 1.5 3/3 23.4 +/- 0.7 4.0 
Id3 3/3 22.0 +/- 0.3 3/3 25.8 +/- 0.2 3/3 23.3 +/- 0.4 2.5 
Id4 2/3 29.7 +/- 0.8 3/3 32.2 +/- 0.8 3/3 29.9 +/- 1.1 2.4 
Max 3/3 24.8 +/- 0.5 3/3 0.0 +/- 0.0 2/3 29.2 +/- 1.6 F 
Mesp1 3/3 31.7 +/- 1.4 3/3 34.0 +/- 0.3 3/3 29.6 +/- 1.5 4.3 
Mlxipl 3/3 31.4 +/- 0.3 3/3 33.8 +/- 0.6 3/3 30.9 +/- 1.2 2.9 
Mxd4 2/3 30.0 +/- 0.7 2/3 32.5 +/- 1.8 3/3 27.4 +/- 0.9 5.1 
Olig1 3/3 34.4 +/- 1.0 2/3 0.0 +/- 0.0 3/3 38.2 +/- 1.6 F 
Scx 2/3 28.2 +/- 0.1 3/3 35.4 +/- 1.3 2/3 31.5 +/- 1.2 3.9 
Tal1 3/3 27.8 +/- 0.6 2/3 0.0 +/- 0.0 2/3 36.2 +/- 2.0 F 
Tcf21 3/3 27.2 +/- 1.4 3/3 35.6 +/- 0.5 2/3 33.2 +/- 0.1 2.4 
Table v.3. Genes that had ≥2.0 cycles difference between male and female E13.5 GC cDNA 














Fold Enrichment                                          
( / ) 
Biological Rep. 1 Biological Rep. 2 
Epas1 6 6 4.1 +/- 1.2 
(*) 4.3 +/- 0.8 (*) 
Helt 6 6 4.9 +/- 2.8 
(*) 3.6 +/- 1.1 (*) 
Mnt 6 6 3.0 +/- 0.8 (*) 3.6 +/- 1.3 (*) 
Ngn3 6 5 11.7 +/- 4.9 
(*) 5.9 +/- 1.2 (*) 
Table vi.1. bHLH Screen Part 2: Male-Enriched Genes (normalised to Gapdh).  See 









Fold Enrichment                                          
( / ) 
Biological Rep. 1 Biological Rep. 2 
A83000Rik 3 4 16.9 +/- 5.3 
(*) 15.2 +/- 10.1 (ns) 
Bhlhb2 6 6 123.6 +/- 52.5 
(*) 130.8 +/- 25.9 (**) 
Ebf4 6 6 84.5 +/- 22.8 (***) 73.3 +/- 13.1 (ns) 
Figla 7 6 36.4 +/-   8.4 
(**) 47.5 +/- 8.3 (**) 
Id1 6 5 31.9 +/- 11.2 (*) 42.1 +/- 7.8 (**) 
Id2 6 6 18.8 +/- 6.9 
(*) 16.3 +/- 3.2 (**) 
Id3 6 6 15.3 +/- 4.2 
(*) 9.9 +/- 1.5 (**) 
Mesp1 6 6 11.0 +/- 4.5 (*) 32.1 +/- 10.2 (*) 
Mlxipl 6 6 6.6 +/- 0.7 
(**) 4.2 +/- 1.3 (*) 
Mxd4 6 6 31.1 +/- 9.7 
(*) 39.7 +/- 15.7 (**) 
Scx 6 6 16.9 +/- 5.3 (*) 15.2 +/- 10.1 (ns) 
Table vi.2. bHLH Screen Part 2: Female-Enriched Genes (normalised to Gapdh).  









Fold Enrichment                                          
( / ) 
Biological Rep. 1 Biological Rep. 2 
Ascl2 6 6 0.5 +/- 0.1 0.9 +/- 0.4 
Hey1 6 6 2.1 +/- 0.5(*) 2.1 +/- 0.3(**) 
Id4 6 6 0.3 +/- 0.1 0.7 +/- 0.1 
Max 6 6 1.0 +/- 0.1 1.2 +/- 0.2 
Olig1 3 3 0.6 +/- 0.1  - 
Table vi.2. bHLH Screen Part 2: Female-Enriched Genes (normalised to Gapdh).  
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